



Vitamin D3 Pharmacology Infographic: Physiologic Dosing versus Bolus Roulette

Alex Vasquez D.O., D.C., N.D. (USA), F.A.C.N.





Pharmacologic dosing (eg, cancer, multiple sclerosis): 200–300 ng/mL (500–750 nmol/L)

Requires professional supervision, diet modification, laboratory surveillance per Charoengam and Holick, *Nutrients* 2020 Jul

Potentially toxic if accompanied by clinical hypercalcemia: > 150 ng/mL (325 nmol/L)

per Grant and Holick, *Altern Med Rev* 2005 Jun

Supraphysiologic: > 100 ng/mL (250 nmol/L)

Higher levels of 25-hydroxy-cholecalciferol are clinically problematic if accompanied by hypercalcemia, calcinosis or urolithogenic hypercalciuria (especially with alkaline urine). Levels above 90-100 ng/mL (225-250 nmol/L) are generally supraphysiologic, but not inherently problematic.

Optimal physiologic range: 50-90 ng/mL (125-225 nmol/L)

Clinical example: prevention/treatment of SAS-2 coronavirus per "Participants were randomised to receive daily 60 000 IU of [Vit D3]..."

cholecalciferol supplementation was continued for those with 25(OH)D <50 ng/ml..." per Rastogi et al. *Postgrad Med J* 2020 Nov

Populations in sunny climates (Grant and Holick, *Altern Med Rev* 2005 Jun): pregnant rural Africans 58 ng/mL (147 nmol/L) per Luxwolda, *Eur J Nutr*

2013 Apr; USA or Israel lifeguards 59-65 ng/mL (148-163 nmol/L), farmers in Puerto Rico 90 ng/mL (225 nmol/L) per Vieth, *Am J Clin Nutr* 1999 May

Review: Clinical importance of vitamin D: paradigm shift with implications for all healthcare providers. *Altern Therap Health Med* 2004 Sep

Context: Supplemented Paleo-Mediterranean Diet. *Nutritional Perspectives* 2011 Jan academia.edu/39751813

Copyright © 2020 Dr Alex Vasquez. See videos, article compilation. InflammationMastery.com/d

Sufficiency (more health, less depression): 40-50 ng/mL (100-125 nmol/L)

Clinical example: enhanced well-being at 40g/ml, reduced use of antidepressant drugs per Bergman et al, *BMC Res Notes* 2015 Sep

Populations: nonpregnant rural Africans 46 ng/mL (115 nmol/L) per Luxwolda et al, *Eur J Nutr* 2013 Apr

Marginal sufficiency, increased mortality: < 30-40 ng/mL (75-100 nmol/L)

Garland et al, *Am J Public Health* 2014 Aug

Insufficiency (increased PTH, respiratory infections, ARDS): < 32 ng/mL (80 nmol/L)

Requires 114 mcg/d (4600 IU/d), per Heaney et al, *Am J Clin Nutr* 2003 Jan

Depletion (osteomalacia, chronic pain, weakness, infections): < 20 ng/mL (50 nmol/L)

Persistent, nonspecific musculoskeletal pain per Plotnikoff and Quigley, *Mayo Clin Proc* 2003 Dec

Infographic: Interpretation of serum 25-hydroxy-cholecalciferol levels in adults: Interpretation of any laboratory variable requires clinical contextualization; assessing renal function and measuring 1,25-dihydroxy-cholecalciferol prior to the initiation of vitamin D3 supplementation is reasonable, especially in patients with higher probability of renal insufficiency or granulomatous/malignant disease, respectively. Coadministration of calcium-sparing drugs (e.g., thiazides) warrants caution; periodic measurement of serum calcium is advised, especially during the first year of higher-dose vitamin D supplementation. Supplementation with cholecalciferol should generally be accompanied by adequate magnesium intake and/or supplementation with magnesium 600 mg/d for adults; vitamins K1 and K2 should also be utilized to optimize calcium metabolism. Dietary optimization, moderation of sodium intake, broad-spectrum nutritional supplementation, and avoidance of diet-induced metabolic acidosis are likewise important; see citations listed below for proper implementation. Treatment should be supervised by a nutrition-knowledgeable clinician.

Infographic citations included in images; see also:

1. Vasquez et al. [Clinical importance of vitamin D: a paradigm shift for all healthcare providers. *Altern Ther Health Med* 2004 Sep](#)
2. Vasquez A. [Textbook of Clinical Nutrition and Functional Medicine](#). ICHNFM.ORG, 2016
3. Vasquez A. How to Plan Studies Using Vitamin D. *Int J Hum Nutr Funct Med* 2017 academia.edu/31412957
4. Vasquez A. Revisiting the Supplemented Paleo-Mediterranean Diet. *Nutr Perspect* 2011 Jan academia.edu/39751813
5. Videos/excerpts 2020, articles and correspondence compilation 2004-2019. InflammationMastery.com/d
6. Heaney et al. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. *Am J Clin Nutr.* 2003 Jan;77(1):204-10. doi: 10.1093/ajcn/77.1.204
7. Heaney et al. 25-Hydroxylation of vitamin D3: relation to circulating vitamin D3 under various input conditions. *Am J Clin Nutr.* 2008 Jun;87(6):1738-42. doi: 10.1093/ajcn/87.6.1738

About the author and presenter: Alex Kennerly Vasquez DO ND DC (USA), Fellow of the American College of Nutrition (FACN), Overseas Fellow of the Royal Society of Medicine: An award-winning clinician-scholar and founding Program Director of the world's first fully-accredited university-based graduate program in Human Nutrition and Functional Medicine, Dr Alex Vasquez is recognized internationally for his high intellectual and academic standards and for his expertise spanning and interconnecting many topics in medicine and nutrition. Dr Vasquez holds three doctoral degrees as a graduate of University of Western States (Doctor of Chiropractic, 1996), Bastyr University (Doctor of Naturopathic Medicine, 1999), and University of North Texas Health Science Center, Texas College of Osteopathic Medicine (Doctor of Osteopathic Medicine, 2010). Dr Vasquez has completed hundreds of hours of post-graduate and continuing education in subjects including Obstetrics, Pediatrics, Basic and Advanced Disaster Life Support, Nutrition and Functional Medicine; while in the final year of medical school, Dr Vasquez completed a Pre-Doctoral Research Fellowship in Complementary and Alternative Medicine Research hosted by the US National Institutes of Health (NIH). Dr Vasquez is the author of many textbooks, including Integrative Orthopedics (2004, 2007 2012), Functional Medicine Rheumatology (Third Edition, 2014), Musculoskeletal Pain: Expanded Clinical Strategies (commissioned and published by Institute for Functional Medicine, 2008), Chiropractic and Naturopathic Mastery of Common Clinical Disorders (2009), Integrative Medicine and Functional Medicine for Chronic Hypertension (2011), Brain Inflammation in Migraine and Fibromyalgia (2016), Mitochondrial Nutrition and Endoplasmic Reticulum Stress in Primary Care, 2nd Edition (2014), Antiviral Strategies and Immune Nutrition (2014), Mastering mTOR (2015), Autism, Dysbiosis, and the Gut-Brain Axis (2017) and the 1200-page Inflammation Mastery 4th Edition (2016) also published as the two-volume set Textbook of Clinical Nutrition and Functional Medicine. "DrV" has also written approximately 100 letters and articles for professional magazines and medical journals such as *TheLancet.com*, *British Medical Journal* (BMJ), *Annals of Pharmacotherapy*, *Nutritional Perspectives*, *Journal of Manipulative and Physiological Therapeutics* (JMPT), *Journal of the American Medical Association* (JAMA), *Original Internist*, *Integrative Medicine*, *Holistic Primary Care*, *Alternative Therapies in Health and Medicine*, *Journal of the American Osteopathic Association* (JAOA), *Dynamic Chiropractic*, *Journal of Clinical Endocrinology and Metabolism*, *Current Asthma and Allergy Reports*, *Complementary Therapies in Clinical Practice*, *Nature Reviews Rheumatology*, *Annals of the New York Academy of Sciences*, and *Arthritis & Rheumatism*, the Official Journal of the American College of Rheumatology. Dr Vasquez lectures internationally to healthcare professionals and has a consulting practice and service for doctors and patients. DrV has served as a consultant, product designer, writer and lecturer for Biotics Research Corporation since 2004. Having served on the Review Boards for *Journal of Pain Research*, *Autoimmune Diseases*, *PLOS One*, *Alternative Therapies in Health and Medicine*, *Neuropeptides*, *International Journal of Clinical Medicine*, *Journal of Inflammation Research*, *BMC Complementary and Alternative Medicine* (all PubMed/Medline indexed), and *Journal of Naturopathic Medicine* and as the founding Editor of *Naturopathy Digest*, Dr Vasquez is currently the Editor (2013-) of International Journal of Human Nutrition and Functional Medicine and Former Editor (2018-2019) of *Journal of Orthomolecular Medicine*, published for more than 50 consecutive years by the International Society for Orthomolecular Medicine.

INFLAMMATION MASTERY

4TH EDITION


CLINICAL NUTRITION, FUNCTIONAL MEDICINE, MITOCHONDRIAL DYSFUNCTION, MICROBIOME & DYSBIOSIS, FUNCTIONAL INFLAMMOLOGY, PAIN MANAGEMENT, INTEGRATIVE RHEUMATOLOGY, NUTRITIONAL IMMUNOMODULATION, IMMUNONUTRITION & ANTIVIRAL STRATEGIES

The Colorful and Definitive Guide Toward Health and Vitality
and away from the Boredom, Risks, Costs, and Inefficacy of
Endless Analgesia, Immunosuppression, and Polypharmacy

3-Part Learning System of Text, Illustrations, and Video


DR. ALEX VASQUEZ
ICHNFM.ORG
INTERNATIONAL COLLEGE OF HUMAN NUTRITION AND FUNCTIONAL MEDICINE

Download your personal copies from inflammationmastery-com-ichnfm-org.dpdcart.com




1. **VIDEO:** [Integrating Functional and Naturopathic Medicine Concepts and Therapeutics into Medical Practice for Primary Care and Specialty Conditions](#)
 - View for free <https://www.InflammationMastery.com/medical>
2. **PDF eBook:** [Antiviral Nutrition 2014-2020](#)
3. **VIDEO:** [Re-Introduction to DrV's Antiviral Strategies and Immune Nutrition \(1hour\)](#)
4. **VIDEO:** [Antiviral Use of the Amino Acid NAC, N-acetyl-L-cysteine \(1hour42minutes\)](#)
5. **VIDEO:** [Antiviral Nutrition against C-V-1-9 \(1hour\)](#)
6. **VIDEO:** [Antiviral Nutrition 2020 Risk Management, Laboratory Assessment of Common Interventions](#)

FREE PDF eBook: Integrating Functional and Naturopathic Medicine Concepts and Therapeutics into Medical Practice for Common Conditions: lnkd.in/gP_9DMN



INFLAMMATION MASTERY
4TH EDITION
CLINICAL NUTRITION, FUNCTIONAL MEDICINE, MITOCHONDRIAL DYSFUNCTION, MICROBIOME & DYSBIOSIS, FUNCTIONAL INFLAMMATOLOGY, NUTRITIONAL PAIN MANAGEMENT, INTEGRATIVE RHEUMATOLOGY & ANTIVIRAL STRATEGIES, IMMUNOMODULATION, IMMUNONUTRITION & ANTIVIRAL STRATEGIES
The Colorful and Definitive Guide Toward Health and Vitality and away from the Boredom, Risks, Costs, and Inefficiency of Endless Analgesia, Immunosuppression, and Polypharmacy
3-Part Learning System of Text, Illustrations, and Video



INFLAMMATION MASTERY 4TH ED.
Clinical Nutrition, Functional Medicine, Inflammation, Integrative Pain Management, Rheumatology, Immunomodulation, Immunonutrition & Antiviral Strategies • Vasquez



DR. ALEX VASQUEZ
ICHNFM.ORG
INTERNATIONAL COLLEGE OF HUMAN NUTRITION AND FUNCTIONAL MEDICINE





DOWNLOAD

Vitamin D Bolus Reconsidered: Physiologic Dosing versus Pandemic Consequences of Codified Confusion

Alex Vasquez DO DC ND (USA) FACN

Vitamin D: Metabolism Dogma


The “vitamin D metabolism dogma”—as discussed here and familiar to many adults—is that vitamin D is produced in the skin following the exposure of intradermal (7-

the dogma of “vitamin D toxicity from physiologic dosages.” Any one of these five citations was more than sufficient scientifically to shift the paradigm of perception and patient care, but intellectual inertia and drug-centered dogma have

statistically attributed to vitamin D insufficiency and could potentially be avoided by eliminating vitamin D insufficiency. ... Given the dynamics of the COVID-19 pandemic and the proven safety of vitamin D supplementation, it therefore appears highly debatable and potentially even unethical to await results of such trials before public health action is taken." Governmental/medical failure to implement population-wide physiologic dosing of vitamin D3 or 25(OH)D (both of which are found in foods and can thus be categorized as nutritional supplements) is medically unethical and socially irresponsible and will continue to result in unnecessary deaths, infections, falls, fractures, chronic pain, drug dependence, inflammatory diseases, diabetes, neuropsychiatric complications and mental

depression—all of which could have been avoided with simple, affordable, and available vitamin D supplementation. Forcing populations to live quarantined in “lockdown” conditions deprives them of sunshine-dependent vitamin D production, and we can expect catastrophic consequences to manifest, the most obvious and immediate of which will be mental depression and vulnerability to infectious diseases.

Oh, the misanthropic irony, disguised as public health! With quarantines/lockdowns and canceled summer vacations, millions of people have been forced into worsened vitamin D deficiency under the pretense of “protecting them” from a viral infection that thrives among and preferentially kills people who are vitamin D deficient. ❄️



serum
25
(OH)
vitamin
D3
in adults

Pharmacologic dosing (eg, cancer, multiple sclerosis): 200–300 ng/mL (500–750 nmol/L)

Requires professional supervision, diet modification, laboratory surveillance per Charoengam and Holick, *Nutrients* 2020 Jul

Potentially toxic if accompanied by clinical hypercalcemia: > 150 ng/mL (325 nmol/L)

per Grant and Holick, *Altern Med Rev* 2005 Jun

Supraphysiologic: > 100 ng/mL (250 nmol/L)

Higher levels of 25-hydroxy-cholecalciferol are clinically problematic if accompanied by hypercalcemia, calcinosis or urolithogenic hypercalciuria (especially with alkaline urine). Levels above 90-100 ng/mL (225-250 nmol/L) are generally supraphysiologic, but not inherently problematic.

Optimal physiologic range: 50-90 ng/mL (125-225 nmol/L)

Clinical example: prevention/treatment of SAS-2 coronavirus per "Participants were randomised to receive daily 60 000 IU of [Vit D3]... cholecalciferol supplementation was continued for those with 25(OH)D <50 ng/ml..." per Rastogi et al. *Postgrad Med J* 2020 Nov

Populations in sunny climates (Grant and Holick, *Altern Med Rev* 2005 Jun): pregnant rural Africans 58 ng/mL (147 nmol/L) per Luxwolda, *Eur J Nutr* 2013 Apr; USA or Israel lifeguards 59-65 ng/mL (148-163 nmol/L), farmers in Puerto Rico 90 ng/mL (225 nmol/L) per Vieth, *Am J Clin Nutr* 1999 May

Review: Clinical importance of vitamin D: paradigm shift with implications for all healthcare providers. *Altern Therap Health Med* 2004 Sep

Context: Supplemented Paleo-Mediterranean Diet. *Nutritional Perspectives* 2011 Jan academia.edu/39751813

Copyright © 2020 Dr Alex Vasquez. See videos, article compilation. InflammationMastery.com/d

Sufficiency (more health, less depression): 40-50 ng/mL (100-125 nmol/L)

Clinical example: enhanced well-being at 40g/ml, reduced use of antidepressant drugs per Bergman et al, *BMC Res Notes* 2015 Sep

Populations: nonpregnant rural Africans 46 ng/mL (115 nmol/L) per Luxwolda et al, *Eur J Nutr* 2013 Apr

Marginal sufficiency, increased mortality: < 30-40 ng/mL (75-100 nmol/L)

Garland et al, *Am J Public Health* 2014 Aug

Insufficiency (increased PTH, respiratory infections, ARDS): < 32 ng/mL (80 nmol/L)

Requires 114 mcg/d (4600 IU/d), per Heaney et al, *Am J Clin Nutr* 2003 Jan

Depletion (osteomalacia, chronic pain, weakness, infections): < 20 ng/mL (50 nmol/L)

Persistent, nonspecific musculoskeletal pain per Plotnikoff and Quigley, *Mayo Clin Proc* 2003 Dec

Calcium and vitamin D in preventing fractures

Data are not sufficient to show inefficacy

EDITOR—The study by Porthouse et al had two major design flaws.¹ Firstly, the dose of vitamin D (800 IU per day) is subphysiological and therefore subtherapeutic. Secondly, their use of "self report" as a measure of compliance is unreliable.

The dose of vitamin D at 800 IU daily was not determined scientifically but determined arbitrarily before sufficient scientific methodology was available.²⁻⁴ Heaney et al determined the physiological requirement of vitamin D by showing that healthy men use 4000 IU cholecalciferol daily,² an amount that is safely attainable with supplementation³ and often exceeded with exposure of the total body to equatorial sun.⁴

We provided six guidelines for interventional studies with vitamin D.⁵ Dosages of vitamin D must reflect physiological requirements and natural endogenous production and should therefore be in the range of 3000-10 000 IU daily. Vitamin D supplementation must be continued for at least five to nine months. The form of vitamin D should be D₃ rather than D₂. Supplements should be assayed for potency. Effectiveness of supplementation must include measurement of serum 25-hydroxyvitamin D. Serum 25(OH)D concentrations must enter the optimal range, which is 40-65 ng/ml (100-160 nmol/l).

Since the study by Porthouse et al met only the second and third of these six criteria, their data cannot be viewed as reliable for documenting the inefficacy of vitamin D supplementation.

Alex Vasquez, *researcher*

Biotics Research Corporation, 6801 Biotics Research Drive, Rosenberg, TX 77471, USA avasquez@bioticsresearch.com

John Cannell, *president*

Vitamin D Council, 9100 San Gregorio Road, Atascadero, CA 93422, USA

Competing interests: AV is a researcher at Biotics Research Corporation, a drug manufacturing facility in the United States that has approval from the Food and Drug Administration.

References

1. Porthouse J, Cockayne S, King C, Saxon L, Steele E, Aspray T, et al. Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D₃) for prevention of fractures in primary care. *BMJ* 2005;330: 1003. (30 April.)[\[Abstract/Free Full Text\]](#)
2. Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. *Am J Clin Nutr* 2003;77: 204-10.[\[Abstract/Free Full Text\]](#)
3. Vieth R, Chan PC, MacFarlane GD. Efficacy and safety of vitamin D₃ intake exceeding the lowest observed adverse effect level. *Am J Clin Nutr* 2001;73: 288-94.[\[Abstract/Free Full Text\]](#)
4. Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. *Am J Clin Nutr* 1999;69: 842-56.[\[Abstract/Free Full Text\]](#)
5. Vasquez A, Manso G, Cannell J. The clinical importance of vitamin D (cholecalciferol): a paradigm shift with implications for all healthcare providers. *Altern Ther Health Med* 2004;10: 28-36.[\[ISI\]](#)[\[Medline\]](#)

Related Article

Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D₃) for prevention of fractures in primary care

Jill Porthouse, Sarah Cockayne, Christine King, Lucy Saxon, Elizabeth Steele, Terry Aspray, Mike Baverstock, Yvonne Birks, Jo Dumville, Roger Francis, Cynthia Iglesias, Suezann Puffer, Anne Sutcliffe, Ian Watt, and David J Torgerson
BMJ 2005 330: 1003. [\[Abstract\]](#) [\[Full Text\]](#)



6801 Biotics Research Drive
Rosenberg, TX 77471
Toll Free: 1-800-231-5777
www.bioticsresearch.com

CME

CONTINUING MEDICAL EDUCATION

THE CLINICAL IMPORTANCE OF VITAMIN D (CHOLECALCIFEROL): A PARADIGM SHIFT WITH IMPLICATIONS FOR ALL HEALTHCARE PROVIDERS

Alex Vasquez, DC, ND, Gilbert Manso, MD, John Cannell, MD

Alex Vasquez, DC, ND is a licensed naturopathic physician in Washington and Oregon, and licensed chiropractic doctor in Texas, where he maintains a private practice and is a member of the Research Team at Biotics Research Corporation. He is a former Adjunct Professor of Orthopedics and Rheumatology for the Naturopathic Medicine Program at Bastyr University. **Gilbert Manso, MD**, is a medical doctor practicing integrative medicine in Houston, Texas. In prac-

rice for more than 35 years, he is Board Certified in Family Practice and is Associate Professor of Family Medicine at University of Texas Medical School in Houston. **John Cannell, MD**, is a medical physician practicing in Atascadero, California, and is president of the Vitamin D Council (Cholecalciferol-Council.com), a non-profit, tax-exempt organization working to promote awareness of the manifold adverse effects of vitamin D deficiency.

InnoVision Communications is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The learner should study the article and its figures or tables, if any, then complete the self-evaluation at the end of the activity. The activity and self-evaluation are expected to take a maximum of 2 hours.

OBJECTIVES

Upon completion of this article, participants should be able to do the following:

1. Appreciate and identify the manifold clinical presentations and consequences of vitamin D deficiency
2. Identify patient groups that are predisposed to vitamin D hypersensitivity
3. Know how to implement vitamin D supplementation in proper doses and with appropriate laboratory monitoring

Reprint requests: InnoVision Communications, 169 Saxony Rd, Suite 103, Encinitas, CA 92024; phone, (760) 633-3910 or (866) 828-2962; fax, (760) 633-3918; e-mail, alternative.therapies@innerdoorway.com. Or visit our online CME Web site by going to <http://www.alternative-therapies.com> and selecting the Continuing Education option.

While we are all familiar with the important role of vitamin D in calcium absorption and bone metabolism, many doctors and patients are not aware of the recent research on vitamin D and the widening range of therapeutic applications available for cholecalciferol, which can be classified as both a vitamin and a pro-hormone. Additionally, we also now realize that the Food and Nutrition Board's previously defined Upper Limit (UL) for safe intake at 2,000 IU/day was set far too low and that the physiologic requirement for vitamin D in adults may be as high as 5,000 IU/day, which is less than half of the >10,000 IU that can be produced endogenously with full-body sun exposure.^{1,2} With the discovery of vitamin D receptors in tissues other than the gut and bone—especially the brain, breast, prostate, and lymphocytes—and the recent research suggesting that higher vitamin D levels provide protection from diabetes mellitus, osteoporosis, osteoarthritis, hypertension, cardiovascular disease, metabolic syndrome, depression, several autoimmune diseases, and cancers of the breast, prostate, and colon, we can now utilize vitamin D for a wider range of preventive and therapeutic applications to maintain and improve our patients' health.³ Based on the research reviewed in this article, the current authors believe that assessment of vitamin D status and treatment of vita-

min D deficiency with oral vitamin D supplements should become a routine component of clinical practice and preventive medicine. Vitamin D supplementation with doses of 4,000 IU/day for adults is clinically safe and physiologically reasonable since such doses are consistent with physiologic requirements.² Higher doses up to 10,000 IU/day appear safe and produce blood levels of vitamin D that are common in sun-exposed equatorial populations.^{1,2} Periodic assessment of serum 25-OH-vitamin D [25(OH)D] and serum calcium will help to ensure that vitamin D levels are sufficient and safe for health maintenance and disease prevention. Clinical research supporting the use of vitamin D in the management of type 2 diabetes, osteoporosis, osteoarthritis, hypertension, cardiovascular disease, metabolic syndrome, multiple sclerosis, polycystic ovary syndrome, musculoskeletal pain, depression, epilepsy, and the prevention of cancer and type 1 diabetes is presented along with our proposals for the interpretation of serum 25(OH)D laboratory values, for the design of future research studies, and for supplementation in infants, children, adults, and during pregnancy and lactation.

BASIC PHYSIOLOGY OF VITAMIN D

Vitamin D is obtained naturally from two sources: sunlight and dietary consumption. Vitamin D₃ (cholecalciferol) is the form of vitamin D produced in the skin and consumed in the diet. Vitamin D₂ (ergocalciferol), which is produced by irradiating fungi, is much less efficient as a precursor to the biologically active 1,25-dihydroxyvitamin D (calcitriol). Additionally, since ergocalciferol shows altered pharmacokinetics compared with D₃ and may become contaminated during its microbial production, it is potentially less effective and more toxic than cholecalciferol.⁴ Although ergocalciferol is occasionally used clinically and in research studies, cholecalciferol is the preferred form of supplementation and will be implied in this article when supplementation is discussed.

Vitamin D can be described as having two pathways for metabolism: one being "endocrine" and the other "autocrine" (within the cell) and perhaps "paracrine" (around the cell). This elucidation, recently reviewed by Heany,⁵ is vitally important in expanding our previously limited conception of vitamin D from only a "bone nutrient with importance only for the prevention of rickets and osteomalacia" to an extraordinary molecule with far-reaching effects in a variety of cells and tissues. Furthermore, Heany's distinction of "short-latency deficiency diseases" such as rickets from "long-latency deficiency diseases" such as cancer provides a conceptual handle that helps us grasp an understanding of the differences between the acute manifestations of severe nutritional deficiencies and the delayed manifestations of chronic subclinical nutritional deficiencies.⁵

In its endocrine metabolism, vitamin D (cholecalciferol) is formed in the skin following exposure to sunlight and then travels in the blood to the liver where it is converted to 25-hydroxyvitamin D (calcidiol, 25(OH)D) by the enzyme vitamin D-25-hydroxylase. 25(OH)D then circulates to the kidney for its final transformation to 1,25-dihydroxyvitamin D (calcitriol) by 25-hydroxyvitamin D₃-

1-alpha-hydroxylase (1-OHase).⁶ Calcitriol is the most biologically active form of vitamin D and increases calcium and phosphorus absorption in the intestine, induces osteoclast maturation for bone remodeling, and promotes calcium deposition in bone and a reduction in parathyroid hormone (PTH). While increased calcium absorption is obviously important for nutritional reasons, suppression of PTH by vitamin D is also clinically important since relatively lower levels of PTH appear to promote and protect health, and higher levels of PTH correlate with increased risk for myocardial infarction, stroke, and hypertension.^{7,8} Relatedly, Fujita⁹ proposed the "calcium paradox" wherein vitamin D or calcium deficiency leads to elevations of PTH which increases intracellular calcium and may thereby promote a cascade of cellular dysfunction that can contribute to the development of diabetes mellitus, neurologic diseases, malignancy, and degenerative joint disease.

In its autocrine metabolism, circulating 25(OH)D is taken up by a wide variety of cells that contain both 1-OHase as well as nuclear vitamin D receptors (VDR). Therefore, these cells are able to make their own calcitriol rather than necessarily relying upon hematogenous supply. Cells and tissues that are known to contain 1-OHase, and which therefore make their own calcitriol, include the breast, prostate, lung, skin, lymph nodes, colon, pancreas, adrenal medulla, and brain (cerebellum and cerebral cortex).^{3,10} Cells and tissues with nuclear, cytosolic, or membrane-bound VDR include islet cells of the pancreas, monocytes, transformed B-cells, activated T-cells, neurons, prostate cells, ovarian cells, pituitary cells, and aortic endothelial cells.¹¹ Indeed, given the wide range of cells and tissues that metabolize vitamin D in an autocrine manner, we see that there is biological potential for vitamin D to influence function and pathophysiology in a wide range of metabolic processes and disease states.

Since many cells and tissues of the body have the ability to metabolize vitamin D, we should not be surprised that vitamin D plays a role in the function of these cells. Calcitriol is known to modulate transcription of several genes, notably those affecting differentiation and proliferation such as *c-myc*, *c-fos*, and *c-sis*,⁶ and this may partially explain the inverse relationship between sun exposure (eg, vitamin D) and cancer mortality.^{12,13} Vitamin D appears to modulate neurotransmitter/neurologic function as shown by its antidepressant¹⁴ and anticonvulsant¹⁵ benefits. Vitamin D is obviously immunoregulatory as manifested by its ability to reduce inflammation,^{16,17} suppress and/or prevent certain autoimmune diseases,^{18,20} reduce the risk for cancer,¹² and possibly reduce the severity and frequency of infectious diseases, such as acute pneumonia in children.²¹

CLINICAL APPLICATIONS AND THERAPEUTIC BENEFITS OF VITAMIN D

Support for a broad range of clinical applications for vitamin D supplementation comes from laboratory experiments, clinical trials, and epidemiologic surveys. Despite the imperfections of current data, we can still see significant benefits from vitamin D supplementation in a variety of human diseases, as briefly reviewed below.

Cardiovascular Disease

Deaths from cardiovascular disease are more common in the winter, more common at higher latitudes and more common at lower altitudes, observations that are consistent with vitamin D insufficiency.²² The risk of heart attack is twice as high for those with 25(OH)D levels less than 34 ng/ml (85 nmol/L) than for those with vitamin D status above this level.²³ Patients with congestive heart failure were recently found to have markedly lower levels of vitamin D than controls,²⁴ and vitamin D deficiency as a cause of heart failure has been documented in numerous case reports.²⁵⁻²⁹

Hypertension

It has long been known that blood pressure is higher in the winter than the summer, increases at greater distances from the equator and is affected by skin pigmentation—all observations consistent with a role for vitamin D in regulating blood pressure.³⁰ When patients with hypertension were treated with ultraviolet light three times a week for six weeks their vitamin D levels increased by 162%, and their blood pressure fell significantly.³¹ Even small amounts of oral cholecalciferol (800 IU) for eight weeks lowered both blood pressure and heart rate.³²

Type 2 Diabetes

Hypovitaminosis D is associated with insulin resistance and beta-cell dysfunction in diabetics and young adults who are apparently healthy. Healthy adults with higher serum 25(OH)D levels had significantly lower 60 min, 90 min and 129 min postprandial glucose levels and significantly better insulin sensitivity than those who were vitamin D deficient.³³ The authors noted that, compared with metformin, which improves insulin sensitivity by 13%, higher vitamin D status correlated with a 60% improvement in insulin sensitivity. In a recent clinical trial using 1,332 IU/day for only 30 days in 10 women with type 2 diabetes, vitamin D supplementation was shown to improve insulin sensitivity by 21%.³⁴

Osteoarthritis

Many practitioners know that vitamin D helps prevent and treat osteoporosis, but few know that the progression of osteoarthritis, the most common arthritis, is lessened by adequate blood levels of vitamin D. Framingham data showed osteoarthritis of the knee progressed more rapidly in those with 25(OH)D levels lower than 36 ng/ml (90 nmol/L).³⁵ Another study found that osteoarthritis of the hip progressed more rapidly in those with 25(OH)D levels lower than 30 ng/ml (75 nmol/L).³⁶

Multiple Sclerosis

The autoimmune/inflammatory disease multiple sclerosis (MS) is notably rare in sunny equatorial regions and becomes increasingly prevalent among people who live farther from the equator and/or who lack adequate sun exposure. In a clinical trial with 10 MS patients, Goldberg, Fleming, and Picard³⁹ pre-

scribed daily supplementation with approximately 1,000 mg calcium, 600 mg magnesium, and 5,000 IU vitamin D (from 20 g cod liver oil) for up to two years and found a reduction in the number of exacerbations and an absence of adverse effects. This is one of very few studies in humans that employed sufficient daily doses of vitamin D (5,000 IU) and had sufficient duration (2 years). More recently, Mahon et al³⁷ gave 800 mg calcium and 1,000 IU vitamin D per day for six months to 39 patients with MS and noted a modest anti-inflammatory effect.

Prevention of Type 1 Diabetes

Type 1 diabetes is generally caused by autoimmune/inflammatory destruction of the pancreatic beta-cells. Vitamin D supplementation shows significant preventive and ameliorative benefits in animal models of type 1 diabetes. In a study with more than 10,000 participants, Hypponen et al¹⁸ showed that supplementation in infants (less than one year of age) and children with 2,000 IU of vitamin D per day reduced the incidence of type 1 diabetes by approximately 80%. Relatedly, several studies using cod liver oil as a rich source of vitamin D have also documented significant reductions in the incidence of type 1 diabetes.

Depression

Seasonal affective disorder (SAD) is a particular subtype of depression characterized by the onset or exacerbation of melancholia during winter months when bright light, sun exposure, and serum 25(OH)D levels are reduced. Recently, a dose of 100,000 IU of vitamin D was found superior to light therapy in the treatment of SAD after one month.³⁸ Similarly, in a study involving 44 subjects, supplementation with 400 or 800 IU per day was found to significantly improve mood within five days of supplementation.¹⁴

Epilepsy

Seizures can be the presenting manifestation of vitamin D deficiency.³⁹ Hypovitaminosis D decreases the threshold for and increases the incidence of seizures, and several "anticonvulsant" drugs interfere with the formation of calcitriol in the kidney and further reduce calcitriol levels via induction of hepatic clearance. Therefore, antiepileptic drugs may lead to iatrogenic seizures by causing iatrogenic hypovitaminosis D.⁴⁰ Conversely, supplementation with 4,000–16,000 IU per day of vitamin D₂ was shown to significantly reduce seizure frequency in a placebo controlled pilot study by Christiansen et al.¹⁵

Migraine Headaches

Calcium clearly plays a role in the maintenance of vascular tone and coagulation, both of which are altered in patients with migraine. Thys-Jacobs⁴¹ reported two cases showing a reduction in frequency, duration, and severity of menstrual migraine attacks following daily supplementation with 1,200 mg of calcium and 1,200–1,600 IU of vitamin D in women with vitamin D deficiency.

Polycystic Ovary Syndrome

Polycystic ovary syndrome (PCOS) is a disease seen only in humans and is classically characterized by polycystic ovaries, amenorrhea, hirsutism, insulin resistance, and obesity. Animal studies have shown that calcium is essential for oocyte activation and maturation. Vitamin D deficiency was highly prevalent among 13 women with PCOS, and supplementation with 1,500 mg of calcium per day and 50,000 IU of vitamin D2 on a weekly basis normalized menstruation and/or fertility in nine of nine women with PCOS-related menstrual irregularities within three months of treatment.⁴²

Musculoskeletal Pain

Patients with non-traumatic, persistent musculoskeletal pain show an impressively high prevalence of overt vitamin D deficiency. Plotnikoff and Quigley⁴³ recently showed that **93% of their 150 patients with persistent, nonspecific musculoskeletal pain were overtly deficient in vitamin D.** Masood et al⁴⁴ found a high prevalence of vitamin D deficiency in children with **limb pain**, and vitamin D supplementation ameliorated pain within three months. Al Faraj and Al Mutairi⁴⁵ found **vitamin D deficiency in 83% of their 299 patients with low-back pain**, and **supplementation with 5,000–10,000 IU of vitamin D per day lead to pain reduction in nearly 100% of patients after three months.**

Critical Illness and Autoimmune/Inflammatory Conditions

Deficiency of vitamin D is common among patients with inflammatory and autoimmune disorders and those with prolonged critical illness. In addition to the previously mentioned epidemic of vitamin D insufficiency in patients with MS, we also see evidence of vitamin D insufficiency in a large percentage of patients with Grave's disease,⁴⁶ ankylosing spondylitis,⁴⁷ systemic lupus erythematosus,⁴⁸ and rheumatoid arthritis.²⁰ Clinical trials with proper dosing and duration need to be performed in these patient groups. C-reactive protein was reduced by 23% and matrix metalloproteinase-9 was reduced by 68% in healthy adults following bolus injections of vitamin D that resulted in an average dose of 547 IU per day for 2.5 years.¹⁷ A recent trial of vitamin D supplementation in patients with prolonged critical illness showed a significant and dose-dependent "anti-inflammatory effect" evidenced by reductions in IL-6 and CRP.¹⁶ However, the insufficient dose of only 400 IU per day (administered intravenously) for only ten days precluded more meaningful and beneficial results, and we present guidelines for future studies later in this paper.

Cancer Prevention and Treatment

The inverse relationship between sunlight exposure and cancer mortality was documented by Apperly in 1941.¹³ Vitamin D has anti-cancer effects mediated by anti-proliferative and proapoptotic mechanisms³ which are augmented by modulation of nuclear receptor function and enzyme action,⁴⁹ and limited research shows that synthetic vitamin D analogs may have a role in the treatment of human cancers.⁵⁰ Grant¹² has shown that

inadequate exposure to sunlight, and hence hypovitaminosis D, is associated with an increased risk of cancer mortality for several malignancies, namely those of the breast, colon, ovary, prostate, bladder, esophagus, kidney, lung, pancreas, rectum, stomach, uterus, and non-Hodgkin lymphoma. He proposes that adequate exposure to ultraviolet light and/or supplementation with vitamin D could save more than 23,000 American lives per year from a reduction in cancer mortality alone.

The aforementioned clinical trials using vitamin D in a wide range of health conditions have helped to expand our concept of vitamin D and to appreciate its manifold benefits. However, in light of new research showing that the physiologic requirement is 3,000–5,000 IU/day for adults and that serum levels plateau only after 3-4 months of daily supplementation,² we must conclude that studies using lower doses and/or shorter durations have underestimated the clinical efficacy of vitamin D. Guidelines for the critique and design of clinical trials are proposed later in this article to aid clinicians and researchers in evaluating and designing clinical studies for the determination of the therapeutic efficacy of vitamin D.

ASSESSMENT OF VITAMIN D STATUS WITH MEASUREMENT OF SERUM 25-OH-VITAMIN D

Current laboratory reference ranges for 25(OH)D were erroneously based on average serum levels for the "apparently healthy" nonrachitic, nonosteomalacic American population, a large proportion of which is vitamin D deficient. Currently, laboratories do not report optimal levels so they will mislead the practitioner unless he or she is aware of current research. For the majority of labs, the bottom of the reference range is set too low due to the previous underappreciation of the clinical benefits of and physiologic requirement for higher vitamin D levels, and the top of the range is too low due to previous misinterpretations of the research resulting in an overestimation of vitamin D toxicity.^{1,2,51,52} Therefore, new reference ranges need to be determined based on the current research, and we present our proposals in Figure 1 and in the following outline:

- **Vitamin D Deficiency: less than 20 ng/mL (50 nmol/L).**

Serum 25(OH)D levels below 20 ng/mL (50 nmol/L) are clearly indicative of vitamin D deficiency. However, several authorities note that this level appears to be too low; Heaney⁵ and Holick⁵¹ both state that 25(OH)D levels should always be greater than 30 ng/mL (75 nmol/L).

- **Vitamin D Insufficiency: less than 40 ng/mL (100 nmol/L).**

According to Zittermann,¹¹ hypovitaminosis D, wherein tissue levels are depleted and PTH is slightly elevated, correlates with serum levels of 30–40 ng/mL (75–100 nmol/L). Independently, Dawson-Hughes et al⁵³ showed that serum levels of PTH begin to elevate when 25(OH)D levels fall below 45 ng/mL (110 nmol/L) in elderly men and women, and these findings were supported by Kinyamu et al⁵⁴ who found that optimal PTH status deteriorates when 25(OH)D levels fall below 49

ng/mL (122 nmol/L) in elderly women. Therefore, in order to maintain physiologic suppression of PTH, serum levels of 25(OH)D need to be greater than 40 ng/mL (100 nmol/L).

• **Optimal Vitamin D Status: 40–65 ng/mL (100–160 nmol/L)**

Based on our review of the literature, we propose that the optimal—“sufficient and safe”—range for 25(OH)D correlates with serum levels of 40–65 ng/mL (100–160 nmol/L).⁵⁵ This proposed optimal range is compatible with other published recommendations: Zittermann¹¹ states that serum levels of 40–80 ng/mL (100–200 nmol/L) are “adequate,” and Mahon et al³⁷ recently advocated an optimal range of 40–100 ng/mL (100–250 nmol/L) for patients with multiple sclerosis. The lower end of our proposed range is consistent with suggestions by Mercola^{56,57} who advocates an optimal range of 45–50 ng/mL (115–128 nmol/L) and by Holick⁵¹ who states that levels should be 30–50 ng/mL (75–125 nmol/L). The upper end of our proposed optimal range is modified from the previously mentioned ranges offered by Zittermann¹¹ (up to 80 ng/mL [200 nmol/L]) and Mahon et al³⁷ (up to 100 ng/mL [250 nmol/L]). According to the authoritative monograph by Vieth,¹ there is no consistent, credible evidence of vitamin D toxicity associated with levels below 80–88 ng/mL (200–220 nmol/L). Vieth¹ states, “Although not strictly within the ‘normal’ range for a clothed, sun-avoiding population, serum 25(OH)D concentrations of 220 nmol/L (88 ng/mL) are consistent with certain environments, are not unusual in the absence of vitamin D supplements, and should be regarded as being within the physiologic range for humans.” Similarly, in his very thorough review of the literature, Zittermann¹¹ concludes that serum 25(OH)D concentrations up to 100 ng/mL (250 nmol/L) are subtoxic. Additional support for the safety of this upper limit comes from documentation that sun exposure alone can raise levels of 25(OH)D to more than 80 ng/mL (200 nmol/L)¹ and that oral supplementation with 10,000 IU/day (mimicking endogenous production from sun exposure) in healthy men resulted in serum levels greater than 80 ng/mL (200 nmol/L) with no evidence of toxicity.² Until more data becomes available, we have chosen 65 ng/mL (160 nmol/L) rather than 80 ng/mL (200 nmol/L) as the upper end of the optimal range to provide a safety zone between the optimal level and the level which may possibly be associated with toxicity, and to allow for other factors which may promote hypercalcemia, as discussed below. Long-term prospective interventional studies with large groups and clinical trials involving patients with vitamin D-associated illnesses (listed above) will be needed in order to accurately define the optimal range—the serum level of vitamin D that affords protection from illness but which does not cause iatrogenic complications. In reviewing much of the current literature, we found no evidence of adverse effects associated with a 25(OH)D level of 65 ng/mL (160 nmol/L), and we found that this level is considered normal by some medical laboratories⁵ and that it can be approximated and safely exceeded with frequent full-body exposure to ultraviolet light¹ or oral administration of physiologic doses of 5,000–10,000 IU cholecalciferol per day for 20 weeks.² Prospective studies and


interventional clinical trials comparing different serum levels of 25(OH)D with clinical outcomes are necessary to elucidate the exact optimal range in various clinical conditions. While no acute or subacute risks are associated with the 25(OH)D levels suggested here, research shows clear evidence of long-term danger associated with vitamin D levels that are insufficient.

• **Vitamin D Excess: Serum Levels Greater than 80 ng/mL (200 nmol/L) with Accompanying Hypercalcemia**

Serum levels of 25(OH)D can exceed 80 ng/mL (200 nmol/L) with ultraviolet light exposure in the absence of oral vitamin D supplementation^{1,6} and with oral supplementation with 10,000 IU per day as previously mentioned²—in neither scenario is toxicity observed. 25(OH)D greater than 80 ng/mL (200 nmol/L) are not indicative of toxicity unless accompanied by clinical manifestations and hypercalcemia. Vieth¹ notes that hypercalcemia due to hypervitaminosis D is always associated with serum 25(OH)D concentrations greater than 88 ng/mL (220 nmol/L), and Holick⁵ previously stated, “Vitamin D intoxication does not occur until the circulating levels of 25(OH)D are over 125 ng/mL [312 nmol/L].” Assessment for hypervitaminosis D is performed by measurement of serum 25(OH)D and serum calcium.

MONITORING FOR VITAMIN D TOXICITY WITH 25(OH)D AND SERUM CALCIUM

Hypercalcemia can occur with vitamin D supplementation by either directly causing direct toxicity (rare) or by being associated with a vitamin D hypersensitivity syndrome (more common). If serum calcium becomes abnormally high, then vitamin D supplementation must be discontinued until the cause of the hypercalcemia is identified; however, direct vitamin D toxicity will rarely be the sole cause of the hypercalcemia.



* Modified from: Vasquez A. *Integrative Orthopedics: Concepts, Algorithms, and Therapeutics*. Houston; Natural Health Consulting Corporation. 2004: 417-419 with permission.

FIGURE 1. Proposed normal and optimal ranges for serum 25(OH)D levels based on current research*

The most important indicator of direct vitamin D toxicity is elevated serum calcium associated with a 25(OH)D level greater than 90 ng/ml (225 nmol/L). Elevated 1,25(OH)D levels are commonly—though not always—seen with vitamin D toxicity. Severe vitamin D intoxication is rare and usually seen only with industrial accidents, such as overdosing the fortification of milk, or with long-term administration of more than 40,000 IU of vitamin D per day. Severe hypercalcemia may require urinary acidification and corticosteroids to expedite the reduction in serum calcium.⁵⁸

Induction of vitamin D toxicity generally requires 1–4 months of 40,000 IU per day in infants.⁵⁸ In adults, toxicity generally requires several months of supplementation of at least 100,000 IU per day. Hypercalcemia appears to be the mechanism of vitamin D toxicity (rather than a direct toxic effect of the vitamin), and 25-OH-vitamin D levels may be normal in patients who are vitamin D toxic and hypercalcemic, particularly with vitamin D hypersensitivity syndrome. It has therefore been suggested that serum calcium be measured on a weekly and then monthly basis in patients receiving high-dose vitamin D. Manifestations attributable to hypervitaminosis D and hypercalcemia include anorexia, nausea, and vomiting followed by weakness, nervousness, pruritus, polyuria, polydipsia, renal impairment, and soft-tissue calcifications.

As a cause of hypercalcemia, vitamin D hypersensitivity syndromes are more common than vitamin D toxicity, and they generally arise when aberrant tissue uncontrollably produces the most active form of the vitamin—calcitriol. Primary hyperparathyroidism, granulomatous disease (such as sarcoidosis, Crohn's disease, and tuberculosis) and various forms of cancer may cause the syndrome. 25(OH)D levels are normal or even low in vitamin D hypersensitivity while serum calcium and 1,25(OH)D levels are elevated. Additional causes include adrenal insufficiency, hyperthyroidism, hypothyroidism, and adverse drug effects, particularly with thiazide diuretics. Whatever the cause, patients with persistent hypercalcemia should discontinue vitamin D supplementation and receive a thorough diagnostic evaluation to determine the cause of the problem.

Interventional Strategies to Treat Vitamin D Deficiency by Increasing Serum Vitamin D Levels

Human physiology adapted to and was shaped by a natural environment with ample exposure to sunlight.^{5, 61} Full-body exposure to ultraviolet light on clear days in equatorial latitudes can easily provide the equivalent of 4,000–20,000 IU of vitamin D.^{1, 61} Slightly longer durations of full-body sun exposure of approximately 30 minutes (3x the minimal erythemal dose) will produce 50,000 IU of vitamin D in lightly pigmented persons, while 5x longer durations are required for more darkly pigmented people to attain the same vitamin D production.⁶¹ The oral dose of vitamin D required to obtain adequate blood levels depends on latitude, sun exposure, body weight, skin pigmentation, dietary sources, efficiency of absorption, presence of intestinal disease (eg, intestinal resection or malabsorption), and medication use, for example with the vitamin D-depleting actions of common anticonvulsant drugs.⁴⁰

Past and Future Vitamin D Studies: Critique and Design

Nearly all published clinical trials have suffered from flawed design, including inadequate dosing, inadequate duration, wrong type of vitamin D (ie, ergocalciferol, D2), failure to test serum vitamin D levels, and/or failure to ensure that serum vitamin D levels entered into the optimal range. The following guidelines are provided for clinicians and researchers using vitamin D in clinical practice and research to improve the quality of research and patient care.

1. Dosages of vitamin D must reflect physiologic requirements and natural endogenous production and should therefore be in the range of 3,000–10,000 IU per day

The physiologic requirement for vitamin D appears to be 3,000–5,000 IU per day in adult males.² Full-body exposure to ultraviolet light (eg, sunshine) can produce the equivalent of 10,000–25,000 IU of vitamin D3 per day.¹ Therefore, intervention trials with supplemental vitamin D should use between 4,000 IU/day, which is presumably sufficient to meet physiologic demands, and 10,000 IU/day, which is the physiologic dose attained naturally via full-body sun exposure. Based on these physiologic criteria, we see that the majority of intervention studies in adults have used inadequate, subphysiologic doses of vitamin D. Therefore, studies that failed to identify therapeutic benefits from vitamin D supplementation were flawed due to insufficient therapeutic intervention—the dose of vitamin D was too low.

2. Vitamin D supplementation must be continued for at least 5-9 months for maximum benefit

Since serum 25(OH)D levels do not plateau until after 3-4 months of supplementation,² and we would expect clinical and biochemical changes to become optimally apparent some time after the attainment of peak serum levels, any intervention study of less than 5-9 months is of insufficient duration to determine either maximum benefit or that vitamin D supplementation is ineffective for the condition being investigated. Conversely, since vitamin D supplementation can alter intracellular metabolism within minutes of administration,¹¹ benefits seen in short-term studies should not be inaccurately attributed to statistical error or placebo effect.

3. Supplementation should be performed with D3 rather than D2

Although cholecalciferol (vitamin D3) and ergocalciferol (vitamin D2) are both used as sources of vitamin D, D3 is the human nutrient and is much more efficient in raising and sustaining serum 25[OH]D levels. Vitamin D2 is a fungal metabolite and has been associated with adverse effects due to contamination and altered pharmacokinetics.⁴ The type of vitamin D must always be clearly stated in published research reports.

4. Supplements should be tested for potency

Some products do not contain their claimed amount. This problem was illustrated in the study by Heaney et al² who found that the vitamin D supplement they used in their study, although produced by a well-known company, contained only 83% of its stated value. To ensure accuracy and consistency of clinical trials, actual dosages must be known.

5. Effectiveness of supplementation must include evaluation of serum vitamin D levels

Supplementation does not maximize therapeutic efficacy unless it raises serum 25(OH)D levels into the optimal range. To assess absorption, compliance, and safety, serum 25(OH)D levels must be monitored in clinical trials involving vitamin D supplementation. Assessment of serum levels is important also to determine the relative dose-effectiveness of different preparations of vitamin D, as some evidence suggests that micro-emulsification facilitates absorption of fat-soluble nutrients.^{56,59,60} Measurement of 1,25-dihydroxyvitamin (calcitriol) is potentially misleading and is not recommended for the evaluation of vitamin D status.

6. Serum vitamin D levels must enter the optimal range

The majority of clinical intervention studies using vitamin D have failed to use supplementation of sufficient dosage and duration to attain optimal serum levels of vitamin D. Our proposed optimal range for 25(OH)D is 40–65 ng/mL (100–160 nmol/L) and is presented in Figure 1.

The above-mentioned criteria will aid future researchers in designing interventional studies that can accurately evaluate the relationship between vitamin D status and human illness. Clinicians, who are not conducting research but rather are interested in attaining clinical improvement in their patients, should follow these guidelines as well when using vitamin D supplementation in patients, while remembering to monitor for toxicity with the triad of clinical assessments, serum 25(OH)D, and serum calcium. Clinicians and researchers need to remember, however, that optimal clinical effectiveness often depends on synergism of diet, lifestyle, exercise, emotional health, and other factors. Single intervention studies are a reasonable research tool only for evaluating cause-and-effect relationships based on the presumption of a simplistic, linear model that is generally inconsistent with the complexity and multiplicity of synergistic and interconnected factors that determine health and disease. Thus, single intervention studies with vitamin D supplementation will be useful from an intellectual standpoint insofar as they will help us to further define the role of vitamin D in human physiology and pathophysiology. However, optimal clinical results with individual patients are more easily attained with the use of multicomponent treatment plans that address many facets of the patient's health.⁵⁵

Vitamin D Supplementation in Adults

When 28 men and women were administered 4,000 IU per day for up to five months, in the absence of UVB from the sun, serum 25(OH)D levels reached approximately 40 ng/mL (100 nmol/L), and no toxicity was observed.⁴ When 67 men were administered 5,000 and 10,000 IU of cholecalciferol per day for twenty weeks, again in the absence of UVB from the sun, serum levels of 25(OH)D increased to approximately 60 ng/mL (150 nmol/L) and 90 ng/mL (225 nmol/L), respectively, and no toxicity was observed.² Therefore, given that endogenous vitamin D production following full-body sun exposure at lower latitudes can produce >10,000 IU¹ and that 4,000 IU per day is a safe level of supplementation⁴ that meets physiologic needs in adults,² we recommend at least 4,000 IU per day for adults, with efficacy and safety ensured by periodic measurement of 25(OH)D and serum calcium.

Vitamin D Supplementation in Pregnant Women

In 1966, two case reports and a brief review of the literature showed no adverse effects of 100,000 IU per day of vitamin D in hypoparathyroid pregnant women.⁶² In 1971, a study of 15 hypoparathyroid pregnant women was reported wherein the women received more than 100,000 IU per day of vitamin D with no adverse effects to the mother or child, leading the authors to conclude that there was “no risk from vitamin D in pregnancy.”⁶³ Doses of vitamin D for pregnant women were extensively reviewed by Hollis and Wagner⁶¹ immediately prior to the completion of this article, and the authors concluded that doses of 100,000 IU per day were safe for pregnant women. The authors write, “Thus, there is no evidence in humans that even a 100,000 IU/day dose of vitamin D for extended periods during pregnancy results in any harmful effects.” Data from several placebo-controlled clinical trials with pregnant women show that vitamin D supplementation results in superior health status for the mother and infant. The current daily reference intake (DRI) for vitamin D of 200–400 IU per day is therefore “grossly inadequate,” and administration of less than 1,000 IU vitamin D per day to pregnant women is scientifically unjustifiable and ethically questionable. Hollis and Wagner⁶¹ conclude that up to 4,000 IU per day is necessary for pregnant women, and this conclusion is consistent with previously cited research on physiologic requirements² and endogenous vitamin D production.¹ In order to ensure safety and efficacy in individual patients, we encourage periodic measurement of serum calcium and 25(OH)D levels.

Vitamin D Supplementation in Infants and Children

In Finland from the mid-1950s until 1964, the recommended daily intake of vitamin D for infants was 4,000–5,000 IU, a dose that was proven safe and was associated with significant protection from type 1 diabetes.⁶¹ More recently, in a study involving more than 10,000 infants and children, daily administration of 2,000 IU per day was safe and effective for reducing the incidence of type 1 diabetes by 80%.¹⁸ Thus, for infants and children, doses of 1,000 IU per day are certainly safe, and higher doses should be monitored by serum calcium and 25(OH)D levels.

Options for Raising Vitamin D Blood Levels

We have two practical options for increasing vitamin D levels in the body: oral supplementation and/or exposure to ultraviolet radiation. Sunlight is commonly unavailable on rainy or cloudy days, during the winter months, and in particular geographic locations. Topical sunscreens block vitamin D production by 97%-100%. Furthermore, since many people work indoors where sunshine is inaccessible, or they are partially or fully clothed when outside, reliance on sunshine to provide optimal levels of vitamin D is generally destined to provide unsatisfactory and inconsistent biochemical and clinical results. The use of UVB tanning beds can increase vitamin D levels; but this option is more expensive and time-consuming than oral supplementation, and excess ultraviolet radiation exposure expedites skin aging and encourages the development of skin cancer. Given the impracticalities and disadvantages associated with relying on sun exposure to provide optimal levels of vitamin D year-round, for the majority of patients, oral vitamin D supplementation is the better option for ensuring that biochemical needs are consistently met.

Vitamin D is either absent or present in non-therapeutic amounts in dietary sources. One of the only major dietary sources of vitamin D is cod-liver oil, but the amount required to obtain a target dose of 4,000 IU per day would require patients to consume at least three tablespoons of cod-liver oil, or the amount contained in >18 capsules of most commercial preparations.⁵⁵ Clearly this would be unpalatable and prohibitively expensive for most patients, and it would result in very low compliance. Additionally, such a high dose of cod-liver oil may produce adverse effects with long-term use, particularly with regard to excess vitamin A, and perhaps an increased tendency for bleeding and reduced biological activity of gamma-linolenic acid due to the high content of eicosapentaenoic acid.^{55,64} Oral supplementation with "pure" vitamin D supplements allows the dose to be tailored to the individual needs of the patient.

DISCUSSION AND CONCLUSIONS

Vitamin D is not a drug, nor should it be restricted to prescription availability. Vitamin D is not a new or unproven "treatment." Vitamin D is an endogenous, naturally occurring, photochemically-produced steroidal molecule with essential functions in systemic homeostasis and physiology, including modulation of calcium metabolism, cell proliferation, cardiovascular dynamics, immune/inflammatory balance, neurologic function, and genetic expression. Insufficient endogenous production due to lack of sufficient sun exposure necessitates oral supplementation to meet physiologic needs. Failure to meet physiologic needs creates insufficiency/deficiency and results in subtle yet widespread disturbances in cellular function which appear to promote the manifestation of subacute long-latency deficiency diseases such as osteoporosis, cardiovascular disease, hypertension, cancer, depression, epilepsy, type 1 diabetes, insulin resistance, autoimmune disease, migraine, polycystic ovary syndrome, and musculoskeletal pain. In case reports, clinical trials, animal studies, and/or epidemiologic surveys, the provision of vitamin D via sunlight or sup-

plementation has been shown to safely help prevent or alleviate all of the aforementioned conditions.

Vitamin D deficiency/insufficiency is an epidemic in the developed world that has heretofore received insufficient attention from clinicians despite documentation of its prevalence, consequences, and the imperative for daily supplementation at levels above the current inadequate recommendations of 200–600 IU.⁶⁵ For example, at least 57% of 290 medical inpatients in Massachusetts, USA were found to be vitamin D deficient,⁶⁶ and overt vitamin D deficiency was recently found in 93% of 150 patients with chronic musculoskeletal pain in Minnesota, USA.⁴³ Other studies in Americans have shown vitamin D deficiency in 48% of patients with multiple sclerosis,³⁷ 50% of patients with fibromyalgia and systemic lupus erythematosus,⁴⁸ 42% of healthy adolescents⁶⁷ and African American women,⁶⁸ and at least 62% of the morbidly obese.⁶⁹ International studies are consistent with the worldwide prevalence of vitamin D deficiency in various patient groups, showing vitamin D deficiency in 83% of 360 patients with chronic low-back pain in Saudi Arabia,⁴⁵ 73% of Austrian patients with ankylosing spondylitis,⁴⁷ up to 58% of Japanese women with Grave's disease,⁴⁶ more than 40% of Chinese adolescent girls,⁷⁰ and 40%-70% of Finnish medical patients.⁷¹ As a medically valid diagnosis (ICD-9 code: 268.9 Unspecified vitamin D deficiency) with a high prevalence and clinically significant morbidity, vitamin D deficiency deserves equal attention and status with other diagnoses encountered in clinical practice. Given the depth and breadth of the peer-reviewed research documenting the frequency and consequences of hypovitaminosis D, failure to diagnose and treat this disorder is ethically questionable (particularly in pregnant women⁶¹) and is inconsistent with the delivery of quality, science-based healthcare. Failure to act prudently based on the research now available in favor of vitamin D supplementation appears likely to invite repetition analogous to the previous failure to act on the research supporting the use of folic acid to prevent cardiovascular disease and neural tube defects—a blunder that appears to have resulted in hundreds of thousands of unnecessary cardiovascular deaths⁷² and which has contributed to incalculable human suffering related to otherwise unnecessary neural tube defects, cervical dysplasia, cancer, osteoporosis, and mental depression. Currently, Grant¹² estimates that at least 23,000 and perhaps as many as 47,000 cancer deaths⁷³ might be prevented each year in America if we employed simple interventions (ie, sunshine or supplementation) to raise vitamin D levels. Of course, additional lives may be saved and suffering reduced by alleviating the morbidity and mortality associated with hypertension, autoimmune disease, depression, epilepsy, migraine, diabetes, polycystic ovary syndrome, musculoskeletal pain, osteoporosis, and cardiovascular disease. **Until proven otherwise, the balance of the research clearly indicates that oral supplementation in the range of 1,000 IU/day for infants, 2,000 IU/day for children, and 4,000 IU/day for adults is safe and reasonable to meet physiologic requirements, to promote optimal health, and to reduce the risk of several serious diseases. Safety and effectiveness of supplementation are assured by periodic monitoring of serum 25(OH)D and serum calcium.**

References

1. Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. *Am J Clin Nutr.* 1999;69(5):842-56.
2. Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. *Am J Clin Nutr.* 2003;77(1):204-10.
3. Holick MF. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. *Am J Clin Nutr.* 2004;79(3):362-71.
4. Vieth R, Chan PC, MacFarlane GD. Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. *Am J Clin Nutr.* 2001;73(2):288-94.
5. Heaney RP. Long-latency deficiency disease: insights from calcium and vitamin D. *Am J Clin Nutr.* 2003;78(5):912-9.
6. Holick MF. Calcium and Vitamin D. Diagnostics and Therapeutics. *Clin Lab Med.* 2000;20(3):569-90.
7. Kamycheva E, Sundsfjord J, Jorde R. Serum parathyroid hormone levels predict coronary heart disease: the Tromso Study. *Eur J Cardiovasc Prev Rehabil.* 2004;11(1):69-74.
8. Sato Y, Kaji M, Metoki N, Satoh K, Iwamoto J. Does compensatory hyperparathyroidism predispose to ischemic stroke? *Neurology.* 2003;60(4):626-9.
9. Fujita T. Calcium paradox: consequences of calcium deficiency manifested by a wide variety of diseases. *J Bone Miner Metab.* 2000;18(4):234-6.
10. Zehnder D, Bland R, Williams MC, McNinch RW, Howie AJ, Stewart PM, Hewison M. Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. *J Clin Endocrinol Metab.* 2001;86(2):888-94.
11. Zittermann A. Vitamin D in preventive medicine: are we ignoring the evidence? *Br J Nutr.* 2003;89(5):552-72.
12. Grant WB. An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. *Cancer.* 2002;94(6):1867-75.
13. Apperly FL. The relation of solar radiation to cancer mortality in North America. *Cancer Res.* 1941;1:191-5.
14. Lansdowne AT, Provost SC. Vitamin D3 enhances mood in healthy subjects during winter. *Psychopharmacology (Berl).* 1998;135(4):319-23.
15. Christiansen C, Rodbro P, Sjo O. "Anticonvulsant action" of vitamin D in epileptic patients? A controlled pilot study. *Br Med J.* 1974;2(913):258-9.
16. Van den Berghe G, Van Roosbroeck D, Vanhove P, Wouters PJ, De Pourcq L, Bouillon R. Bone turnover in prolonged critical illness: effect of vitamin D. *J Clin Endocrinol Metab.* 2003;88(10):4623-32.
17. Timms PM, Mannan N, Hitman GA, Noonan K, Mills PG, Syndercombe-Court D, Aganna E, Price CP, Boucher BJ. Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? *QJM.* 2002;95:787-96.
18. Hypponen E, Laara E, Reunanen A, Jarvelin MR, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. *Lancet.* 2001;358(9292):1500-3.
19. Goldberg P, Fleming MC, Picard EH. Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D. *Med Hypotheses.* 1986 Oct;21(2):193-200.
20. Cantorna MT. Vitamin D and autoimmunity: is vitamin D status an environmental factor affecting autoimmune disease prevalence? *Proc Soc Exp Biol Med.* 2000;223(3):230-3.
21. Wayse V, Yousafzai A, Mogale K, Filteau S. Association of subclinical vitamin D deficiency with severe acute lower respiratory infection in Indian children under 5 y. *Eur J Clin Nutr.* 2004;58(4):563-7.
22. Scragg R. Seasonality of cardiovascular disease mortality and the possible protective effect of ultra-violet radiation. *Int J Epidemiol.* 1981;10(4):337-41.
23. Scragg R, Jackson R, Holdaway IM, Lim T, Beaglehole R. Myocardial infarction is inversely associated with plasma 25-hydroxyvitamin D3 levels: a community-based study. *Int J Epidemiol.* 1990;19(3):559-63.
24. Zittermann A, Schleithoff SS, Tenderich G, Berthold HK, Korfer R, Stehle P. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? *J Am Coll Cardiol.* 2003;41:105-12.
25. Gulati S, Bajpai A, Juneja R, Kabra M, Bagga A, Kalra V. Hypocalcemic heart failure masquerading as dilated cardiomyopathy. *Indian J Pediatr.* 2001;68(3):287-90.
26. Brunvand L, Haga P, Tangsrud SE, Haug E. Congestive heart failure caused by vitamin D deficiency? *Acta Paediatr.* 1995;84(1):106-8.
27. Kini SM, Pednekar SJ, Nabar ST, Varthakavi P. A reversible form of cardiomyopathy. *J Postgrad Med.* 2003;49(1):85-7.
28. Olgun H, Ceviz N, Ozkan B. A case of dilated cardiomyopathy due to nutritional vitamin D deficiency rickets. *Turk J Pediatr.* 2003;45(2):152-4.
29. Price DI, Stanford LC Jr, Braden DS, Ebeid MR, Smith JC. Hypocalcemic rickets: an unusual cause of dilated cardiomyopathy. *Pediatr Cardiol.* 2003;24(5):510-2.
30. Rostand SG. Ultraviolet light may contribute to geographic and racial blood pressure differences. *Hypertension.* 1997;30(2 Pt 1):150-6.
31. Krause R, Buhning M, Hopfenmuller W, Holick MF, Sharma AM. Ultraviolet B and blood pressure. *Lancet.* 1998;352(9129):709-10.
32. Pfeifer M, Begerow B, Minne HW, Nachtigall D, Hansen C. Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. *J Clin Endocrinol Metab.* 2001;86(4):1633-7.
33. Chiu KC, Chu A, Vay LWG, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. *Am J Clin Nutr.* 2004;79:820-5.
34. Borissova AM, Tankova T, Kirilov G, Dakovska L, Kovacheva R. The effect of vitamin D3 on insulin secretion and peripheral insulin sensitivity in type 2 diabetic patients. *Int J Clin Pract.* 2003;57(4):258-61.
35. McAlindon TE, Felson DT, Zhang Y, Hannan MT, Aliajadi P, Weissman B, Rush D, Wilson PW, Jacques P. Relation of dietary intake and serum levels of vitamin D to progression of osteoarthritis of the knee among participants in the Framingham Study. *Ann Intern Med.* 1996;125(5):353-9.
36. Lane NE, Gore LR, Cummings SR, Hochberg MC, Scott JC, Williams EN, Nevitt MC. Serum vitamin D levels and incident changes of radiographic hip osteoarthritis: a longitudinal study. Study of Osteoporotic Fractures Research Group. *Arthritis Rheum.* 1999;42(5):854-60.
37. Mahon BD, Gordon SA, Cruz J, Cosman F, Cantorna MT. Cytokine profile in patients with multiple sclerosis following vitamin D supplementation. *J Neuroimmunol.* 2003;134(1-2):128-32.
38. Gloth FM 3rd, Alam W, Hollis B. Vitamin D vs broad spectrum phototherapy in the treatment of seasonal affective disorder. *J Nutr Health Aging.* 1999;3(1):5-7.
39. Johnson GH, Willis F. Seizures as the presenting feature of rickets in an infant. *Med J Aust.* 2003;178(9):467; discussion 467-8.
40. Ali FE, Al-Bustan MA, Al-Busairi WA, Al-Mulla FA. Loss of seizure control due to anticonvulsant-induced hypocalcemia. *Ann Pharmacother.* 2004;38(6):1002-5.
41. Thys-Jacobs S. Vitamin D and calcium in menstrual migraine. *Headache.* 1994 Oct;34(9):544-6.
42. Thys-Jacobs S, Donovan D, Papadopoulos A, Sarrel P, Bilezikian JP. Vitamin D and calcium dysregulation in the polycystic ovarian syndrome. *Steroids.* 1999;64(6):430-5.
43. Plotnikoff GA, Quigley JM. Prevalence of severe hypovitaminosis D in patients with persistent, nonspecific musculoskeletal pain. *Mayo Clin Proc.* 2003;78(12):1463-70.
44. Masood H, Narang AP, Bhat IA, Shah GN. Persistent limb pain and raised serum alkaline phosphatase the earliest markers of subclinical hypovitaminosis D in Kashmir. *Indian J Physiol Pharmacol.* 1989;33(4):259-61.
45. Al Faraj S, Al Mutairi K. Vitamin D deficiency and chronic low back pain in Saudi Arabia. *Spine.* 2003;28(2):177-9.
46. Yamashita H, Noguchi S, Takatsu K, Koike E, Murakami T, Watanabe S, Uchino S, Yamashita H, Kawamoto H. High prevalence of vitamin D deficiency in Japanese female patients with Graves' disease. *Endocr J.* 2001;48(1):63-9.
47. Falkenbach A, Tripathi R, Sedlmeyer A, Staudinger M, Herold M. Serum 25-hydroxyvitamin D and parathyroid hormone in patients with ankylosing spondylitis before and after a three-week rehabilitation treatment at high altitude during winter and spring. *Wien Klin Wochenschr.* 2001;113(9):328-32.
48. Huisman AM, White KP, Algra A, Harth M, Vieth R, Jacobs JW, Bijlsma JW, Bell DA. Vitamin D levels in women with systemic lupus erythematosus and fibromyalgia. *J Rheumatol.* 2001;28(11):2535-9.
49. Banerjee P, Chatterjee M. Antiproliferative role of vitamin D and its analogs—a brief overview. *Mol Cell Biochem.* 2003;253(1-2):247-54.
50. Trouillas P, Honnorat J, Bret P, Jouve A, Gerard JP. Redifferentiation therapy in brain tumors: long-lasting complete regression of glioblastomas and an anaplastic astrocytoma under long term 1-alpha-hydroxycholecalciferol. *J Neurooncol.* 2001;51(1):57-66.
51. Holick MF. Vitamin D deficiency: what a pain it is. *Mayo Clin Proc.* 2003;78(12):1457-9.
52. Wright JV. Vitamin D: Its Role in Autoimmune Disease and Hypertension. *Townsend Letter for Doctors and Patients.* 2004; May #250: 75-78.
53. Dawson-Hughes B, Harris SS, Dallal GE. Plasma calcidiol, season, and serum parathyroid hormone concentrations in healthy elderly men and women. *Am J Clin Nutr.* 1997;65(1):67-71.
54. Kinyamu HK, Gallagher JC, Rafferty KA, Balhorn KE. Dietary calcium and vitamin D intake in elderly women: effect on serum parathyroid hormone and vitamin D metabolites. *Am J Clin Nutr.* 1998;67(2):342-8.
55. Vasquez A. *Integrative Orthopedics: Concepts, Algorithms, and Therapeutics.* Houston; Natural Health Consulting Corporation (www.OptimalHealthResearch.com): 2004. Pages 417-419 and website updates.
56. Mercola J. Available at: <http://www.mercola.com/forms/vitaminD.htm>. Accessed July 23, 2004.
57. Mercola J. Test Values and Treatment for Vitamin D Deficiency. Available at: http://www.mercola.com/2002/feb/23/vitamin_d_deficiency.htm. Accessed July 23, 2004.
58. Berkow R, Fletcher AJ. *The Merck Manual of Diagnosis and Therapy.* Fifteenth Edition. Rahway; Merck Sharp and Dohme Research Laboratories. 1987: 928, 974-5.
59. Bucci LR, Pillors M, Medlin R, Henderson R, Stiles JC, Robol HJ, Sparks WS. Enhanced uptake in humans of coenzyme Q10 from an emulsified form. Third International Congress of Biomedical Gerontology; Acapulco, Mexico; June 1989.
60. Bucci LR, Pillors M, Medlin R, Klenda B, Robol H, Stiles JC, Sparks WS. *Enhanced blood levels of coenzyme Q-10 from an emulsified oral form.* In Faruqi SR and Ansari MS (editors). Second Symposium on Nutrition and Chiropractic Proceedings. April 15-16, 1989 in Davenport, Iowa.
61. Hollis BW, Wagner CL. Assessment of dietary vitamin D requirements during pregnancy and lactation. *Am J Clin Nutr.* 2004;79(5):717-26.
62. O'Leary JA, Klainer LM, Neuwirth RS. The management of hypoparathyroidism in pregnancy. *Am J Obstet Gynecol.* 1966;94(8):1103-7.
63. Goodenay LS, Gordon GS. No risk from vitamin D in pregnancy. *Ann Intern Med.* 1971;75(5):807-8.
64. Horrobin DF. Interactions between n-3 and n-6 essential fatty acids (EFAs) in the regulation of cardiovascular disorders and inflammation. *Prostaglandins Leukot Essent Fatty Acids.* 1991;44(2):127-31.
65. Utiger RD. The need for more vitamin D. *N Engl J Med.* 1998;338:828-9.
66. Thomas MK, Lloyd-Jones DM, Thadhani RI, Shaw AC, Deraska DJ, Kitch BT, Vamvakas EC, Dick IM, Prince RL, Finkelstein JS. Hypovitaminosis D in medical inpatients. *N Engl J Med.* 1998;338(12):777-83.
67. Gordon CM, DePeter KC, Feldman HA, Grace E, Emans SJ. Prevalence of vitamin D deficiency among healthy adolescents. *Arch Pediatr Adolesc Med.* 2004;158(6):531-7.
68. Nesby-O'Dell S, Scanlon KS, Cogswell ME, Gillespie C, Hollis BW, Looker AC, Allen C, Dougherty C, Gunter EW, Bowman BA. Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: third National Health and Nutrition Examination Survey, 1988-1994. *Am J Clin Nutr.* 2002;76:187-92.
69. Buffington C, Walker B, Cowan GS Jr, Scruggs D. Vitamin D Deficiency in the Morbidly Obese. *Obes Surg.* 1993;3:421-424.
70. Fraser DR. Vitamin D-deficiency in Asia. *J Steroid Biochem Mol Biol.* 2004;89-90:491-5.
71. Kauppinen-Makelin R, Tahela R, Lyytyniemi E, Karkkainen J, Valimaki MJ. A high prevalence of hypovitaminosis D in Finnish medical in- and outpatients. *J Intern Med.* 2001;249(6):559-63.
72. Ellis A. Inertia on folic acid has caused thousands of unnecessary deaths. *BMJ.* 2003;326(7398):1054.
73. Grant WB. Personal communication by email, "My current estimate is 47,000 premature cancer deaths/year." June 3, 2004.

CME

CONTINUING MEDICAL EDUCATION

CME TEST INSTRUCTIONS

To receive 2.0 hours of CME credit for this article, visit www.cecmeonline.com, log in, purchase the CME course for \$10 and take the online test. This test is valid for 1 year from the date of publication. Within 3 to 4 weeks of InnoVision Communications receiving your completed online test, you will receive a CME certificate.

InnoVision Communications is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. InnoVision Communications designates these educational activities on an hour-for-hour basis toward category 1 credit of the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

CME TEST QUESTIONS*

THE CLINICAL IMPORTANCE OF VITAMIN D (CHOLECALCIFEROL): A PARADIGM SHIFT WITH IMPLICATIONS FOR ALL HEALTHCARE PROVIDERS

In the following questions, only one answer is correct.

- In clinical trials, augmentation of vitamin D levels with ultraviolet light exposure or oral supplementation has been shown to benefit which of the following conditions:
 - Osteoporosis; Hypertension
 - Depression; Multiple sclerosis
 - Back pain; Insulin resistance
 - All of the above
- In the absence of vitamin D supplementation, ultraviolet light exposure (ie, sunshine) can produce 25(OH)D levels that exceed current laboratory reference ranges:
 - True
 - False
- Which of the following can cause hypercalcemia?
 - Sarcoidosis and Crohn's disease
 - Adrenal insufficiency and hypothyroidism
 - Coadministration of vitamin D and thiazide diuretics
 - All of the above
- According to the current research literature reviewed in this article, which of the following may be considered long-latency deficiency diseases associated with insufficiency of vitamin D?
 - Metabolic syndrome
 - Autoimmune disease such as multiple sclerosis and type 1 diabetes
 - Depression and cancer
 - All of the above
- If a patient has hypovitaminosis D and a vitamin D-responsive condition such as depression, hypertension, insulin resistance, or multiple sclerosis, which of the following is appropriate first-line treatment?
 - Drugs only
 - Vitamin D only
 - Correction of the vitamin D deficiency, and co-administration of medications if necessary
 - Use of synthetic vitamin D analogs
- Since vitamin D is highly effective for the prevention and alleviation of several health problems, and because it has a wide range of safety, physiologic doses should be regulated as a prescription drug and prohibited from public access:
 - True
 - False
- Given the prevalence and consequences of vitamin D deficiency, failure to test for and treat vitamin D insufficiency is ethical:
 - True
 - False
- Since vitamin D has a wide margin of safety, patients should be administered vitamin D routinely and receive which of the following types of monitoring:
 - Periodic measurement of serum 1,25-dihydroxyvitamin D (calcitriol) and urinary creatinine
 - Periodic measurement of serum 25-hydroxyvitamin D (calcidiol) and serum calcium
 - Clinical assessments only
 - Liver function tests and electrocardiography

* See page 94 for Self-Assessment answers


INFLAMMATION MASTERY

4TH EDITION

CLINICAL NUTRITION, FUNCTIONAL MEDICINE, MITOCHONDRIAL DYSFUNCTION, MICROBIOME & DYSBIOSIS, FUNCTIONAL INFLAMMOLOGY, PAIN MANAGEMENT, INTEGRATIVE RHEUMATOLOGY, NUTRITIONAL IMMUNOMODULATION, IMMUNONUTRITION & ANTIVIRAL STRATEGIES

The Colorful and Definitive Guide Toward Health and Vitality
*and away from the Boredom, Risks, Costs, and Inefficacy of
Endless Analgesia, Immunosuppression, and Polypharmacy*

3-Part Learning System of Text, Illustrations, and Video



DR. ALEX VASQUEZ

ICHNFM.ORG

INTERNATIONAL COLLEGE OF HUMAN NUTRITION AND FUNCTIONAL MEDICINE

Chapter and Introduction		Page
Preamble		i
1.	<u>Patient Assessments, Laboratory Interpretation, Clinical Concepts, Patient Management, Practice Management and Risk Reduction:</u> <i>This chapter introduces/reviews/updates patient assessments, laboratory interpretation, musculoskeletal emergencies, healthcare paradigms; the common and important conditions hemochromatosis and hypothyroidism are also included in this chapter since these need to be considered on a frequent basis in clinical practice</i>	1
2.	<u>Wellness Promotion & Re-Establishing the Foundation for Health:</u> <i>Reviewed here are diet, lifestyle, psychosocial health, and – given the pervasiveness of persistent organic pollutants and their increasingly recognized clinical importance – an introduction to environmental medicine</i>	187
3.	<u>Basic Concepts and Therapeutics in (Nondrug) Musculoskeletal Care and Integrative Pain Management:</u> <i>Nonpharmacologic management of musculoskeletal problems is preferred over pharmacologic (e.g., NSAID, Coxib, steroid, opioid) management because of the collateral benefits, safety, and cost-effectiveness associated with manual, dietary, botanical, and nutritional treatments. A brief discussion of the current crisis in musculoskeletal medicine is provided for contextualization and emphasis of the importance of expanding clinicians' knowledge of effective nondrug treatments</i>	243
4.	<u>The Major Modifiable Factors in Sustained Inflammation:</u> <i>Major components of the "Functional Inflammation Protocol" are reviewed here, from concepts and molecular biology to an emphasis on practical clinical applications</i>	303
	1) Food & Basic Nutrition	307
	2) Infections: Dysbiosis / Viral	396 / 540
	3) Nutritional Immunomodulation	609
	4) Dysmetabolism, Mitochondrial Dysfunction, ERS/UPR, mTOR	622
	5) Special Considerations: Sleep, Sociopsychology, Stress, Surgery	674
	6) Endocrine Imbalances	688
	7) Xenobiotic Immunotoxicity	699
5.	<u>Clinical Applications</u>	713
	1) Hypertension	727
	2) Diabetes Mellitus	819
	3) Migraine & Headaches	863
	4) Fibromyalgia	901
	5) Allergic Inflammation	984
	6) Rheumatoid Arthritis	1019
	7) Psoriasis and Psoriatic Arthritis	1038
	8) Systemic Lupus Erythematosus	1053
	9) Scleroderma & Systemic Sclerosis	1074
	10) Vasculitic Diseases	1094
	11) Spondyloarthropathies & Reactive Arthritis	1108
	12) Sjögren Syndrome/Disease	1119
	13) Raynaud's Syndrome/Phenomenon/Disorder	1127
	14) Clinical Notes on Additional Conditions: Behçet's Disease, Sarcoidosis, Dermatomyositis and Polymyositis	1131
Index & Appendix		1154

Chapter 4:

Introduction to DrV's Functional Inflammation Protocol: The Seven Major Modifiable Factors in Systemic Inflammation, Allergy, and Autoimmunity

Major Modifiable Influences on Immune and Inflammatory Balance

This section reviews clinically-relevant information related to the pathogenesis and etiology of inflammatory/allergic/autoimmune conditions. Following extensive reviews of the research literature in conjunction with the author's impressively successful clinical experience with patients with "idiopathic" and inflammatory/autoimmune disorders, the original version of this information was published in the first edition of *Integrative Rheumatology* (2006). This section is a distillation of thousands of research articles, abstracts, seminar notes, conversations with colleagues, one-on-one patient encounters and the author's own considerations and reflections.

Following my review and perusal of thousands of research articles in addition to the attentive application of my interest in these conditions throughout three doctoral programs, I have come to appreciate seven major modifiable factors that are chiefly relevant for the initial and long-term management of patients with inflammatory conditions and rheumatic diseases. These 7 factors are:

1. **Food intake and nutritional status:** The pro/anti-inflammatory effects of diet, including food allergies and intolerances, nutrient deficiencies and dependencies,
2. **Infections and dysbiosis:** Chronic exposure to microbial effectors/effects,
3. **Nutritional modulation of the immune system:** Nutrigenomic modification of immunocyte phenotype,
4. **Dysmetabolism and Dysfunctional organelles, most notably mitochondria:** Especially the pro-inflammatory, pro-oxidant, and anti-apoptotic consequences of dysfunctional mitochondria (DysMito or MitoDys); more recently the conversation has extended beyond mitochondrial dysfunction to include endoplasmic reticulum stress/dysfunction (ERS) and resultant unfolded protein response (UPR),
5. **Stress, sleep deprivation vs sleep sufficiency, spinal health, social and psychological considerations:** Included in this section is a collection of important considerations which—in the first draft of this acronym—started with stress management, sleep hygiene, and pSychological and social factors. Later versions have included spinal health (chiropractic model), somatic dysfunction (osteopathic model), surgery, specialized supplementation, and "stamp your passport"—sometimes we all just need to vacate for a while and implement some *geographic cure* for the sake of inspiration, life enhancement, exposure to new ideas and lifestyles, and the breaking of (dysfunctional) thought patterns and routines,
6. **Endocrine imbalances:** Hormones can promote or retard the genesis and perpetuation of inflammation/allergy/autoimmunity; therapeutic correction with prescription or nonprescription interventions can have a profound anti-inflammatory benefit.
7. **Xenobiotic immunotoxicity:** Exposure to and accumulation of toxic chemicals and/or toxic metals can alter immune responses toward allergy and autoimmunity and away from immunosurveillance against infections and cancer.

Common diseases such as psoriasis and rheumatoid arthritis are greater public health concerns and are more commonly encountered in clinical practice than are the more rare conditions; proportionate mention is made in the following section. Importantly, readers should appreciate that the information in various sections likely applies either conceptually or specifically to conditions described in other sections and that therefore the best way to understand inflammatory/allergic/autoimmune disorders in their totality is to appreciate the nuances of each and the common themes among all.

I am quite pleased to see that the original five variables that I defined in the first two editions of *Integrative Rheumatology* (2006, 2007) have stood the tests of time, science, and clinical practice: in fact, all have been strengthened in the intervening years.

Affirmation and consistency of common themes in an interconnected reality; the importance of transitioning from reception to comprehension to conception to behavior


"The fact that today I still stand by these ideas, **that in the intervening time they themselves have constantly become more strongly associated with one another, even to the point of growing into each other, intertwining, and becoming one**, that has reinforced in me the joyful confidence that they may not have originally developed in me as single, random, or sporadic ideas, but up out of common roots, from some fundamental *will for knowledge* ruling from deep within, always speaking with greater clarity, always demanding greater clarity.

In fact, this is the only thing appropriate and proper for a philosopher. **We have no right to be isolated in any way: we are not permitted to make isolated mistakes or to run into isolated truths.** Our ideas, our values, our affirmations and denials, our *ifs* and *buts*—these rather grow out of us from the same necessity which makes a tree bear its fruit—totally related and interlinked amongst each other: witnesses of one will, one health, one soil, one sun."

Nietzsche FW. *On the Genealogy of Morals*, 1887, Preface essay #2

"In order for a particular species to maintain itself and increase its power, **its conception of reality must comprehend enough of the calculable and constant for it to base a scheme of behavior on it.**"

Nietzsche FW. *Will to Power*, 1901, #480



Inflammation in a simple cause-and-effect diagram: The major causative factors amenable to clinical implementation are represented, along with the pathophysiologic consequences and clinical effects. Molecular details, clinical assessments, and therapeutic interventions are introduced/reviewed in this chapter; in later volumes of this work, clinical protocols detail the drugs and doses, etc.

1 Food: Diet and Basic Nutritional Supplementation

Major Concepts in this Section

"Food" is the first part of the protocol and the foundation of the overall plan, not simply for improving nutritional status, but for setting the biochemical stage for more profound improvements in immune balance, mitochondrial function, et al. Patients can and should appreciate that they have near complete control over what they consume; unfortunately and conversely, however, in countries such as the United States where much of the food supply is contaminated with pesticide residues and genetically manipulated food-type (GMO) products, consuming a health-promoting diet can present unique challenges.

Contents of this section:

1. Introduction to Nutrigenomics: Gene-Expression Effects of Foods and Nutrients
2. Basic Concepts and Practical Applications via Previously Published Articles
 - a. A Five-Part Nutritional Wellness Protocol That Produces Consistently Positive Results: Brief Review of Scientific Rationale
 - b. Implementing the Five-Part Nutritional Wellness Protocol for the Treatment of Various Health Problems
 - c. Common Oversights and Shortcomings in the Study and Implementation of Nutritional Supplementation
 - d. Revisiting the Five-Part Nutritional Wellness Protocol: The Supplemented Paleo-Mediterranean Diet
3. Diet Details, Biochemical Concepts, and Clinical Pearls
 - a. Macronutrients and "The Big Picture": Protein, Carbohydrates, Lipids, Fiber, pH Balance
 - b. Micronutrients and Nutritional Supplementation—Overview and Concepts: Vitamins, Minerals, Combination Fatty Acids, Probiotics
 - c. Additional Considerations: GMO (Genetically Manipulated Organisms/Foods) and related toxins, Gluten, Fructose, TLR, AGE/RAGE, food-induced hypothalamic inflammation, GPR-120
4. Additional Details and Mini-Monographs:
 - a. The Major Fatty Acids and End-products of Clinical Significance
 - b. NFkB and Its Phytonutritional Modulation
 - c. Food Allergy and Adverse Food Reactions: A few considerations and perspectives

Introduction to Nutrigenomics: Pro-Inflammatory and Anti-Inflammatory Effects of Foods and Nutrients

We must look beyond the nutritional properties of foods to appreciate that dietary patterns and the consumption of specific foods can influence genetic expression and either promote or retard the development of inflammation and related clinical disorders. The purpose of this section is to help clinicians attain a more profound understanding of the value of nutrition and its critical role as a foundational component in the treatment plan of patients with inflammatory disorders. The "correct" diet for the vast majority of patients with inflammatory disorders is the "supplemented Paleo-Mediterranean diet" which I have described in several other publications. The diet is modified for the specific exclusion of allergenic foods; it is implemented on a rotation basis, and it allows for periodic fasting and vegetarianism/veganism. The implementation of health-promoting dietary modifications is an *absolutely mandatory* component of the treatment plan, upon which other treatments depend for their success. The study of how dietary components and nutritional supplements influence genetic expression is referred to as *nutrigenomics* or *nutritional genomics* and has been described as "the next frontier in the postgenomic era."⁷ Various nutrients have been shown to modulate genetic expression and thus alter phenotypic manifestations of disease by upregulating or downregulating specific genes, interacting with nuclear receptors, altering hormone receptors, and modifying the influence of transcription factors, such as pro-inflammatory NFkB (NFkB) and the anti-inflammatory peroxisome-proliferator activated receptors (PPARs),^{8,9,10,11} **The previous view that nutrients only interact with human physiology at the metabolic/post-transcriptional level must be updated in light of current research showing that nutrients can, in fact, modify human physiology and phenotype at the genetic/pre-transcriptional**

⁷ Kaput J, Rodríguez RL. Nutritional genomics: the next frontier in the postgenomic era. *Physiol Genomics*. 2004 Jan 15;16(2):166-77. Very important article.

⁸ Vamecq J, Latruffe N. Medical significance of peroxisome proliferator-activated receptors. *Lancet*. 1999;354:141-8

⁹ Ehrmann et al. Peroxisome proliferator-activated receptors (PPARs) in health and disease. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub*. 2002 Dec;146(2):11-4

¹⁰ Kliewer SA, Xu HE, Lambert MH, Willson TM. Peroxisome proliferator-activated receptors: from genes to physiology. *Recent Prog Horm Res*. 2001;56:239-63

¹¹ Delerive P, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors in inflammation control. *J Endocrinol*. 2001;169(3):453-9

level. Fatty acids and their *icosanoid*, *leukotriene*, and *isoprostane* intermediates and end-products modulate genetic expression in several ways. In general, n-3 fatty acids decrease inflammation and promote health while n-6 fatty acids (except for GLA, which is generally health-promoting) increase inflammation, oxidative stress, and the manifestation of disease. Corn oil, probably as a result of its high n-6 LA (linoleic acid) content, rapidly activates NFκB and thus promotes tumor development, atherosclerosis, and elaboration of proinflammatory mediators such as TNFα.^{12,13,14} Similarly n-6 arachidonic acid increases production of the free radical *superoxide* approximately 4-fold when added to isolated Kupffer cells *in vitro*. Prostaglandin-E2 is produced from arachidonic acid by cyclooxygenase and increases genetic expression of cyclooxygenase and IL-6; thus, an increase in PG-E2 leads to additive expression of cyclooxygenase, which further increases inflammation and elevates C-reactive protein.¹⁵ Some of the unique health-promoting effects of GLA are nutrigenomically mediated via activation of PPAR-γ, resultant inhibition of NFκB, and impairment of estrogen receptor function.^{16,17} Supplementation with ALA leads to a dramatic reduction of prostaglandin formation in humans¹⁸, and this effect is probably mediated by downregulation of proinflammatory gene transcription, as evidenced by reductions in CRP, IL-6, and serum amyloid A.¹⁹ EPA appears to exert much of its anti-inflammatory benefit by suppressing NFκB activation and thus reducing elaboration of proinflammatory mediators.^{20,21} EPA also indirectly modifies gene expression and cell growth by reducing intracellular calcium levels and thus activating protein kinase R which impairs eukaryotic initiation factor-2α and inhibits protein synthesis at the level of translation initiation, thereby mediating an anti-cancer benefit.²² DHA is the precursor to docosatrienes and resolvins which downregulate gene expression for IL-1, inhibit TNFα, and reduce neutrophil entry to sites of inflammation.²³ Oxidized EPA activates PPAR-α and thereby suppresses NFκB.^{24,25} Other nutrients that inhibit the activation of NFκB include vitamin D^{26,27}, lipoic acid²⁸, green tea²⁹, rosemary³⁰, grape seed extract³¹, resveratrol^{32,33}, caffeic acid phenethyl ester (CAPE) from bee propolis³⁴, indole-3-carbinol³⁵, N-acetyl-L-cysteine³⁶, selenium³⁷, and zinc.³⁸ Therefore, we see that fatty acids and nutrients

¹² Rusyn I, et al. Corn oil rapidly activates nuclear factor-kappaB in hepatic Kupffer cells by oxidant-dependent mechanisms. *Carcinogenesis*. 1999 Nov;20(11):2095-100

¹³ Rose DP, et al. Effect of diets containing different levels of linoleic acid on human breast cancer growth and lung metastasis in nude mice. *Cancer Res* 1993;53:4686-90

¹⁴ Dichtl et al. Linoleic acid-stimulated vascular adhesion molecule-1 expression in endothelial cells depends on nuclear factor-kappaB. *Metabolism* 2002;51:327-33

¹⁵ Bagga et al. Differential effects of prostaglandin from n-6 and n-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. *Proc Natl Acad Sci*. 2003 Feb;175:1-6.

¹⁶ Mendendez JA, Colomer R, Lupu R. Omega-6 polyunsaturated fatty acid gamma-linolenic acid (18:3n-6) is a selective estrogen-response modulator in human breast cancer cells: gamma-linolenic acid antagonizes estrogen receptor-dependent transcriptional activity, transcriptionally represses estrogen receptor expression and synergistically enhances tamoxifen and ICI 182,780 (Faslodex) efficacy in human breast cancer cells. *Int J Cancer*. 2004 May 10;109(6):949-54

¹⁷ Jiang WG, Redfern A, Bryce RP, Mansel RE. Peroxisome proliferator activated receptor-gamma (PPAR-gamma) mediates the action of gamma linolenic acid in breast cancer cells. *Prostaglandins Leukot Essent Fatty Acids*. 2000 Feb;62(2):119-27

¹⁸ Adam O, et al. Effect of alpha-linolenic acid in the human diet on linoleic acid metabolism and prostaglandin biosynthesis. *J Lipid Res*. 1986 Apr;27(4):421-6

¹⁹ Rallidis et al. Dietary alpha-linolenic acid decreases C-reactive protein, serum amyloid A and interleukin-6 in dyslipidaemic patients. *Atherosclerosis*. 2003;167:237-42

²⁰ Zhao et al. Eicosapentaenoic acid prevents LPS-induced TNF-alpha expression by preventing NFκB activation. *J Am Coll Nutr*. 2004 Feb;23(1):71-8

²¹ Mishra et al. Oxidized omega-3 fatty acids inhibit NFκB activation via a PPARalpha-dependent pathway. *Arterioscler Thromb Vasc Biol*. 2004 Sep;24:1621-7

²² Palakurthi et al. Inhibition of translation initiation mediates the anti-cancer effect of the n-3 polyunsaturated fatty acid EPA. *Cancer Res*. 2000 Jun 1;60(11):2919-25

²³ "These results indicate that DHA is the precursor to potent protective mediators generated via enzymatic oxygenations to novel docosatrienes and 17S series resolvins that each regulate events of interest in inflammation and resolution." Hong S, Gronert K, Devchand PR, Moussignac RL, Serhan CN. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. *J Biol Chem*. 2003 Apr 25;278(17):14677-87

²⁴ Mishra et al. Oxidized omega-3 fatty acids inhibit NFκB activation via a PPARalpha-dependent pathway. *Arterioscler Thromb Vasc Biol*. 2004 Sep;24:1621-7

²⁵ Delerive P, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors in inflammation control. *J Endocrinol*. 2001;169(3):453-9

²⁶ "1Alpha,25-dihydroxyvitamin D3 (1,25-(OH)2-D3), the active metabolite of vitamin D, can inhibit NFκB activity in human MRC-5 fibroblasts, targeting DNA binding of NFκB ..."

²⁷ Harant et al. 1Alpha,25-dihydroxyvitamin D3 decreases DNA binding of nuclear factor-kappaB in human fibroblasts. *FEBS Lett*. 1998 Oct 9;436(3):329-34

²⁸ "Thus, 1,25(OH)2D3 may negatively regulate IL-12 production by downregulation of NF-κB activation and binding to the p40-kB sequence." D'Ambrosio D, et al. Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NFκB downregulation. *J Clin Invest*. 1998 Jan 1;101(1):252-62

²⁹ "ALA reduced TNF-alpha-stimulated ICAM-1 expression in a dose-dependent manner, to levels observed in unstimulated cells. Alpha-lipoic acid also reduced NFκB activity in a dose-dependent manner." Lee et al. Alpha-lipoic acid modulates NFκB activity in human monocytic cells by direct interaction with DNA. *Exp Gerontol*. 2002 Jan;40:1-10

³⁰ "In conclusion, EGCG is an effective inhibitor of IKK activity. This may explain, at least in part, some of the reported anti-inflammatory and anti-cancer effects of green tea." Yang et al. The green tea polyphenol (-)-epigallocatechin-3-gallate blocks nuclear factor-kappa B activation by inhibiting I kappa B kinase activity in the intestinal epithelial cell line IEC-6. *Mol Pharmacol*. 2001 Sep;60(3):528-33

³¹ "These results suggest that carnosol suppresses the NO production and iNOS gene expression by inhibiting NFκB activation, and provide possible mechanisms for its anti-inflammatory and chemopreventive action." Lo AH, Liang YC, Lin-Shiau SY, Ho CT, Lin JK. Carnosol, an antioxidant in rosemary, suppresses inducible nitric oxide synthase through down-regulating nuclear factor-kappaB in mouse macrophages. *Carcinogenesis*. 2002 Jun;23(6):983-91

³² "Constitutive and TNFα-induced NFκB DNA binding activity was inhibited by GSE at doses > or =50 microg/ml and treatments for > or =12 h." Dhanalakshmi et al. Inhibition of NFκB pathway in grape seed extract-induced apoptotic death of human prostate carcinoma DU145 cells. *Int J Oncol*. 2003 Sep;23(3):721-7

³³ "Resveratrol's anticarcinogenic, anti-inflammatory, and growth-modulatory effects may thus be partially ascribed to the inhibition of activation of NFκB and AP-1 and the associated kinases." Manna SK, Mukhopadhyay A, Aggarwal BB. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-κappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. *J Immunol*. 2000 Jun 15;164(12):6509-19

³⁴ "Both resveratrol and quercetin inhibited NFκB-, AP-1- and CREB-dependent transcription to a greater extent than the glucocorticosteroid, dexamethasone." Donnelly LE, et al. Anti-inflammatory Effects of Resveratrol in Lung Epithelial Cells. *Am J Physiol Lung Cell Mol Physiol*. 2004 Oct;287(4):L774-83

³⁵ "Caffeic acid phenethyl ester (CAPE) is an anti-inflammatory component of propolis (honeybee resin). CAPE is reportedly a specific inhibitor of nuclear factor-kappaB (NFκB)." Fitzpatrick LR, Wang J, Le T. Caffeic acid phenethyl ester, an inhibitor of nuclear factor-kappaB, attenuates bacterial peptidoglycan polysaccharide-induced colitis in rats. *J Pharmacol Exp Ther*. 2001 Dec;299(3):915-20


³⁶ Takada Y, Andreeff M, Aggarwal BB. Indole-3-carbinol suppresses NF-κappaB and IκappaBα kinase activation causing inhibition of expression of NF-κappaB-regulated antiapoptotic and metastatic gene products and enhancement of apoptosis in myeloid and leukemia cells. *Blood*. 2005 Apr 5; [Epub ahead of print]

³⁷ Paterson RL, Galley HF, Webster NR. The effect of N-acetylcysteine on nuclear factor-kappa B activation, interleukin-6, interleukin-8, and intercellular adhesion molecule-1 expression in patients with sepsis. *Crit Care Med*. 2003 Nov;31(11):2574-8

³⁸ Faure et al. Selenium supplementation decreases nuclear factor-kappa B activity in blood mononuclear cells from type 2 diabetic patients. *Eur J Clin Invest*. 2004;34(7):475-81

³⁹ Uzzo et al. Zinc inhibits nuclear factor-kappa B activation and sensitizes prostate cancer cells to cytotoxic agents. *Clin Cancer Res*. 2002;8(11):3579-83

directly affect gene expression by complex and multiple mechanisms, as graphically illustrated in the accompanying diagram, and the synergism and potency of these anti-inflammatory nutraceuticals supports the rationale for the use of nutrition and select botanicals for the safe and effective treatment of inflammatory disorders.



Schematic Representation of Simultaneous Nutrigenomic and Metabolic Effects of Nutrients: Although conceptually accurate, this diagram is highly simplified and not all-inclusive; rather, this diagram focuses exclusively on nutrients that affect the NFkB pathway. Updated from Vasquez 2005.³⁹

³⁹ Vasquez A. New Insights into Fatty Acid Supplementation and Its Effect on Eicosanoid Production and Genetic Expression. *Nutritional Perspectives* 2005; Jan: 5-16

A Five-Part Nutritional Wellness Protocol That Produces Consistently Positive Results: Brief Review of Scientific Rationale

This article was originally published in *Nutritional Wellness*
nutritionalwellness.com/archives/2005/sep/09_vasquez.php

Introduction: When I am lecturing here in the U.S., as well as in Europe, doctors often ask if I will share the details of my protocols with them. Thus, in 2004, I published a 486-page textbook for doctors that includes several protocols and important concepts for the promotion of wellness and treatment of musculoskeletal disorders.⁴⁰ In this article, I will share with you what I consider a basic protocol for wellness promotion. I've implemented this protocol as part of the treatment plan for a wide range of clinical problems. In my next column, I will provide several case reports of patients from my office to exemplify the effectiveness of this program and show how it can be the foundation upon which additional treatments can be added as necessary.

Nutrients are required in the proper amounts, forms, and approximate ratios for essential physiologic function; if nutrients are lacking, the body cannot function normally, let alone optimally. Impaired function results in subjective and objective manifestations of what is commonly labeled as "disease." Thus, a powerful and effective alternative to treating diseases with drugs is to re-establish normal/optimal physiologic function by replenishing the body with essential nutrients.

Of course, many diseases are multifactorial and therefore require multicomponent treatment plans, and some diseases actually require the use of drugs. However, while only a relatively small portion of patients actually need drugs for their problems, I am sure we all agree that everyone needs a foundational nutrition plan, as outlined and substantiated below.

1. **Health-promoting diet:** Following an extensive review of the research literature, I developed what I call the "supplemented Paleo-Mediterranean diet," which I have described in greater detail elsewhere.⁴¹ In essence, this diet plan combines the best of the Mediterranean diet with the best of the Paleolithic diet, the latter of which has been detailed and popularized by Dr. Loren Cordain in his book, *The Paleo Diet*, and his numerous scientific articles.⁴² This diet places emphasis on fruits, vegetables, nuts, seeds, and berries that meet the body's needs for fiber, carbohydrates, and most importantly, the 8,000+ phytonutrients that have additive and synergistic health benefits.⁴³ Preferred protein sources are lean meats such as fish and poultry. In contrast to Cordain's Paleo diet, I also advocate soy and whey for their high-quality protein and anticancer, cardioprotective, and mood-enhancing benefits. Rice and potatoes are discouraged due to their relatively high glycemic indexes and high glycemic loads, and their lack of fiber and phytonutrients (compared to other fruits and vegetables). Generally speaking, grains such as barley, rye, and wheat (e.g., the "toxic triad" of inflammatory gluten) are discouraged due to the high glycemic loads/indexes of most breads and pastries, as well as the allergenicity/immunogenicity of gluten, a protein that appears to help trigger disorders such as migraine, celiac disease, psoriasis, epilepsy, and autoimmunity. Sources of simple sugars such as high-fructose corn syrup (e.g., cola, soda) and processed foods (e.g., "TV dinners" and other manufactured snacks and convenience foods) are strictly forbidden. Chemical preservatives, colorants, sweeteners and carrageenan are likewise prohibited. In summary, this diet plan provides plenty of variety, as most dishes comprised of poultry, fish, soy, fruits, vegetables, nuts, berries, and seeds are allowed. The diet also provides plenty of fiber, phytonutrients, carbohydrates, potassium, and protein, while simultaneously being low in fat, sodium, arachidonic acid, and "simple sugars." The diet must be customized with regard to total protein and calorie intake, as determined by the size, status, and activity level of the patient, and individual food allergens should be avoided. Regular consumption of this diet has shown the ability to reduce hypertension, alleviate diabetes, ameliorate migraine headaches, and result in improvement of overall health and a lessening of the severity of many common "diseases." This diet is supplemented with vitamins, minerals, and fatty acids as described below.
2. **Multivitamin and multimineral supplementation:** Vitamin and mineral supplementation finally received endorsement from "mainstream" medicine when researchers from Harvard Medical School published a review

⁴⁰ Vasquez A. *Integrative Orthopedics: The Art of Creating Wellness While Managing Acute and Chronic Musculoskeletal Disorders*. 2004, 2007, 2012

⁴¹ Vasquez A. The Importance of Integrative Chiropractic Health Care in Treating Musculoskeletal Pain and Reducing the Nationwide Burden of Medical Expenses and Iatrogenic Injury and Death: Concise Review of Current Research and Implications for Clinical Practice and Healthcare Policy. *The Original Internist* 2005; 12(4): 159-182

⁴² Cordain L. *The Paleo Diet*. (John Wiley and Sons, 2002). Also: Cordain L. Cereal grains: humanity's double edged sword. *World Rev Nutr Diet* 1999;84:19-73 Access to most of Dr Cordain's articles is available at thepaleodiet.com/

⁴³ Liu RH. Health benefits of fruit and vegetables are from additive and synergistic combinations of phytochemicals. *Am J Clin Nutr* 2003;78(3 Suppl):517S-520S

article in *Journal of the American Medical Association* that concluded, "Most people do not consume an optimal amount of all vitamins by diet alone. ...It appears prudent for all adults to take vitamin supplements."⁴⁴ Long-term nutritional insufficiencies experienced by the majority of the population promote the development of "long-latency deficiency diseases" such as cancer, neuroemotional deterioration, and cardiovascular disease.⁴⁵ Impressively, the benefits of multivitamin/multimineral supplementation have been demonstrated in numerous clinical trials. Multivitamin/multimineral supplementation has been shown to improve nutritional status and reduce the risk for chronic diseases⁴⁶, improve mood⁴⁷, potentiate antidepressant drug treatment⁴⁸, alleviate migraine headaches (when used with diet improvement and fatty acids⁴⁹), improve immune function and infectious disease outcomes in the elderly⁵⁰ (especially diabetics⁵¹), reduce morbidity and mortality in patients with HIV infection^{52,53} alleviate premenstrual syndrome^{54,55} and bipolar disorder⁵⁶, reduce violence and antisocial behavior in children⁵⁷ and incarcerated young adults (when used with essential fatty acids⁵⁸), and improve scores of intelligence in children.⁵⁹ Vitamin supplementation has anti-inflammatory benefits, as evidenced by significant reduction in C-reactive protein, (CRP) in a double-blind, placebo-controlled trial.⁶⁰ The ability to safely and affordably deliver these benefits makes multimineral-multivitamin supplementation an essential component of any and all health-promoting and disease-prevention strategies. Vitamin A can result in liver damage with chronic consumption of 25,000 IU or more, and intake should generally not exceed 10,000 IU per day in women of childbearing age. Iron should not be supplemented except in patients diagnosed with iron deficiency by the blood test ferritin. Additional vitamin D should be used, as described in the next section.

3. **Physiologic doses of vitamin D3:** The prevalence of vitamin D deficiency varies from 40 percent (general population) to almost 100 percent (patients with musculoskeletal pain) in the American population. I described the many benefits of vitamin D3 supplementation in the previous issue of *Nutritional Wellness* and in the major monograph published in 2004.⁶¹ In summary, vitamin D deficiency causes or contributes to depression, hypertension, seizures, migraine, polycystic ovary syndrome, inflammation, autoimmunity, and musculoskeletal pain such as low-back pain. Clinical trials using vitamin D supplementation have proven the cause-and-effect relationship between vitamin D deficiency and these conditions by showing that each of these could be cured or alleviated with vitamin D supplementation. In our review of the literature, we concluded that daily vitamin D doses should be 1,000 IU for infants, 2,000 IU for children, and 4,000 IU for adults. Cautions and contraindications include the use of thiazide diuretics (e.g., hydrochlorothiazide) or any other medications that can promote hypercalcemia, as well as granulomatous diseases such as sarcoidosis, tuberculosis, and certain types of cancer, especially lymphoma. Effectiveness is monitored by measuring serum 25-OH-vitamin D, and safety is monitored by measuring serum calcium.
4. **Balanced and complete fatty acid supplementation:** A detailed survey of the literature reveals five major health-promoting anti-inflammatory fatty acids found in the human diet.⁶² These are alpha-linolenic acid (ALA; omega-3, from flaxseed oil), eicosapentaenoic acid (EPA; omega-3, from fish oil), docosahexaenoic acid (DHA; omega-3, from fish oil and algae), gamma-linolenic acid (GLA; omega-6, most concentrated in borage oil), and oleic acid (omega-9, mainly from olive oil, also found in flaxseed and borage oils). Each of these fatty acids has health benefits that cannot be fully attained from supplementing a different fatty acid. The benefits of GLA

⁴⁴ Fletcher RH, Fairfield KM. Vitamins for chronic disease prevention in adults: clinical applications. *JAMA* 2002;287:3127-9

⁴⁵ Heaney RP. Long-latency deficiency disease: insights from calcium and vitamin D. *Am J Clin Nutr* 2003;78:912-9

⁴⁶ McKay DL, Perrone G, Rasmussen H, Dallal G, Hartman W, Cao G, Prior RL, Roubenoff R, Blumberg JB. The effects of a multivitamin/mineral supplement on micronutrient status, antioxidant capacity and cytokine production in healthy older adults consuming a fortified diet. *J Am Coll Nutr* 2000;19(5):613-21

⁴⁷ Benton D, Haller J, Fordy J. Vitamin supplementation for 1 year improves mood. *Neuropsychobiology* 1995;32(2):98-105

⁴⁸ Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial. *J Affect Disord* 2000;60:121-30

⁴⁹ Wagner W, Nootbaar-Wagner U. Prophylactic treatment of migraine with gamma-linolenic and alpha-linolenic acids. *Cephalalgia* 1997;17:127-30

⁵⁰ Langkamp-Henken et al. Nutritional formula enhanced immune function and reduced days of symptoms of URI in seniors. *J Am Geriatr Soc* 2004;52:3-12

⁵¹ Barringer TA, et al. Effect of a multivitamin and mineral supplement on infection and quality of life. *Ann Intern Med* 2003;138:365-71

⁵² Fawzi WW, Msamanga GI, et al. A randomized trial of multivitamin supplements and HIV disease progression and mortality. *N Engl J Med* 2004;351:23-32

⁵³ Burbano X, et al. Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV-infected participants. *HIV Clin Trials* 2002;3:483-91

⁵⁴ Abraham GE. Nutritional factors in the etiology of the premenstrual tension syndromes. *J Reprod Med* 1983;28(7):446-64

⁵⁵ Stewart A. Clinical and biochemical effects of nutritional supplementation on the premenstrual syndrome. *J Reprod Med* 1987;32:435-41

⁵⁶ Kaplan BJ, et al. Effective mood stabilization with a chelated mineral supplement: an open-label trial in bipolar disorder. *J Clin Psychiatry* 2001;62:936-44

⁵⁷ Kaplan BJ, et al. Treatment of mood lability and explosive rage with minerals and vitamins: two case studies. *J Child Adolesc Psychopharmacol* 2002;12(3):205-19

⁵⁸ Gesch et al. Influence of supplementary vitamins, minerals and essential fatty acids on the antisocial behaviour of young adult prisoners. *Br J Psychiatry* 2002;181:22-8

⁵⁹ Benton D. Micro-nutrient supplementation and the intelligence of children. *Neurosci Biobehav Rev* 2001;25:297-309

⁶⁰ Church TS, Earnest CP, Wood KA, Kampert JB. Reduction of C-reactive protein levels through use of a multivitamin. *Am J Med* 2003;115:702-7

⁶¹ Vasquez A, Manso G, Cannell J. The clinical importance of vitamin D (cholecalciferol): a paradigm shift. *Alternative Therapies in Health and Medicine* 2004;10:28-37

⁶² Vasquez A. New Insights into Fatty Acid Supplementation and Its Effect on Eicosanoid Production and Genetic Expression. *Nutritional Perspectives* 2005; Jan: 5-16

(borage oil) are not attained by consumption of EPA and DHA (fish oil); in fact, consumption of fish oil can actually promote a deficiency of GLA.⁶³ Likewise, consumption of GLA alone can reduce EPA levels while increasing levels of proinflammatory arachidonic acid; both of these problems are avoided with co-administration of fish oil any time borage oil is used. Using ALA (flaxseed oil) alone only slightly increases EPA but generally leads to no improvement in DHA status and can lead to a reduction of oleic acid; thus, fish oil, olive oil (and borage oil) should be supplemented when flaxseed oil is used.⁶⁴ Obviously, the goal here is a balanced intake of all of the health-promoting fatty acids; using only one or two sources of fatty acids is not balanced and results in suboptimal improvement, at best. In clinical practice, I routinely use combination fatty acid therapy comprised of ALA, EPA, DHA, and GLA for essentially all patients. The product also contains a modest amount of oleic acid, and I encourage use of olive oil for salads and cooking. This approach results in complete and balanced fatty acid intake, and the clinical benefits are impressive.

5. **Probiotics /gut flora modification:** Proper levels of good bacteria promote intestinal health, proper immune function, and support overall health. Excess bacteria or yeast, or the presence of harmful bacteria, yeast, or "parasites" such as amoebas and protozoans, can cause "leaky gut," systemic inflammation, and a wide range of clinical problems. Intestinal flora can become imbalanced by poor diets, excess stress, immunosuppressive drugs, antibiotics, or exposure to contaminated food or water, all of which are common among American patients. Thus, as a rule, I reinstate the good bacteria by the use of probiotics (good bacteria and yeast), prebiotics (fiber, arabinogalactan, and inulin), and the use of fermented foods such as kefir (in patients not allergic to milk). Harmful yeast, bacteria, and other "parasites" can be eradicated with the combination of dietary change, drugs, and/or herbal extracts. For example, oregano oil in an emulsified, time-released form has proven safe and effective for the elimination of various parasites encountered in clinical practice.⁶⁵ Likewise, the herb *Artemisia annua* (sweet wormwood) commonly is used to eradicate specific bacteria and has been used for thousands of years in Asia for the treatment and prevention of infectious diseases, including malaria.⁶⁶

Conclusion: In this brief review, I have outlined and scientifically substantiated a fundamental protocol that can serve as effective therapy for patients with a wide range of "diseases." Customizing the Paleo-Mediterranean diet to avoid food allergens, using vitamin-mineral supplements along with physiologic doses of vitamin D and broad-spectrum balanced fatty acid supplementation, and ensuring gastrointestinal health with the skillful use of probiotics, prebiotics, and antimicrobial treatments provides an excellent health-promoting and disease-eliminating foundation and lifestyle for many patients. Often, this simple protocol is all that is needed for the effective treatment of a wide range of clinical problems. For other patients with more complex illnesses, of course, additional interventions and laboratory assessments can be used to customize the treatment plan. However, we must always remember that the attainment and preservation of health requires that we meet the body's basic nutritional needs. This five-step protocol begins the process of meeting those needs. In my next article, I'll give you some examples from my clinical practice and additional references to show this protocol's safety and effectiveness.

Ayurvedic proverb
"When the diet is wrong,
medicine is of no use.
When the diet is correct,
medicine is of no need."

Implementing the Five-Part Nutritional Wellness Protocol for the Treatment of Various Health Problems

This article was originally published in *Nutritional Wellness*
nutritionalwellness.com/archives/2005/nov/11_vasquez.php

Introduction: In my last article in *Nutritional Wellness* I described a 5-part nutritional protocol that can be used in the vast majority of patients without adverse effects and with major benefits. For many patients, the basic protocol consisting of 1) the Paleo-Mediterranean diet, 2) multivitamin/multimineral supplementation, 3) additional vitamin D3, 4) combination fatty acid therapy with an optimal balance of ALA, GLA, EPA, DHA, and oleic acid, and 5) probiotics (including the identification and eradication of harmful yeast, bacteria, and other "parasites") is all the

⁶³ Cleland LG, Gibson RA, Neumann M, French JK. The effect of dietary fish oil supplement upon the content of dihomo-gammalinolenic acid in human plasma phospholipids. *Prostaglandins Leukot Essent Fatty Acids* 1990 May;40(1):9-12

⁶⁴ Jantti J, Nikkari T, Solakivi T, et al. Evening primrose oil in rheumatoid arthritis: changes in serum lipids and fatty acids. *Ann Rheum Dis* 1989;48(2):124-7

⁶⁵ Force M, Sparks WS, Ronzio RA. Inhibition of enteric parasites by emulsified oil of oregano in vivo. *Phytother Res* 2000;14:213-4

⁶⁶ Schuster BG. Demonstrating the validity of natural products as anti-infective drugs. *J Altern Complement Med* 2001;7 Suppl 1:S73-82

treatment that they need. For patients who need additional treatment, this foundational plan still serves as the core of the biochemical aspect of their intervention. Of course, in some cases, we have to use other lifestyle modifications (such as exercise), additional supplements (such as policosanol or antimicrobial herbs), manual treatments (including spinal manipulation) and occasionally select medications (such as hormone modulators) to obtain our goal of maximum improvement.

The following examples show how the 5-part protocol serves to benefit patients with a wide range of conditions. For the sake of saving space, I will use only highly specific citations to the research literature, since I have provided the other references in the previous issue of *Nutritional Wellness* and elsewhere.⁶⁷

- **A Man with High Cholesterol:** This patient is a 41-year-old slightly overweight man with very high cholesterol. His total cholesterol was 290 (normal < 200), LDL cholesterol was 212 (normal <130), and his triglycerides were 148 (optimal <100). I am quite certain that nearly every medical doctor would have put this man on cholesterol-lowering statin drugs for life. **Treatment:** In contrast, I advised a low-carb Paleo-Mediterranean diet because such diets have been shown to reduce cardiovascular mortality more powerfully than “statin” cholesterol-lowering drugs in older patients.⁶⁸ Likewise, fatty acid supplementation is more effective than statin drugs for reducing cardiac and all-cause mortality.⁶⁹ We added probiotics, because supplementation with *Lactobacillus* and *Bifidobacterium* has been shown to lower cholesterol levels in humans with high cholesterol.⁷⁰ Finally, I also prescribed 20 mg of policosanol for its well-known ability to favorably modify cholesterol levels.⁷¹ **Results:** Within *one month* the patient had lost weight, felt better, and his total cholesterol had dropped to normal at 196 (from 290!), LDL was reduced to 141, and triglycerides were reduced to 80. Basically, this treatment plan was “the protocol + policosanol.” Drug treatment of this patient would have been more expensive, more risky, and would not have resulted in global health improvements.
- **A Child with Intractable Seizures:** This is a 4-year-old nonverbal boy with 3-5 seizures per day despite being on two anti-seizure medications and having previously had several other “last resort” medical and surgical procedures. He also had a history of food allergies. **Treatment:** Obviously, there was no room for error in this case. We implemented a moderately low-carb hypoallergenic diet since both carbohydrate restriction⁷² and allergy avoidance⁷³ can reduce the frequency and severity of seizures. Since many “anti-seizure” medications actually cause seizures by causing vitamin D deficiency⁷⁴, I added 800 IU per day of emulsified vitamin D3 for its antiseizure benefit.⁷⁵ We used 1 tsp per day of a combination fatty acid supplement that provides balanced amounts of ALA, GLA, EPA, and DHA, since fatty acids appear to have potential antiseizure benefits.⁷⁶ Vitamin B-6 (250 mg of P5P) and magnesium (bowel tolerance) were also added to reduce brain hyperexcitability.⁷⁷ Stool testing showed an absence of *Bifidobacteria* and *Lactobacillus*; probiotics were added for their anti-allergy benefits.⁷⁸ **Results:** Within about 2 months seizure frequency reduced from 3-5 per day to one seizure every other day: *an 87% reduction in seizure frequency.* Patient was able to discontinue one of the anti-seizure medications. His parents also noted several global improvements: the boy started making eye contact with people, he was learning again, and intellectually he was “making gains every day.” His parents considered this an “amazing difference.” Going from 30 seizures per week to 4 seizures per week while reducing medication use by 50% is a major achievement. Notice that we simply used the basic wellness protocol with some additional B6 and magnesium. It is highly unlikely that B6 and magnesium alone would have produced such a favorable response.
- **A Young Woman with Full-Body Psoriasis Unresponsive to Drug Treatment:** This is a 17-year-old woman with head-to-toe psoriasis since childhood. She wears long pants and long-sleeved shirts year-round, and the

⁶⁷ Vasquez A. *Integrative Orthopedics*. By now of course, this book has been surpassed in content of nutritional information, particularly in books printed past 2009.

⁶⁸ Knoop KT, et al. Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women. *JAMA*. 2004 Sep 22;292(12):1433-9

⁶⁹ Studer M, et al. Effect of different antilipidemic agents and diets on mortality: a systematic review. *Arch Intern Med*. 2005;165:725-30

⁷⁰ Xiao JZ, et al. Effects of milk products fermented by *Bifidobacterium longum* on blood lipids in rats and healthy adult male volunteers. *J Dairy Sci*. 2003;86:2452-61

⁷¹ Cholesterol-lowering action of policosanol compares well to that of pravastatin and lovastatin. *Cardiovasc J S Afr*. 2003;14(3):161

⁷² Freeman JM, et al. The efficacy of the ketogenic diet-1998: a prospective evaluation of intervention in 150 children. *Pediatrics*. 1998;102:1358-63

⁷³ Egger J, Carter CM, Soothill JF, Wilson J. Oligoantigenic diet treatment of children with epilepsy and migraine. *J Pediatr*. 1989;114:51-8

⁷⁴ Ali FE, Al-Bustan MA, Al-Busairi WA, Al-Mulla FA. Loss of seizure control due to anticonvulsant-induced hypocalcemia. *Ann Pharmacother*. 2004;38:1002-5

⁷⁵ Christiansen C, Rodbro P, Sjo O. "Anticonvulsant action" of vitamin D in epileptic patients? A controlled pilot study. *Br Med J*. 1974 May 4;2(913):258-9

⁷⁶ Yuen AW, et al. Omega-3 fatty acid supplementation in patients with chronic epilepsy: A randomized trial. *Epilepsy Behav*. 2005 Sep;7(2):253-8

⁷⁷ Mousain-Bosc M, et al. Magnesium VitB6 intake reduces central nervous system hyperexcitability in children. *J Am Coll Nutr*. 2004;23(5):545S-548S

⁷⁸ Majamaa H, Isolauri E. Probiotics: a novel approach in the management of food allergy. *J Allergy Clin Immunol*. 1997 Feb;99(2):179-85

psoriasis is a major interference to her social life. Medications have ceased to help. **Treatment:** The Paleo-Mediterranean diet was implemented with an emphasis on food allergy identification.¹ We used a multivitamin-mineral supplement with 200 mcg selenium to compensate for the nutritional insufficiencies and selenium deficiency that are common in patients with psoriasis; likewise 10 mg of folic acid was added to address the relative vitamin deficiencies and elevated homocysteine that are common in these patients.⁷⁹ Combination fatty acid therapy with EPA and DHA from fish oil and GLA from borage oil was used for the anti-inflammatory and skin-healing benefits.⁸⁰ Vitamin E (1200 IU of mixed tocopherols) and lipoic acid (1,000 mg per day) were added for their anti-inflammatory benefits and to combat the oxidative stress that is characteristic of psoriasis.⁸¹ Of course, probiotics were used to modify gut flora, which is commonly deranged in patients with psoriasis.⁸² **Results:** Within a few weeks, this patient's "lifelong psoriasis" was essentially gone. Food allergy identification and avoidance played a major role in the success of this case. When I saw the patient again 9 months later for her second visit, she had no visible evidence of psoriasis. Her "medically untreatable" condition was essentially cured by the use of my basic protocol, with the addition of a few extra nutrients.

- **A Man with Fatigue and Recurrent Numbness in Hands and Feet.** This 40-year-old man had seen numerous neurologists and had spent tens of thousands of dollars on MRIs, CT scans, lumbar punctures, and other diagnostic procedures. No diagnosis had been found, and no effective treatment had been rendered by medical specialists. **Assessments:** We performed a modest battery of lab tests which revealed elevations of fibrinogen and C-reactive protein (CRP), two markers of acute inflammation. Assessment of intestinal permeability with the lactulose-mannitol assay showed major intestinal damage ("leaky gut"). Follow-up parasite testing on different occasions showed dysbiosis caused by *Proteus*, *Enterobacter*, *Klebsiella*, *Citrobacter*, and *Pseudomonas aeruginosa*—of course, these are gram-negative bacteria that can induce immune dysfunction and autoimmunity, as described elsewhere.¹ Specifically, *Pseudomonas aeruginosa* has been linked to the development of nervous system autoimmunity, such as multiple sclerosis.⁸³ **Treatment:** We implemented a plan of diet modification, vitamins, minerals, fatty acids, and probiotics. The dysbiosis was further addressed with specific antimicrobial herbs (including caprylic acid and emulsified oregano oil⁸⁴) and drugs (such as tetracycline, Bactrim, and Augmentin). The antibiotic drugs proved to be ineffective based on repeat stool testing. **Results:** Within one month we witnessed impressive improvements, both subjectively and objectively. Subjectively, the patient reported that the numbness and tingling almost completely resolved. Fatigue was reduced, and energy was improved. Objectively, the patient's elevated CRP plummeted from abnormally high at 11 down to completely normal at 1. Eighteen months later, the patient's CRP had dropped to less than 1 and fatigue and numbness were no longer problematic. Notice that this treatment plan was basically "the protocol" with additional attention to eradicating the dysbiosis we found with specialized stool testing.
- **A 50-year-old Man with Rheumatoid Arthritis.** This patient presented with a 3-year history of rheumatoid arthritis that had been treated unsuccessfully with drugs (methotrexate and intravenous Remicade). The first time I tested his hsCRP level, it was astronomically high at 124 mg/L (normal is <3). Because of the severe inflammation and other risk factors for sudden cardiac death, I referred this patient to an osteopathic internist for immune-suppressing drugs; the patient refused, stating that he was no longer willing to rely on immune-suppressing chemical medications. His treatment was entirely up to me. **Assessments and Treatments:** We implemented the Paleo-Mediterranean diet and a program of vitamins, minerals, optimal combination fatty acid therapy (providing ALA, GLA, EPA, DHA, and oleic acid), and 4000 IU of vitamin D in emulsified form to overcome defects in absorption that are seen in older patients and those with gastrointestinal problems.⁸⁵ Hormone testing showed abnormally low DHEA, low testosterone, and slightly elevated estrogen; these problems were corrected with DHEA supplementation and the use of a hormone-modulating drug (Arimidex) that lowers estrogen and raises testosterone. Specialized stool testing showed absence of *Lactobacillus* and *Bifidobacteria* and intestinal overgrowth of *Citrobacter* and *Enterobacter* which was corrected with probiotics and antimicrobial treatments including undecylenic acid and emulsified oregano oil. Importantly, I also decided to

⁷⁹ Vanizor Kural B, et al. Plasma homocysteine and its relationships with atherothrombotic markers in psoriatic patients. *Clin Chim Acta*. 2003 Jun;332(1-2):23-3

⁸⁰ Vasquez A. New Insights into Fatty Acid Supplementation and Its Effect on Eicosanoid Production and Genetic Expression. *Nutritional Perspectives* 2005; January: 5-16

⁸¹ Kokcam I, Naziroglu M. Antioxidants and lipid peroxidation status in the blood of patients with psoriasis. *Clin Chim Acta*. 1999 Nov;289(1-2):23-31

⁸² Waldman A, et al. Incidence of Candida in psoriasis--a study on the fungal flora of psoriatic patients. *Mycoses*. 2001 May;44(3-4):77-81

⁸³ Hughes LE, et al. Antibody responses to *Acinetobacter* spp. and *Pseudomonas aeruginosa* in multiple sclerosis. *Clin Diagn Lab Immunol*. 2001;8(6):1181-8

⁸⁴ Force M, Sparks WS, Ronzio RA. Inhibition of enteric parasites by emulsified oil of oregano in vivo. *Phytother Res*. 2000 May;14(3):213-4

⁸⁵ Vasquez A. Subphysiologic Doses of Vitamin D are Subtherapeutic: Comment on the Study by The Record Trial Group. *TheLancet.com* Accessed June 16, 2005

inhibit NFκB (the primary transcription factor that upregulates the pro-inflammatory response⁸⁶) by using a combination botanical formula that contains curcumin, piperine, lipoic acid, green tea extract, propolis, rosemary, resveratrol, ginger, and Phytolens™ (an antioxidant extract from lentils that may inhibit autoimmunity⁸⁷)—all of these herbs and nutrients have been shown to inhibit NFκB and to thus downregulate inflammatory responses.⁸⁸ **Results:** Within 6 weeks, this patient had happily lost 10 lbs of excess weight and was able to work without pain for the first time in years. **Follow-up testing showed that his hsCRP had dropped from 124 to 7 mg/L—a drop of 114 points—95%!—in less than one month: better than had ever been achieved even with the use of intravenous immune-suppressing drugs!** This patient continues to make significant progress. Obviously this case was complex, and we needed to do more than the basic protocol. Nonetheless, the basic protocol still served as the foundation for the treatment plan. Note that vitamin D has significant anti-inflammatory benefits and can cause major reductions in inflammation measured by CRP.⁸⁹ The correction of the hormonal abnormalities and the dysbiosis, and downregulating NFκB with several botanical extracts were also critical components of this successful treatment plan.

Summary and Conclusions: These examples show how the nutritional wellness protocol that I described in the September issue of *Nutritional Wellness* can be used as the foundational treatment for a wide range of health problems. In many cases, implementation of the basic protocol is all that is needed. In more complex situations, we use the basic protocol and then add more specific treatments to address dysbiosis and hormonal problems, and we can add additional nutrients as needed. However, nothing will ever replace a healthy diet, sufficiencies of vitamin D and all five of the health-promoting fatty acids (i.e., ALA, GLA, EPA, DHA, and oleic acid), and normalization of gastrointestinal flora. Without these basics, survival and the appearance of health are possible, but true health and recovery from “untreatable” illnesses is not possible. In order to attain optimal health, we have to create the conditions that allow for health to be attained, and we start this process by supplying the body with the nutrients that it needs to function optimally. In the words of naturopathic physician Jared Zeff from the *Journal of Naturopathic Medicine*, “The work of the naturopathic physician is to elicit healing by helping patients to create or recreate the conditions for health to exist within them. Health will occur where the conditions for health exist. Disease is the product of the conditions which allow for it.”⁹⁰

Common Oversights and Shortcomings in the Study and Implementation of Nutritional Supplementation

This article was originally published in *Naturopathy Digest* naturopathydigest.com/archives/2007/jun/vasquez.php

Introduction: An impressive discrepancy often exists between the low efficacy of nutritional interventions reported in the research literature and the higher efficacy achieved in the clinical practices of clinicians trained in the use of interventional nutrition (i.e., naturopathic physicians). This discrepancy is dangerous for at least two reasons. First, it results in an undervaluation of the efficacy of nutritional supplementation, which ultimately leaves otherwise treatable patients untreated. Second, such untreated and undertreated patients are often then forced to use dangerous and expensive pharmaceutical drugs and surgical interventions to treat conditions that could have otherwise been easily and safely treated with nutritional supplementation and diet modification. Consequently, the burden of suffering, disease, and healthcare expense in the US is higher than it would be if nutritionally-trained clinicians were more fully integrated into the healthcare system.

Obstacles to Efficacy in the Use of Nutritional Supplementation: Below are listed some of the most common causes for the underachievement of nutritional supplementation in practice and in published research. While this list is not all-inclusive, it will serve as a review for clinicians and an introduction for chiropractic/naturopathic

⁸⁶ Tak PP, Firestein GS. NFκB: a key role in inflammatory diseases. *J Clin Invest*. 2001 Jan;107(1):7-11

⁸⁷ Sandoval M, et al. Peroxynitrite-induced apoptosis in epithelial (T84) and macrophage (RAW 264.7) cell lines: effect of legume-derived polyphenols (phytolens). *Nitric Oxide*. 1997;1(6):476-83

⁸⁸ Vasquez A. Nutritional and Botanical Inhibition of NFκB, the Major Intracellular Amplifier of the Inflammatory Cascade. A Practical Clinical Strategy Exemplifying Anti-Inflammatory Nutrigenomics. *Nutritional Perspectives* 2005;July: 5-12

⁸⁹ Timms PM, et al. Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype. *QJM*. 2002 Dec;95(12):787-96

⁹⁰ Zeff JL. The process of healing: a unifying theory of naturopathic medicine. *Journal of Naturopathic Medicine* 1997; 7: 122-5

students. In both practice and research, the problems listed below often overlap and function synergistically to reduce the efficacy of nutritional supplementation.

1. **Inadequate dosing (quantity):** Many clinical trials published in major journals and many doctors in clinical practice have used inadequate doses of vitamins (and other natural therapeutics) and have thus failed to achieve the results that would have easily been obtained had they implemented their protocol with the proper physiologic or supraphysiologic dose of intervention. The best example in my experience centers on vitamin D, where so many of the studies are performed with doses of 400-800 IU per day only to conclude that vitamin supplementation is ineffective for the condition being treated. The problem here is that the researchers failed to appreciate that the physiologic requirement for vitamin D3 in adults is approximately 3,000-5,000 IU per day⁹¹ and that therefore their supplemental dose of 400-800 IU is only 10-20% of what is required. Subphysiologic doses are generally subtherapeutic. In this regard, I have had to correct journals such as *The Lancet*⁹², *JAMA*⁹³, and *British Medical Journal*⁹⁴ from misleading their readers (many of whom are major policymakers) from concluding that nutritional supplementation is impotent; rather, their researchers and editors were not sufficiently educated in the design and review of studies using nutritional interventions. These journals should hire chiropractic and naturopathic physicians so that they have staff trained in natural treatments and who can thus provide an educated review of studies on these topics.⁹⁵
2. **Inadequate dosing (duration):** Often the effects of long-term nutritional deficiency are not fully reversible and/or may require a treatment period of months or years to achieve maximal clinical response. For example, full replacement of fatty acids in human brain phospholipids is an ongoing process that occurs over a period of several years; thus studies using fatty acid supplements for a period of weeks or 2-3 months generally underestimate the enhanced effectiveness that can be obtained with administration over many months or several years of treatment. Relatedly, recovery from vitamin D deficiency takes several weeks of high-dose supplementation in order to achieve tissue saturation and subsequent cellular replenishment; studies of short duration are destined to underestimate the results that could have been achieved with supplementation carried out over several months.⁹⁶
3. **Failure to use proper forms of nutrients (quality):** Nutrients are often available in different forms, not the least of which are “active” versus “inactive” and “natural” versus “unnatural.” Most vitamin supplements, particularly high-potency B vitamins, are manufactured synthetically and are not from “natural sources” despite the marketing hype promulgated by companies that, for example, mix their synthetic vitamins with a vegetable powder and then call their vitamin supplements “natural.” The simple fact is that production of high-potency supplements from purely natural sources would be prohibitively wasteful, inefficient, and expensive. Thus, while it is not necessary for vitamins to be “natural” in order to be useful, it is necessary that the vitamins are useable and preferably not “unnatural.” The best example of the use of unnatural supplements is the use of synthetic DL-tocopherol in the so-called “vitamin E” studies; DL-tocopherol is 50% comprised of the L-isomer of tocopherol which is not only unusable by the human body but is actually harmful in that it interferes with normal metabolism and can exacerbate hypertension and cause symptomatic complications (e.g., headaches). Further, tocopherols exist within the body in relationship with the individual forms of the vitamin, such that supplementation with one form (e.g., alpha-tocopherol) can result in a relative deficiency of another form (e.g., gamma-tocopherol). One final example of the failure to use proper forms of nutrients is in the use of pyridoxine HCl as a form of vitamin B6; while this practice itself is not harmful, clinicians need to remember that pyridoxine HCl is ineffective until converted to the more active forms of the vitamin including pyridoxal-5-phosphate. Since this conversion requires co-nutrients such as magnesium and zinc, we can easily see that the reputed failure of B6 supplementation when administered in the form of pyridoxine HCl might actually be due to untreated insufficiencies of required co-nutrients, as discussed in the following section.
4. **Failure to ensure adequacy of co-nutrients:** Vitamins, minerals, amino acids, and fatty acids work together in an intricately choreographed and delicately orchestrated dance that culminates in the successful completion of

⁹¹ Heaney RP, et al. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. *Am J Clin Nutr.* 2003 Jan;77(1):204-10

⁹² Vasquez A. Subphysiologic Doses of Vitamin D are Subtherapeutic: Comment on the Study by The Record Trial Group. *The Lancet* 2005 Published on-line May 6

⁹³ Muanza DN, Vasquez A, Cannell J, Grant WB. Isoflavones and Postmenopausal Women. [letter] *JAMA* 2004; 292: 2337

⁹⁴ Vasquez A, Cannell J. Calcium and vitamin D in preventing fractures: data are not sufficient to show inefficacy. [letter] *BMJ: British Medical Journal* 2005;331:108-9

⁹⁵ Vasquez A. Allopathic Usurpation of Natural Medicine. *Naturopathy Digest* 2006 Feb naturopathydigest.com/archives/2006/feb/vasquez.php

⁹⁶ Vasquez A, Manso G, Cannell J. The clinical importance of vitamin D (cholecalciferol): a paradigm shift. *Altern Ther Health Med.* 2004 Sep-Oct;10(5):28-36

interconnected physiologic functions. If any of the performers in this event are missing (i.e., nutritional deficiency) or if successive interconversions are impaired due to lack of enzyme function, then the show cannot go on, or—if it does go on—impaired metabolism and defective function will result. So, if we take a patient with “vitamin B6 deficiency” and give him vitamin B6 in the absence of other co-nutrients needed for the proper activation and metabolic utilization of vitamin B6, we cannot honestly expect the “nutritional supplementation” to work in this case; rather, we might see a marginal benefit or perhaps even a negative outcome as an imbalanced system is pushed into a different state of imbalance despite supplementation with the “correct” vitamin. In the case of vitamin B6, necessary co-nutrients include zinc, magnesium, and riboflavin; deficiency of any of these will result in a relative “failure” of B6 supplementation even if a patient has a B6-responsive condition. Notably, overt magnesium deficiency is alarmingly common among patients and citizens in industrialized nations^{97,98,99}, and this epidemic of magnesium deficiency is due not only to insufficient intake but also to excessive excretion caused by consumption of high-glycemic foods, caffeine, and a diet that promotes chronic metabolic acidosis with resultant urinary acidification.

5. **Failure to achieve urinary alkalization:** Western/American-style diets typified by overconsumption of grains, dairy, sugar, and salt result in a state of subclinical chronic metabolic acidosis which results in urinary acidification, relative hypercortisolemia, and consequent hyperexcretion of minerals such as calcium and magnesium.¹⁰⁰⁻¹⁰¹ Thus, the common conundrum of magnesium replenishment requires not only magnesium supplementation but also dietary interventions to change the internal climate to one that is conducive to bodily retention and cellular uptake of magnesium.¹⁰²
6. **Use of mislabeled supplements:** Even in the professional arena of nutritional supplement manufacturers, some companies habitually underdose their products either in an attempt to spend less in the manufacture of their products or as a consequence of poor quality control. If a product is labeled to contain 1,000 IU of vitamin D but only contains 836 IU of the nutrient, then obviously full clinical efficacy will not be achieved; this was a problem in a recent clinical trial involving vitamin D.¹⁰³ The problem for clinicians is in trusting the companies that supply nutritional supplements; some companies do “in house” testing which lacks independent review, while other companies use questionable “independent testing” which is not infrequently performed by a laboratory that is a wholly owned subsidiary of the parent nutritional company. Manufacturing regulations that are sweeping through the industry will cleanse the nutritional supplement world of poorly made products, and these same regulations will sweep some unprepared companies right out the door when they are unable to meet the regulatory requirements.
7. **Failure to ensure/assess bioavailability and optimal serum/cellular levels:** Clinical trials with nutritional therapies need to monitor serum or cellular levels to ensure absorption, product bioavailability, and the attainment of optimal serum levels. This is particularly relevant in the treatment of chronic disorders such as the autoimmune diseases, wherein so many of these patients have gastrointestinal dysbiosis and often have concomitant nutrient malabsorption.¹⁰⁴ Simply dosing these patients with supplements is not always efficacious; often the gut must be cleared of dysbiosis so that the mucosal lining can be repaired and optimal nutrient absorption can be reestablished.
8. **Coadministration of food with nutritional supplements (sometimes right, sometimes wrong):** Food can help or hinder the absorption of nutritional supplements. Phytate and tannins in grains and teas, respectively, are notorious for inhibiting mineral absorption. Some supplements, like coenzyme Q10, should be administered with fatty food to enhance absorption. Other supplements, like amino acids, should be administered away from

⁹⁷ "Altogether 43% of 113 trauma patients had low magnesium levels compared to 30% of noninjured cohorts." Frankel H, Haskell R, Lee SY, Miller D, Rotondo M, Schwab CW. Hypomagnesemia in trauma patients. *World J Surg.* 1999 Sep;23(9):966-9

⁹⁸ "There was a 20% overall prevalence of hypomagnesemia among this predominantly female, African American population." Fox CH, Ramsoomair D, Mahoney MC, Carter C, Young B, Graham R. An investigation of hypomagnesemia among ambulatory urban African Americans. *J Fam Pract.* 1999 Aug;48(8):636-9

⁹⁹ "Suboptimal levels were detected in 33.7 per cent of the population under study. These data clearly demonstrate that the Mg supply of the German population needs increased attention." Schimatschek et al. Prevalence of hypomagnesemia in an unselected German population of 16,000 individuals. *Magnes Res.* 2001 Dec;14(4):283-90

¹⁰⁰ Cordain L, et al. Origins and evolution of the Western diet: health implications for the 21st century. *Am J Clin Nutr.* 2005 Feb;81(2):341-54

¹⁰¹ Maurer M, Riesen W, Muser J, Hulter HN, Krapf R. Neutralization of Western diet inhibits bone resorption independently of K intake and reduces cortisol secretion in humans. *Am J Physiol Renal Physiol.* 2003 Jan;284(1):F32-40

¹⁰² Vormann J, et al. Supplementation with alkaline minerals reduces symptoms in patients with chronic low back pain. *J Trace Elem Med Biol.* 2001;15(2-3):179-83

¹⁰³ Heaney RP, et al. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. *Am J Clin Nutr.* 2003 Jan;77(1):204-10

¹⁰⁴ Vasquez A. Nutritional and Botanical Treatments Against “Silent Infections” and Gastrointestinal Dysbiosis. *Nutritional Perspectives* 2006; January

protein-rich foods and are often better administered with simple carbohydrate to enhance cellular uptake; this is especially true with tryptophan.

9. **Correction of gross dietary imbalances enhances supplement effectiveness:** If the diet is grossly imbalanced, then nutritional supplementation is less likely to be effective. The best example of this is in the use of fatty acid supplements, particularly in the treatment of inflammatory disorders. If the diet is laden with dairy, beef, and other sources of arachidonate, then fatty acid supplementation with EPA, DHA, and GLA is much less likely to be effective, or much higher doses of the supplements will need to be used in order to help restore fatty acid balance. Generally speaking, the diet needs to be optimized to enhance the efficacy of nutritional supplementation.

Conclusion: In this brief review, I have listed and discussed some of the most common impediments to the success of nutritional supplementation. I hope that naturopathic students, clinicians, and researchers will find these points helpful in their design of clinical treatment protocols.

Revisiting the Five-Part Nutritional Wellness Protocol: Supplemented Paleo-Mediterranean Diet

This article was originally published in the January 2011 issue of *Nutritional Perspectives*

Abstract: This article reviews the five-part nutritional protocol that incorporates a health-promoting nutrient-dense diet and essential supplementation with vitamins/minerals, specific fatty acids, probiotics, and physiologic doses of vitamin D3. This foundational nutritional protocol has proven benefits for disease treatment, disease prevention, and health maintenance and restoration. Additional treatments such as botanical medicines, additional nutritional supplements, and pharmaceutical drugs can be used atop this foundational protocol to further optimize clinical effectiveness. The rationale for this five-part protocol is presented, and consideration is given to adding iodine-iodide as the sixth component of the protocol.

Introduction: In 2004 and 2005 I first published a “five-part nutrition protocol”^{105,106} that provides the foundational treatment plan for a wide range of health disorders. This protocol served and continues to serve as the foundation upon which other treatments are commonly added, and without which those other treatments are likely to fail, or attain suboptimal results at best.¹⁰⁷ Now as then, I will share with you what I consider a basic foundational protocol for wellness promotion and disease treatment. I have used this protocol in my own self-care for many years and have used it in the treatment of a wide range of health-disease conditions in clinical practice.

This nutritional protocol is validated by biochemistry, physiology, experimental research, peer-reviewed human trials, and the clinical application of common sense. It is the most nutrient-dense diet available, satisfying nutritional needs and thereby optimizing metabolic processes while promoting satiety and weight loss/optimization. Nutrients are required in the proper amounts, forms, and approximate ratios for critical and innumerable physiologic functions; if nutrients are lacking, the body cannot function *normally*, let alone *optimally*. Impaired function results in subjective and objective manifestations of what is eventually labeled as “disease.” Thus, a powerful and effective alternative to treating diseases with drugs is to re-establish normal/optimal physiologic function by replenishing the body with essential nutrients, reestablishing hormonal balance (“orthoendocrinology”), promoting detoxification of environmental toxins, and by reestablishing the optimal microbial milieu, especially the eradication of (multifocal) dysbiosis; this multifaceted approach can be applied to several diseases, especially those of the inflammatory and autoimmune varieties.¹⁰⁸

Of course, most diseases are multifactorial and therefore require multicomponent treatment plans, and some diseases actually require the use of drugs in conjunction with assertive interventional nutrition. However, while only a smaller portion of patients actually need drugs for the long-term management their problems, all clinicians should agree that everyone needs a foundational nutrition plan because nutrients—not drugs—are universally required for life and health. This five-part nutrition protocol is briefly outlined below; a much more detailed substantiation of the underlying science and clinical application of this protocol was recently published in a review of more than 650 pages and approximately 3,500 citations.¹⁰⁹

¹⁰⁵ Vasquez A. *Integrative Orthopedics: The Art of Creating Wellness While Managing Acute and Chronic Musculoskeletal Disorders*. 2004, 2007, 2012

¹⁰⁶ Vasquez A. Five-Part Nutritional Protocol that Produces Consistently Positive Results. *NutrWellness* 2005 Sep nutritionalwellness.com/archives/2005/sep/09_vasquez.php

¹⁰⁷ Vasquez A. Common Oversights and Shortcomings in the Study and Implementation of Nutritional Supplementation. *Naturopathy Digest* 2007 June.

¹⁰⁸ Vasquez A. *Integrative Rheumatology*. IBMRC: 2006, 2009.

¹⁰⁹ Vasquez A. *Chiropractic and Naturopathic Mastery of Common Clinical Disorders*. IBMRC: 2009

1. **Health-promoting Paleo-Mediterranean diet:** Following an extensive review of the research literature, I developed what I call the "supplemented Paleo-Mediterranean diet." In essence, this diet plan combines the best of the Mediterranean diet with the best of the Paleolithic diet, the latter of which has been best distilled by Dr. Loren Cordain in his book "The Paleo Diet"¹¹⁰ and his numerous scientific articles.^{111,112,113} The Paleolithic diet is superior to the Mediterranean diet in nutrient density for promoting satiety, weight loss, and improvements/normalization in overall metabolic function.^{114,115} This diet places emphasis on fruits, vegetables, nuts, seeds, and berries that meet the body's needs for fiber, carbohydrates, and most importantly, the 8,000+ phytonutrients that have additive and synergistic health effects¹¹⁶—including immunomodulating, antioxidant, anti-inflammatory, and anti-cancer benefits. High-quality protein sources such as fish, poultry, eggs, and grass-fed meats are emphasized. Slightly modifying Cordain's Paleo diet, I also advocate soy and whey protein isolates for their high-quality protein and their anticancer, cardioprotective, and mood-enhancing (due to the high tryptophan content) benefits. Potatoes and other starchy vegetables, wheat and other grains including rice are discouraged due to their high glycemic indexes and high glycemic loads, and their relative insufficiency of fiber and phytonutrients compared to fruits and vegetables. Grains such as wheat, barley, and rye are discouraged due to the high glycemic loads/indexes of most breads, pastries, and other grain-derived products, as well as due to the immunogenicity of constituents such as gluten, a protein composite (consisting of a prolamin and a glutelin) that can contribute to disorders such as migraine, epilepsy, eczema, arthritis, celiac disease, psoriasis and other types of autoimmunity. Sources of simple sugars and foreign chemicals such as colas/sodas (which contain artificial colors, flavors, and high-fructose corn syrup, which contains mercury¹¹⁷ and which can cause the hypertensive-diabetic metabolic syndrome¹¹⁸) and processed foods (e.g., "TV dinners" and other manufactured snacks and convenience foods) are strictly forbidden. Chemical preservatives, colorants, sweeteners, flavor-enhancers such as monosodium glutamate and carrageenan are likewise avoided. In summary, this diet plan provides plenty of variety, as most dishes comprised of poultry, fish, lean meats, soy, eggs, fruits, vegetables, nuts, berries, and seeds are allowed. The diet provides an abundance of fiber, phytonutrients, carbohydrates, potassium, and protein, while simultaneously being low in fat, sodium, arachidonic acid, and "simple sugars." The diet must be customized with regard to total protein and calorie intake, as determined by the size, status, and activity level of the patient; individual per-patient food allergens should be avoided. Regular consumption of this diet has shown the ability to reduce hypertension, alleviate diabetes, ameliorate migraine headaches, and result in improvement of overall health and a lessening of the severity of many common "diseases", particularly those with an autoimmune or inflammatory component. This Paleo-Mediterranean diet is supplemented with vitamins, minerals, fatty acids, and probiotics—making it the "supplemented Paleo-Mediterranean diet" as described below. The main considerations/contraindications to recommending increased intake of fruits and vegetables are 1) increased intake of vitamin K in the few patients taking warfarin for anticoagulation, and 2) increased intake of potassium in patients with pre-existing renal insufficiency as discussed in this video tutorial: vimeo.com/152296851 also at vimeo.com/152293616.
2. **Multivitamin and multiminerall supplementation:** Vitamin and mineral supplementation has been advocated for decades by the chiropractic/naturopathic professions while being scorned by so-called "mainstream

¹¹⁰ Cordain L. *The Paleo Diet*. John Wiley and Sons, 2002.

¹¹¹ O'Keefe JH Jr, Cordain L. Cardiovascular disease resulting from a diet and lifestyle at odds with our Paleolithic genome. *Mayo Clin Proc*. 2004 Jan;79(1):101-8

¹¹² Cordain L. Cereal grains: humanity's double edged sword. *World Rev Nutr Diet* 1999;84:19-73

¹¹³ Cordain L, et al. Origins and evolution of the Western diet: health implications for the 21st century. *Am J Clin Nutr*. 2005 Feb;81(2):341-54

¹¹⁴ "A high micronutrient density diet mitigates the unpleasant aspects of the experience of hunger even though it is lower in calories. Hunger is one of the major impediments to successful weight loss. Our findings suggest that it is not simply the caloric content, but more importantly, the micronutrient density of a diet that influences the experience of hunger. It appears that a high nutrient density diet, after an initial phase of adjustment during which a person experiences "toxic hunger" due to withdrawal from pro-inflammatory foods, can result in a sustainable eating pattern that leads to weight loss and improved health." Fuhrman J, Sarter B, Glaser D, Acocella S. Changing perceptions of hunger on a high nutrient density diet. *Nutr J*. 2010 Nov 7;9:51 nutritionj.com/content/9/1/51

¹¹⁵ "The Paleolithic group were as satiated as the Mediterranean group but consumed less energy per day (5.8 MJ/day vs. 7.6 MJ/day, Paleolithic vs. Mediterranean, p=0.04). Consequently, the quotients of mean change in satiety during meal and mean consumed energy from food and drink were higher in the Paleolithic group (p=0.03). Also, there was a strong trend for greater Satiety Quotient for energy in the Paleolithic group (p=0.057). Leptin decreased by 31% in the Paleolithic group and by 18% in the Mediterranean group with a trend for greater relative decrease of leptin in the Paleolithic group." Jonsson T, Granfeldt Y, Erlanson-Albertsson C, Ahren B, Lindeberg S. A Paleolithic diet is more satiating per calorie than a Mediterranean-like diet in individuals with ischemic heart disease. *Nutr Metab (Lond)*. 2010 Nov 30;7(1):85.

¹¹⁶ Liu RH. Health benefits of fruit and vegetables are from additive and synergistic combinations of phytochemicals. *Am J Clin Nutr* 2003;78(3 Suppl):517S-520S

¹¹⁷ "With daily per capita consumption of HFCS in the US averaging about 50 grams and daily mercury intakes from HFCS ranging up to 28 µg, this potential source of mercury may exceed other major sources of mercury especially in high-end consumers of beverages sweetened with HFCS." Dufault R, et al. Mercury from chlor-alkali plants: measured concentrations in food product sugar. *Environ Health*. 2009 Jan 26;8:2 ehjournal.net/content/8/1/2

¹¹⁸ Vasquez A. *Integrative Medicine and Functional Medicine for Chronic Hypertension: An Evidence-based Patient-Centered Monograph for Advanced Clinicians*. IBMRC; 2011. See also: Reungjui S, et al. Thiazide diuretics exacerbate fructose-induced metabolic syndrome. *J Am Soc Nephrol*. 2007 Oct;18(10):2724-31

medicine." Vitamin and mineral supplementation finally received bipartisan endorsement when researchers from Harvard Medical School published a review article in *Journal of the American Medical Association* that concluded, "Most people do not consume an optimal amount of all vitamins by diet alone. ...it appears prudent for all adults to take vitamin supplements."¹¹⁹ Long-term nutritional insufficiencies experienced by "most people" promote the development of "long-latency deficiency diseases"¹²⁰ such as cancer, neuroemotional deterioration, and cardiovascular disease. Impressively, the benefits of multivitamin/multimineral supplementation have been demonstrated in numerous clinical trials. Multivitamin/multimineral supplementation has been shown to improve nutritional status and reduce the risk for chronic diseases¹²¹, improve mood¹²², potentiate antidepressant drug treatment¹²³, alleviate migraine headaches (when used with diet improvement and fatty acids¹²⁴), improve immune function and infectious disease outcomes in the elderly¹²⁵ (especially diabetics¹²⁶), reduce morbidity and mortality in patients with HIV infection^{127,128}, alleviate premenstrual syndrome^{129,130} and bipolar disorder¹³¹, reduce violence and antisocial behavior in children¹³² and incarcerated young adults (when used with essential fatty acids¹³³), and improve scores of intelligence in children.¹³⁴ Multivitamin and multimineral supplementation provides anti-inflammatory benefits, as evidenced by significant reduction in C-reactive protein (CRP) in a double-blind, placebo-controlled trial.¹³⁵ The ability to safely and affordably deliver these benefits makes multimineral-multivitamin supplementation an essential component of any and all health-promoting and disease-prevention strategies. A few cautions need to be observed; for example, vitamin A can (rarely) result in liver damage with chronic consumption of 25,000 IU or more, and intake should generally not exceed 10,000 IU per day in women of childbearing age. Also, iron should not be supplemented except in patients diagnosed with iron deficiency by a blood test (serum ferritin).

3. Physiologic doses of vitamin D3: The prevalence of vitamin D deficiency varies from 40-80 percent (general population) to almost 100 percent (patients with musculoskeletal pain) among Americans and Europeans. Vasquez, Manso, and Cannell described the many benefits of vitamin D3 supplementation in a "paradigm-shifting" review published in 2004.¹³⁶




Image right: Interpretation of serum 25(OH) vitamin D levels: Updated from Vasquez et al, *Alternative Therapies in Health and Medicine* 2004 Sep

¹¹⁹ Fletcher RH, Fairfield KM. Vitamins for chronic disease prevention in adults: clinical applications. *JAMA* 2002;287:3127-9

¹²⁰ Heaney RP. Long-latency deficiency disease: insights from calcium and vitamin D. *Am J Clin Nutr* 2003;78:912-9

¹²¹ McKay et al. The effects of a multivitamin/mineral supplement on micronutrient status, antioxidant capacity and cytokine production in healthy older adults consuming a fortified diet. *J Am Coll Nutr* 2000;19(5):613-21

¹²² Benton D, Haller J, Fordy J. Vitamin supplementation for 1 year improves mood. *Neuropsychobiology* 1995;32(2):98-105

¹²³ Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial. *J Affect Disord* 2000;60:121-30

¹²⁴ Wagner W, Nootbaar-Wagner U. Prophylactic treatment of migraine with gamma-linolenic and alpha-linolenic acids. *Cephalalgia* 1997;17:127-30

¹²⁵ Langkamp-Henken et al. Nutritional formula enhanced immune function and reduced days of symptoms upper respiratory tract infection in seniors. *J Am Geriatr Soc* 2004;3-12

¹²⁶ Barringer TA, et al. Effect of a multivitamin and mineral supplement on infection and quality of life. *Am Intern Med* 2003;138:365-71

¹²⁷ Fawzi WW, Msamanga GI, et al. A randomized trial of multivitamin supplements and HIV disease progression and mortality. *N Engl J Med* 2004;351:23-32

¹²⁸ Burbano X, et al. Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV-infected participants. *HIV Clin Trials* 2002;3:483-91

¹²⁹ Abraham GE. Nutritional factors in the etiology of the premenstrual tension syndromes. *J Reprod Med* 1983;28(7):446-64

¹³⁰ Stewart A. Clinical and biochemical effects of nutritional supplementation on the premenstrual syndrome. *J Reprod Med* 1987;32:435-41

¹³¹ Kaplan BJ, et al. Effective mood stabilization with a chelated mineral supplement: an open-label trial in bipolar disorder. *J Clin Psychiatry* 2001;62:936-44

¹³² Kaplan et al. Treatment of mood lability and explosive rage with minerals and vitamins: two case studies in children. *J Child Adolesc Psychopharmacol* 2002;12(3):205-19

¹³³ Gesch et al. Influence of supplementary vitamins, minerals and essential fatty acids on the antisocial behaviour of young adult prisoners. *Br J Psychiatry* 2002;181:22-8

¹³⁴ Benton D. Micro-nutrient supplementation and the intelligence of children. *Neurosci Biobehav Rev* 2001;25:297-309

¹³⁵ Church TS, Earnest CP, Wood KA, Kampert JB. Reduction of C-reactive protein levels through use of a multivitamin. *Am J Med* 2003;115:702-7

¹³⁶ Vasquez A, Manso G, Cannell J. The clinical importance of vitamin D (cholecalciferol). *Alternative Therapies in Health and Medicine* 2004;10:28-37

Our review showed that vitamin D deficiency causes or contributes to depression, hypertension, seizures, migraine, polycystic ovary syndrome, inflammation, autoimmunity, and musculoskeletal pain, particularly low-back pain. Clinical trials using vitamin D supplementation have proven the cause-and-effect relationship between vitamin D deficiency and most of these conditions by showing that each could be cured or alleviated with vitamin D supplementation. Per our review, daily vitamin D doses should be 1,000 IU for infants, 2,000 IU for children, and 4,000 IU for adults, although some adults respond better to higher doses of 10,000 IU per day. Cautions/contraindications include the use of thiazide diuretics (e.g., hydrochlorothiazide) or any other medications that promote hypercalcemia, as well as granulomatous diseases such as sarcoidosis, tuberculosis, and certain types of cancer, especially lymphoma. Effectiveness is monitored by measuring serum 25-OH-vitamin D, and safety is monitored by measuring serum calcium. Dosing should be tailored for the attainment of optimal serum levels of 25-hydroxy-vitamin D3, generally 50-100 ng/ml (125-250 nmol/l) as illustrated.

4. **Balanced and complete fatty acid supplementation:** A detailed survey of the literature shows that five fatty acids have major health-promoting disease-preventing benefits and should therefore be incorporated into the daily diet and/or regularly consumed as dietary supplements.¹³⁷ These are alpha-linolenic acid (ALA; omega-3, from flaxseed oil), eicosapentaenoic acid (EPA; omega-3, from fish oil), docosahexaenoic acid (DHA; omega-3, from fish oil and algae), gamma-linolenic acid (GLA; omega-6, most concentrated in borage oil but also present in evening primrose oil, hemp seed oil, black currant seed oil), and oleic acid (omega-9, most concentrated in olive oil, which contains in addition to oleic acid many anti-inflammatory, antioxidant, and anticancer phytonutrients). Supplementing with one fatty acid can exacerbate an insufficiency of other fatty acids; hence the importance of balanced combination supplementation. Each of these fatty acids has health benefits that cannot be fully attained from supplementing a different fatty acid; hence, again, the importance of balanced combination supplementation. The benefits of GLA are not attained by consumption of EPA and DHA; in fact, consumption of fish oil can actually promote a deficiency of GLA.¹³⁸ Likewise, consumption of GLA alone can reduce EPA levels while increasing levels of proinflammatory arachidonic acid; both of these problems are avoided with co-administration of EPA any time GLA is used because EPA inhibits delta-5-desaturase, which converts dihomo-GLA into arachidonic acid. Using ALA alone only slightly increases EPA but generally leads to no improvement in DHA status and can lead to a reduction of oleic acid; thus, DHA and oleic acid should be supplemented when flaxseed oil is used.¹³⁹ Obviously, the goal here is physiologically-optimal (i.e., “balanced”) intake of all of the health-promoting fatty acids; using only one or two sources of fatty acids is not balanced and results in suboptimal improvement. In clinical practice, I routinely use combination fatty acid therapy comprised of ALA, EPA, DHA, and GLA for essentially all patients; when one appreciates that the average daily Paleolithic intake of n-3 fatty acids was 7 grams per day contrasted to the average daily American intake of 1 gram per day, we can see that—by using combination fatty acid therapy emphasizing n-3 fatty acids—we are simply meeting physiologic expectations via supplementation, rather than performing an act of recklessness or heroism. The product I use also contains a modest amount of oleic acid that occurs naturally in flax and borage seed oils, and I encourage use of olive oil for salads and cooking. This approach results in complete and balanced fatty acid intake, and the clinical benefits are impressive. Benefits are to be expected in the treatment of premenstrual syndrome, diabetic neuropathy, respiratory distress syndrome, Crohn’s disease, lupus, rheumatoid arthritis, cardiovascular disease, hypertension, psoriasis, eczema, migraine headaches, bipolar disorder, borderline personality disorder, mental depression, schizophrenia, osteoporosis, polycystic ovary syndrome, multiple sclerosis, and musculoskeletal pain. The discovery in September 2010 that the G protein-coupled receptor 120 (GPR120) functions as an n-3 fatty acid receptor that, when stimulated with EPA or DHA, exerts broad anti-inflammatory effects (in cell experiments) and enhances systemic insulin sensitivity (in animal study) confirms a new mechanism of action of fatty acid supplementation and shows that we as clinician-researchers are still learning the details of the beneficial effects of commonly used treatments.¹⁴⁰

¹³⁷ Vasquez A. New Insights into Fatty Acid Biochemistry and the Influence of Diet. *Nutritional Perspectives* 2004; October: 5, 7-10, 12, 14

¹³⁸ Cleland LG, Gibson RA, Neumann M, French JK. The effect of dietary fish oil supplement upon the content of dihomo-gammalinolenic acid in human plasma phospholipids. *Prostaglandins Leukot Essent Fatty Acids* 1990 May;40(1):9-12

¹³⁹ Jantti J, Nikkari T, Solakivi T, et al. Evening primrose oil in rheumatoid arthritis: changes in serum lipids and fatty acids. *Ann Rheum Dis* 1989;48(2):124-7

¹⁴⁰ Oh da Y, et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. *Cell*. 2010 Sep 3;142(5):687-98

5. Probiotics /gut flora modification: Proper levels of good bacteria promote intestinal health, support proper immune function, and encourage overall health. Excess bacteria or yeast, or the presence of harmful bacteria, yeast, or "parasites" such as amoebas and protozoans, can cause "leaky gut," systemic inflammation, and a wide range of clinical problems, especially autoimmunity. Intestinal flora can become imbalanced by poor diets, excess stress, immunosuppressive drugs, and antibiotics, and all of these factors are common among American patients. Thus, as a rule, I reinstate the good bacteria by the use of probiotics (good bacteria and yeast), prebiotics (fiber, arabinogalactan, and inulin), and the use of fermented foods such as kefir and yogurt for patients not allergic to milk. Harmful yeast, bacteria, and other "parasites" can be eradicated with the combination of dietary change, antimicrobial drugs, and/or herbal extracts. For example, oregano oil in an emulsified, time-released form has proven safe and effective for the elimination of various parasites encountered in clinical practice.¹⁴¹ Likewise, the herb *Artemisia annua* (sweet wormwood) commonly is used to eradicate specific bacteria and has been used for thousands of years in Asia for the treatment and prevention of infectious diseases, including drug-resistant malaria.¹⁴² Restoring microbial balance by providing probiotics, restoring immune function (immunorestitution) and eliminating sources of dysbiosis, especially in the gastrointestinal tract, genitourinary tract, and oropharynx, is a very important component in the treatment plan of autoimmunity and systemic inflammation.¹⁴³

Should combinations of iodine and iodide be the sixth component of the Protocol?*: Both iodine and iodide have biological activity in humans. An increasing number of clinicians are using combination iodine-iodide products to provide approximately 3-6 mg/d [changed/corrected*]. Collectively, iodine and iodide provide antioxidant, antimicrobial, mucolytic, immunosupportive, antiestrogen, and anticancer benefits that extend far beyond the mere incorporation of iodine into thyroid hormones.⁵ Benefits of iodine/iodide in the treatment of asthma^{144,145} and systemic fungal infections^{146,147} have been documented, and many clinicians use combination iodine/iodide supplementation for the treatment of estrogen-driven conditions such as fibrocystic breast disease.¹⁴⁸ While additional research is needed and already underway to further establish the role of iodine-iodide as a routine component of clinical care, clinicians can reasonably begin incorporating this nutrient into their protocols based on the above-mentioned physiologic roles and clinical benefits. **See update/addendum following this reprint.*

Summary and Conclusions: In this brief review, I have described and substantiated a fundamental protocol that can serve as effective therapy for patients with a wide range of diseases and health disorders. Customizing the Paleo-Mediterranean diet to avoid patient-specific food allergens, using vitamin-mineral supplements along with physiologic doses of vitamin D and broad-spectrum balanced fatty acid supplementation, and ensuring "immunomicrobial" health with the skillful use of probiotics, prebiotics, immunorestitution, and antimicrobial treatments provides an excellent health-promoting and disease-eliminating foundation and lifestyle for many patients. Often, this simple protocol is all that is needed for the effective treatment of a wide range of clinical problems, even those that have been "medical failures" for many years. For other patients with more complex illnesses, of course, additional interventions and laboratory assessments can be used to optimize and further customize the treatment plan. Clinicians should avoid seeking "silver bullet" treatments that ignore overall metabolism, immune function, and inflammatory balance, and we must always remember that the attainment and preservation of health requires that we first meet the body's basic nutritional and physiologic needs. This five-step protocol begins the process of meeting those needs. With it, health can be restored and the need for disease-specific treatment is obviated or reduced; without it, fundamental physiologic needs are not met, and health cannot be obtained and maintained. Addressing core physiologic needs empowers doctors to deliver the most effective healthcare possible, and it allows patients to benefit from such treatment.

¹⁴¹ Force M, Sparks WS, Ronzio RA. Inhibition of enteric parasites by emulsified oil of oregano in vivo. *Phytother Res* 2000;14:213-4

¹⁴² Schuster BG. Demonstrating the validity of natural products as anti-infective drugs. *J Altern Complement Med* 2001;7 Suppl 1:S73-82

¹⁴³ Vasquez A. Integrative Rheumatology. IBMRC: 2006, 2009.

¹⁴⁴ Tuft L. Iodides in bronchial asthma. *J Allergy Clin Immunol*. 1981 Jun;67(6):497

¹⁴⁵ Falliers CJ, McCann WP, Chai H, Ellis EF, Yazdi N. Controlled study of iodotherapy for childhood asthma. *J Allergy*. 1966 Sep;38(3):183-92

¹⁴⁶ Tripathy S, et al. Rhinofacial zygomycosis successfully treated with oral saturated solution of potassium iodide. *J Eur Acad Dermatol Venereol*. 2007 Jan;21(1):117-9

¹⁴⁷ Bonifaz A, et al. Sporotrichosis in childhood: clinical and therapeutic experience in 25 patients. *Pediatr Dermatol*. 2007 Jul-Aug;24(4):369-72

¹⁴⁸ Ghent WR, Eskin BA, Low DA, Hill LP. Iodine replacement in fibrocystic disease of the breast. *Can J Surg*. 1993 Oct;36(5):453-60

***Update and addendum to information on iodine and iodide:**

- **Authoritative enthusiasm for high-dose iodine-iodide:** Several authoritative articles/authors stated that an advisable level of intake for iodine-iodide for the prevention and treatment of various conditions is approximately 12 mg/d. Because of these well-referenced and apparently authoritative publications, many clinicians and nutrition professionals began using higher doses iodine-iodide with patients and clients, quite often with benefit and nearly always with the absence of serious adverse effects. Several popular nutritional supplements used by clinicians and nutritionists contain both *iodine* (the *natural*, diatomic form) and *iodide* (the *divided/ionic* form most commonly consumed in *dietary* supplements, such as potassium *iodide*); both forms of this volatile metal have biologic properties in humans. Benefits of iodine-iodide supplementation focus mostly on the mucolytic, antimicrobial, and anti-estrogen effects.
 - **Dr Jonathan V Wright (*Nutrition and Healing* 2002 Nov and 2005 May):** In *Nutrition and Healing* (2002 Nov), well-respected nutrition expert, pioneer, and clinician Jonathan V. Wright MD advocated high-dose iodine-iodide for a wide range of conditions, particularly those related to inflammation, excess estrogen, and microbial infections. In another issue of *Nutrition and Healing* (2005 May) Dr Wright wrote “12.5 milligrams (that's 12,500 micrograms) is the optimal daily amount of iodine, not only for your thyroid but for the rest of your body, too.” In that same article, Dr Wright stated, “The Japanese have traditionally consumed more iodine, mostly from seaweed, than any other population. The average daily intake of iodine in Japan [is] 13.8 milligrams...”, and throughout the article Dr Wright advocates that 12.5 mg/d is “the optimal daily dose” of combined iodine-iodine.
 - **Extrathyroidal benefits of iodine (*Journal of American Physicians and Surgeons* 2006 Winter):** Independently and in a peer-reviewed publication, Donald Miller MD (Professor of Surgery, Division of Cardiothoracic Surgery, University of Washington School of Medicine) supported the daily intake of 12.5 mg/d in *Journal of American Physicians and Surgeons* and even supported higher doses with the statement “More than 4,000 patients in this project [Iodine Project] take iodine in daily doses ranging from 12.5 to 50 mg, and those with diabetes can take up to 100 mg /day.” Miller also noted that dermatologists “treat inflammatory dermatoses, like nodular vasculitis and pyoderma gangrenosum, with SSKI (supersaturated potassium iodide), beginning with an iodine dose of 900 mg/day, followed by weekly increases of up to 6 g/day as tolerated. Fungal eruptions, like sporotrichosis, are treated initially in gram amounts with great effect.”
 - **Iodine deficiency and therapeutic considerations (*Alternative Medicine Review* 2008 Jun):** In 2008, Patrick wrote “Estimates of the average daily Japanese iodine consumption vary from 5,280 mcg to 13,800 mcg...” and this again supported and reinforced enthusiasm for doses of approximately 12 mg/d of iodine-iodine. However, in this article, Patrick did not advocate any specific daily dosage, citing 3-6 mg/d as beneficial and without adverse effect.
- **Review, reanalysis, and caution:** Soon after these enthusiastic publications, Alan Gaby MD published in several magazines, presented in post-graduate educational events, and discussed in his book *Nutritional Medicine* a review and reanalysis of the original data and concluded that the estimated average daily intake of iodine-iodine in Japan had been *overestimated* by a mathematical error (mistakenly interchanging wet and dry weights of seaweed and thus overestimating the daily Japanese intake of iodine-iodine). Per Gaby (*Nutritional Medicine*, page 175), the true intake of iodine-iodide in Japan averages 330-500 mcg/d, which is 25-fold lower than the estimate of 13.8 mg/d, upon which rested much of the rationale for implementing high-dose iodine-iodide supplementation empirically and routinely.
- **Benefits, perspectives, and additional research:** Many clinicians including the current author have used high-dose iodine-iodide ranging from approximately 12-48 mg/d for variable periods of time without personally experiencing or clinically observing apparent adverse effects; that statement does not imply endorsement of routine universal high-dose iodine-iodide supplementation. Some degree of caution is advised in consideration of the risks of inducing thyroid dysfunction (hyperthyroidism, hypothyroidism), intestinal hemorrhage¹⁴⁹, and

¹⁴⁹ Kinoshita et al. Severe duodenal hemorrhage induced by Lugol's solution administered for thyroid crisis treatment. *Intern Med.* 2010;49(8):759-61

anaphylaxis-like reactions.¹⁵⁰ Topical and systemic antimicrobial benefits of iodine-iodide are well known and well documented; oral high-dose iodine-iodide has been used to treat drug-resistant fungal infections (cited below). When applied for sufficient concentrations and durations, both diatomic iodine and ionic iodide possess potent broad-spectrum antimicrobial properties; essentially no “drug resistance” against iodine-iodide exists for bacteria, fungi, viruses, and protozoans. Iodine also has documented molecular and clinical anti-estrogen effects, thus providing scientific explanation for its ability to treat and prevent estrogen-related disorders ranging from fibrocystic breast disease to cancer. Indeed, iodine treatment of breast cancer cells has been shown to increase the mRNA levels of several genes involved in estrogen metabolism and “detoxification” such as cytochrome p450-1A1 while also decreasing the levels of estrogen responsive genes such as TFF1 and WISP2; also noted following iodine treatment is upregulation of gene expression for the enzyme glutathione peroxidase, an important selenium-dependent component of antioxidant defense mechanisms.¹⁵¹

- Ultra-high dose iodide for sporotrichosis in childhood (*Pediatric Dermatology* 2007 Jul-Aug): Nineteen pediatric patients with proven sporotrichosis were successfully treated with potassium iodide per the following quoted protocol: “All patients were initially treated with potassium iodide (KI), and only those who were unresponsive or who developed side effects were given itraconazole. The dose of KI used was 1–3 g/day, starting at 1 g/day and increasing until the dose of 3 g/day was reached. ... Treatments were sustained until remission was reached, which ranged from 3 to 6 months.”¹⁵² Per the review by Miller¹⁵³ cited previously, KI 1g (1,000 mg) contains 770 mg of iodide. Thus, the pediatric patients in this case series were treated with 770-2,310 mg/d of iodide for successful antimycotic treatment. Two patients from the original group of 23 patients experienced nausea and vomiting from the KI and were switched to itraconazole; two other patients were lost to follow-up. The authors note that, “Side effects occur in 5% to 10% of patients, mainly presenting as gastrointestinal symptoms as well as headache and rhinorrhea to a lesser extent.”
- Ultra-high dose iodide for rhinofacial zygomycosis—case report (*Journal of European Academy of Dermatology and Venereology* 2007 Jan): A 19-year-old male “was put on oral SSKI at an initial dose of 0.5 mL three times daily. This was gradually increased by 0.1 mL/dose/day until a dose of 5 mL three times daily was reached.”¹⁵⁴ Generic formulation of “saturated solution of potassium iodide” (SSKI) contains 1000 mg of KI per mL of solution, which provides roughly 750 mg iodide; thus, SSKI dosed at 5 mL thrice daily = 15 mL/d = 11,250 mg/d (slightly more than 11 grams per day) of iodide for this adult patient with rhinofacial zygomycosis. Treatment was continued for at least 12 months without report of adverse effect.
- Modest dose iodine replacement in fibrocystic disease of the breast (*Canadian Journal of Surgery* 1993 Oct): Ghent and colleagues¹⁵⁵ sought to determine the response of patients with fibrocystic breast disease to “iodine replacement therapy” and reviewed three clinical studies of different design containing 233, 145 (later up to 1365), and 23 subjects; overall, subjective alleviation of pain and objective alleviation of breast fibrosis was seen in approximately 70% of patients. Consistent with other reports and impressions, the authors noted that, “Molecular iodine is nonthyrotropic and was the most beneficial.” The dose of molecular iodine averaged 0.08 mg/kg body weight, which for an average 140-lb (63-kg) patient equates to approximately 5 mg/d.
- Modest dose iodine in patients with cyclic mastalgia (*Breast Journal* 2004 Jul-Aug): Kessler¹⁵⁶ reports a randomized, double-blind, placebo-controlled, multicenter clinical trial was conducted with 111 otherwise healthy euthyroid women with a history of breast pain and fibrosis; subjects received molecular iodine for 6 months. Physicians assessed breast pain, tenderness, and nodularity each cycle; patients assessed breast pain and tenderness with the Lewin breast pain scale at 3-month intervals and with a VAS at each cycle. All iodine-treated subjects improved compared to no improvement seen in

¹⁵⁰ Indraccolo et al. Anaphylactic-like reaction to Lugol solution during colposcopy. *South Med J* 2009 Jan;102(1):96-7

¹⁵¹ “Quantitative RT-PCR confirmed the array data demonstrating that iodine/iodide treatment increased the mRNA levels of several genes involved in estrogen metabolism (CYP1A1, CYP1B1, and AKR1C1) while decreasing the levels of the estrogen responsive genes TFF1 and WISP2.” Stoddard FR 2nd, et al. Iodine alters gene expression in the MCF7 breast cancer cell line: evidence for an anti-estrogen effect of iodine. *Int J Med Sci.* 2008 Jul 8;5(4):189-96

¹⁵² Bonifaz A, et al. Sporotrichosis in childhood: clinical and therapeutic experience in 25 patients. *Pediatr Dermatol.* 2007 Jul-Aug;24(4):369-72

¹⁵³ Said of KI, “The standard dose was 1g, which contains 770 mg of iodine.” Miller DW. Extrathyroidal benefits of iodine. *J Am Physicians Surgeons* 2006;Winter,106-10

¹⁵⁴ Tripathy et al. Rhinofacial zygomycosis successfully treated with oral saturated solution of potassium iodide. *J Eur Acad Dermatol Venereol.* 2007;21:117-9

¹⁵⁵ Ghent et al. Iodine replacement in fibrocystic disease of the breast. *Can J Surg.* 1993 Oct;36(5):453-60

¹⁵⁶ Kessler JH. The effect of supraphysiologic levels of iodine on patients with cyclic mastalgia. *Breast J.* 2004 Jul-Aug;10(4):328-36

the placebo group. “Reductions in all three physician assessments were observed in patients after 5 months of therapy in the 3.0 mg/day (7/28; 25%) and 6.0 mg/day (15/27; 18.5%) treatment groups, but not the 1.5 mg/day or placebo group. Patients recorded statistically significant decreases in pain by month 3 in the 3.0 and 6.0 mg/day treatment groups, but not the 1.5 mg/day or placebo group; more than 50% of the 6.0 mg/day treatment group recorded a clinically significant reduction in overall pain. All doses were associated with an acceptable safety profile. No dose-related increase in any adverse event was observed.” Notably, the failure of the 1.5 mg/day dose implies that this dose is inadequate and thereby justifies higher routine dosing.

- Clinical implementation and the author’s perspective: Iodide has a stronger effect on thyroid function and provides tissue-penetrating antimicrobial benefits from oral administration. Molecular iodine has anti-estrogen effects that correlate with the clinical alleviation of cyclic breast pain and fibrocystic breast disease; other anti-estrogen benefits such as an anti-cancer benefit are reasonably anticipated from supplemental iodine. Products with combined iodine and iodide are available and reasonable for clinical use, and a daily dose range of 3-6 mg does not appear unreasonable and has been shown to be beneficial in human studies. Iodine and iodide are impressively well tolerated. Nicely summarized in a personal email from Michael Gonzalez DSc PhD in November 2012, an overview of iodine-iodide’s clinical applications may be stated as follows:

“Different tissues of the body respond to different forms of iodine. The Iodide form is believed to be particularly useful for the thyroid. But the supplement of choice for the breast is “iodine” not “iodide.” Lugol’s formula is Iodine 5% + Potassium iodide (KI) 10% in distilled water. Because different tissues concentrate different forms of iodine, using a supplement that contains both iodine and iodide is preferable to using a supplement that contains only one form. With different tissues responding to different forms of iodine, it would make common sense that a greater therapeutic benefit from iodine will be achieved by using a combination of iodide and iodine. ... The most frequent adverse reactions to potassium iodide are stomach upset, diarrhea, nausea, vomiting, stomach pain, salivary gland swelling/tenderness, acne and skin rash.”

Antioxidant support in general and supplementation with selenium in particular are recommended always, and particularly when iodine-iodide doses greater than 1-3 mg/d are used. Selenium 200 mcg/d has been shown in several studies to have an ameliorating effect on thyroid autoimmunity and a supportive effect on peripheral thyroid hormone metabolism. Although iodine is generally considered nonthyrotropic, periodic assessment of thyroid function and for thyroid autoimmunity is reasonable for patients taking long-term high-dose treatment. Clinicians should take advantage of iodine-iodide’s safe and effective mucolytic, antimicrobial, and anti-estrogen benefits.

Distinguishing iodiNe from iodiDe	
iodiNe	<ul style="list-style-type: none"> • Natural elemental form—diatomic. • Nonthyrotropic—no immediate adverse effects on thyroid function. • Nuclear—affects gene expression, for example by promoting estrogen detoxification and reducing estrogen responsiveness. • Nixes microbes, antimicrobial—very broad spectrum; povidone iodine is one of the most widely used topical antimicrobials in the history of microbiology and medicine.
iodiDe	<ul style="list-style-type: none"> • Divided—ionic, nondiatomc. • Dietary form, such as in iodized salt which typically contains potassium iodate, potassium iodide, sodium iodate, or sodium iodide. • Dissolves mucus—mucolytic benefits advantageous in the treatment of asthma, bronchitis and respiratory tract infections. Potassium iodide is thought to act as an expectorant by increasing respiratory tract secretions and thereby decreasing the viscosity of mucus; iodide levels increase in respiratory secretions within approximately 15 minutes after oral administration. • Directly thyrotropic—necessary for thyroid hormone production; high doses can cause thyroid dysfunction, which may be problematic (exacerbation of thyroid autoimmunity, hypothyroidism, or hyperthyroidism) or therapeutic (inhibition of thyroid hormone production during hyperthyroidism). • Deals death to microbes, antimicrobial—very broad spectrum, used in the form of potassium iodide (KI, SSKI) for the treatment of microbial infections such as zygomycosis and sporotrichosis.



Purple coneflower (*Echinacea purpurea*) with honey bee (*Apis* genus): Portland Oregon 2011, photo by DrV

Progressive awakening

"Only that day dawns to which we are awake."

Henry David Thoreau, *Walden*⁴¹²

"In virtually all of the great spiritual and philosophical traditions of the world there appears some form of the idea that most human beings are sleepwalking through their own existence. **Enlightenment is identified with waking up.** Evolution and progress are identified with an expansion of consciousness."

Nathaniel Branden, *Six Pillars of Self-Esteem*⁴¹³

"And once you are awake, then shall you ever remain awake."

Friedrich Nietzsche, *Thus Spoke Zarathustra*⁴¹⁴

⁴¹² Thoreau HD. (Owen Thomas, Ed). *Walden and Civil Disobedience*. New York; WW Norton and Company: 1966, page 221

⁴¹³ Nathaniel Branden *The Six Pillars of Self-Esteem*, p. 67

⁴¹⁴ Nietzsche FW. *Thus Spoke Zarathustra*.

Reply to “Role of Western Diet in Inflammatory Autoimmune Diseases” by Manzel et al. in *Current Allergy and Asthma Reports* (Volume 14, Issue 1, January 2014)

Alex Vasquez

Published online: 20 June 2014

© Springer Science+Business Media New York 2014

To the Editor,

Regarding the recent review “Role of Western Diet in Inflammatory Autoimmune Diseases” [1], while I appreciate the importance of this topic and the authors’ review, I noted several shortcomings in this review and have questions about the omission of certain information. The authors failed to include relevant and important human data while instead relying on animal studies (their Table 1). The authors also include erroneous information, without appropriate citation.


The authors state that “a high-fat diet is a prominent factor in promoting obesity” but failed to provide citation for this. Importantly, other researchers have shown that high-fat ketogenic diets promote weight loss rather than obesity.

I found the reliance on animal data (especially their Table 1) and the exclusion of human data inappropriate for a review article of this nature and at this time in biomedical history. Several clinical trials have already documented the effectiveness of dietary intervention in human autoimmune diseases. For example, diets which emphasize increased consumption of plant foods (excluding gluten-containing grains) and dietary alteration of gastrointestinal flora have already shown clinical benefits [2]. Exclusion of gluten is of critical

importance for some patients, and well established is gluten’s role in inflammation, alteration of gastrointestinal flora, increasing intestinal permeability, and direct stimulation of inflammatory pathways. The authors mentioned hypertension four times in their review but failed to mention the remarkable efficacy of therapeutic fasting for this condition [3]. Clinical trials showing the safety and efficacy of dietary fatty acid supplementation were also excluded from the review, despite showing remarkable clinical safety and antirheumatic efficacy [4]. Antiinflammatory mechanisms of dietary intervention not mentioned in their review include alleviation of oxidative stress, alleviation of dysbiosis, reduced reactivity to dietary antigens, normalization of intestinal hyperpermeability, and alleviation of proinflammatory mitochondrial dysfunction [5].

References

1. Manzel A, Muller DN, Hafler DA, Erdman SE, Linker RA, Kleiweitfeld M. Role of “Western diet” in inflammatory autoimmune diseases. *Curr Allergy Asthma Rep.* 2014;14(1):404.
2. Peltonen R, Nenonen M, Helve T, et al. Faecal microbial flora and disease activity in rheumatoid arthritis during a vegan diet. *Br J Rheumatol.* 1997;36(1):64–8.
3. Goldhamer A, Lisle D, Parpia B, Anderson SV, Campbell TC. Medically supervised water-only fasting in the treatment of hypertension. *J Manip Physiol Ther.* 2001;24(5):335–9.
4. Belch JJ, Ansell D, Madhok R, O’Dowd A, Sturrock RD. Effects of altering dietary essential fatty acids on requirements for non-steroidal anti-inflammatory drugs in patients with rheumatoid arthritis: a double blind placebo controlled study. *Ann Rheum Dis.* 1988;47(2):96–104.
5. Vasquez A. Integrative rheumatology and inflammation mastery, Third Edition. Create Space Publishers; 2014.




This article is part of the Topical Collection on *Autoimmunity*

A. Vasquez (✉)
International College of Human Nutrition and Functional
Medicine in Barcelona, Barcelona, Spain
e-mail: ichnfm@gmail.com

A. Vasquez
Biotics Research Corporation in Rosenberg, Rosenberg, TX, USA

Mechanisms of diet in autoimmunity—partial representation: Vasquez A. Reply to “role of Western diet in inflammatory autoimmune diseases” by Manzel et al. In *Current Allergy and Asthma Reports* (volume 14, issue 1, January 2014). *Curr Allergy Asthma Rep.* 2014 Aug;14(8):454. [Copyright Statement from Publisher](#): The final publication is available at Springer via [dx.doi.org/10.1007/s11882-014-0454-4](https://doi.org/10.1007/s11882-014-0454-4). Author retains the right to use his/her article for his/her further scientific career by including the final published journal article in other publications such as dissertations and postdoctoral qualifications provided acknowledgement is given to the original source of publication.


- The manipulative thrust is applied to the patient's upper arm, then pulls downward (not muscular force) while raising the contact hand
- Body-drop thrust generally superiorly and laterally at the shoulder; the angle of the thrust changes depending on the more superior segments requiring a more superiorly directed thrust. Notably, the manipulative thrust requires a progressively laterally-yet-sagittally directed thrust. Applied to the anterior thorax via contact with the patient's upper arm, yet the true manipulative force is from posterior to anterior via the doctor's thenar eminence positioned posteriorly.



© ICHNFM.ORG

© ICHNFM.ORG

Myofascial Release Techniques for the Treatment of Carpal Tunnel Syndrome: Respectfully attributed to and adapted from the work of Benjamin Sucher, D.O., M.D., M.P.H.



In this demonstration, the doctor is working on the patient's right wrist. In the doctor's right hand, the patient's pisiform, triquetral, and hamate bones are grasped and rolled externally, in a clockwise direction. In the doctor's left hand, the patient's scaphoid and trapezium bones are grasped and rolled externally from midline, in a counterclockwise direction. The combination of these two motions generates strong tension in the transverse carpal ligament (flexor retinaculum) that eventually leads to relaxation of the ligament and allows for increased cross-sectional area within the carpal tunnel, thus relieving pressure on its contents, particularly the median nerve. This maneuver is generally referred to as the *opponents roll*, and the following techniques are variations of same.


In this maneuver, the doctor's contacts and motions are the same as above, except that in this case the doctor's fingers are interposed between those of the patient. This positioning provides for greater control of the patient's distal palm, allowing the doctor to force the patient's wrist into extension while applying tension to the transverse carpal ligament. The addition of wrist extension appears to increase the clinical efficacy of the maneuver.

...ions are the same as above, but the thumbs to apply the... the patient's rolled

Chapter 3: Concepts and Ther...

Proprioceptive Rehabilitation


The central nervous system plays a role in the prevention of joint injury... essential for proper muscul... either by injury or more co... chronic pain. Muscle spasm... a context that appreciate... painful musculoskeletal



use the search feature

INFLAMMATION MASTERY 4TH EDITION

ON, FUNCTIONAL MEDICINE, MITOCHONDRIAL BIOME & DYSBIOSIS, FUNCTIONAL INFLAMMOLOGY, INTEGRATIVE RHEUMATOLOGY, NUTRITIONAL IMMUNONUTRITION & ANTIVIRAL STRATEGIES
Definitive Guide Toward Health and Vitality
The Boredom, Risks, Costs, and Inefficacy of
Medicine, Immunosuppression, and Polypharmacy
A System of Text, Illustrations, and Video



Google / Wikipedia



Navigation icons: back, forward, copy

QWERTY keyboard layout with a blue 'Search' button on the right.

potassium:chloride ratio (chloride reduces effectiveness and retention of potassium), and the overall pH/acid-base balance of the human host (i.e., metabolic acidosis reduces effectiveness and retention of potassium, while an alkaline state improves retention and effectiveness of potassium). Importantly, magnesium status is an important positive-direct determinant of potassium status, particularly in patients with recalcitrant hypokalemia and/or hyperaldosteronism.¹²² Respective amounts of potassium per serving of food or juice (1 cup = 8 fluid ounces =240 milliliters) are provided in the table below; renal insufficiency and potassium-sparing drugs/diuretics promote hyperkalemia, generally contraindicate high intake of potassium, and mandate periodic assessment of serum potassium.

Potassium content of common foods

Food serving	Potassium in mg (Na as available)
One papaya	780
One cup of mixed vegetable juice	740 (35-630 mg Na)
One cup of prune juice	700
One cup of carrot juice	520 (160 mg Na)
One cup plain low-fat yogurt	510 (150 mg Na)
One cup of cantaloupe	490
One cup of orange juice	470
One small banana	465
One cup of honeydew melon	460
One-third cup of raisins	365
One cup of carrot-orange juice	360 (35 mg Na)
One medium mango	320
One medium kiwi	250
One small orange	240
One medium pear	210

The importance of potassium

“Adults should consume at least 4.7 grams of potassium per day to lower blood pressure, blunt the effects of salt, and reduce the risk of kidney stones and bone loss. However, most American women 31 to 50 years old consume no more than half of the recommended amount of potassium, and men’s intake is only moderately higher.”

Food and Nutrition Board of the Institute of Medicine of the National Academies. "Dietary Reference Intakes: Water, Potassium, Sodium, Chloride, and Sulfate." Released: February 11, 2004
iom.edu/Reports/2004/Dietary-Reference-Intakes-Water-Potassium-Sodium-Chloride-and-Sulfate.aspx

Antihypertensive mechanisms of potassium include vasodilator activity, diuretic and natriuretic effects, and suppression of renin, angiotensin, and adrenergic tone.¹²³ In February 2004, the Institute of Medicine (IOM) set the Adequate Intake of potassium for adults at 4.7 grams a day – more than double previous recommendations; more than 90% of American adults do not meet these recommendations. If 90% of the population is not meeting recommended intakes of potassium, and these recommendations from the IOM come after an extensive review of the scientific literature, then potassium assessment and supplementation should be routine components of patient care; furthermore, this shows to the inadequacy of current laboratory assessments for evaluating potassium status and potassium balance.

- Randomized trial with 1-year follow-up and a title that says it all: Increasing the dietary potassium intake reduces the need for antihypertensive medication (Annals of Internal Med 1991 Nov): Forty-seven patients with medication-controlled hypertension completed one year of dietary treatment (or control nonintervention); dietary intervention focused on potassium-rich foods, with compliance monitored by 3-day food records and 24-hour urinary potassium excretion. Results showed: “After 1 year, the average drug consumption (number of pills per day) relative to that at baseline was 24% in group 1 (potassium-rich diet) and 60% in group 2 (control diet). By the end of the study, blood pressure could be controlled using less than 50% of the initial [drug] therapy in 81% of the patients in group 1 compared with 29% of the patients in group 2. ... CONCLUSION: Increasing the dietary potassium intake from natural foods is a feasible and effective measure to reduce antihypertensive drug treatment.”

¹²² "Magnesium deficiency is frequently associated with hypokalemia. Concomitant magnesium deficiency aggravates hypokalemia and renders it refractory to treatment by potassium. Herein is reviewed literature suggesting that magnesium deficiency exacerbates potassium wasting by increasing distal potassium secretion. A decrease in intracellular magnesium, caused by magnesium deficiency, releases the magnesium-mediated inhibition of ROMK channels and increases potassium secretion. Magnesium deficiency alone, however, does not necessarily cause hypokalemia. An increase in distal sodium delivery or elevated aldosterone levels may be required for exacerbating potassium wasting in magnesium deficiency." Huang CL, Kuo E. Mechanism of hypokalemia in magnesium deficiency. *J Am Soc Nephrol.* 2007 Oct;18(10):2649-52

¹²³ Patki et al. Efficacy of potassium and magnesium in essential hypertension: a double-blind, placebo controlled, crossover study. *BMJ.* 1990 Sep 15;301(6751):521-3

Practical overview of common abnormalities on the chemistry/metabolic panel—continued

Low values—considerations	Analyte	High values—considerations
<p>Hypokalemia can cause fatal cardiac arrhythmias and needs to be taken seriously. Replacement is generally via oral administration of potassium-rich foods, juices, or supplements such as potassium citrate (best option) or potassium chloride (KCl, inexpensive and therefore commonly used in medical settings even though KCl is clearly not optimal therapy due to the acidifying effect of the chloride anion). Recalcitrant hypokalemia is often a sign of magnesium depletion.⁹⁵ Causes of hypokalemia include diarrhea, vomiting, diuretics, Cushing disease/syndrome, dietary insufficiency, overhydration with mineral-free fluids, hyperaldosteronism and renal artery stenosis. Acute metabolic acidosis should cause relative or absolute elevations in serum K; the finding of normal or low serum K in a patient with acidosis (e.g., diabetic ketoacidosis) indicates (severe) potassium depletion.</p>	<p>Potassium: 3.6 - 5.2 mEq/L (mmol/L)</p>	<p>Hyperkalemia is defined as a potassium level greater than 5.5 mmol/L. Severe hyperkalemia (>7 mmol/L) can be fatal and needs to be taken seriously. In severe hyperkalemia, treatment and emergency management should be implemented before a complete evaluation and differential diagnosis are performed.⁹⁶ ❶ Ensure that blood sample was not hemolyzed. Repeat test if patient is stable and time allows. ❷ If hyperkalemia is severe or patient is symptomatic or has electrocardiographic changes, treat hyperkalemia with intravenous calcium, beta-adrenergic agonists (e.g., albuterol), bicarbonate, insulin and glucose; magnesium sulfate may also help alleviate arrhythmias; oral sodium polystyrene sulfonate (SPS, also known as Kayexalate) is a frequently used potassium-binding agent. ❸ DDX includes adrenal insufficiency, potassium-sparing diuretics, ACE-inhibitors and ARBs, NSAIDs, rhabdomyolysis, renal failure, and massive cell necrosis such as with tumor lysis syndrome.</p>
<p>Evaluate hypocalcemia clinically with Chvostek's sign (~30% sensitive) and Trousseau sign (~90% sensitive) which may also be present in hypomagnesemia; evaluate clinically for arrhythmia, muscle spasm/hypertonicity, and hyperreflexia. Measure serum albumin and perform equation for “corrected calcium” if albumin is low. DDX includes renal failure, hypoparathyroidism, malabsorption, and drug effect (e.g., rarely a loop diuretic such as furosemide). Chronic mild hypocalcemia is treated with oral vitamin D and calcium supplementation; subacute symptomatic hypocalcemia can be treated with intravenous calcium gluconate especially if cardiac arrhythmias are present.</p>	<p>Calcium: 8.6 - 10.2 mg/dL</p>	<p>Outpatient hypercalcemia is potentially serious and needs to be evaluated in a stepwise manner: ❶ repeat the test to rule out lab error unless you are confident in the performance of the laboratory and stability of the submitted sample, ❷ review drug list for adverse effect, such as from hydrochlorothiazide (HCTZ) or rarely from excess cholecalciferol intake, ❸ test intact parathyroid hormone (iPTH) to evaluate for hyperparathyroidism, ❹ evaluate for possible granulomatous disease such as sarcoidosis, tuberculosis, Crohn's disease, and possible leukemia or lymphoma, ❺ consider metabolic bone disease such as Paget disease of bone or metastatic bone disease, ❻ evaluate for cancer, ❼ test urine calcium for familial hypocalciuric hypercalcemia, ❽ refer to specialist such as internist or endocrinologist if hypercalcemia persists and answer is not forthcoming.</p>

Corrected calcium (cCa) equations: Used when both serum calcium and albumin are low

American units: $cCa \text{ (mg/dL)} = \text{serum Ca (mg/dL)} + 0.8 (4.0 - \text{serum albumin [g/dL]})$

International units: $cCa \text{ (mmol/L)} = \text{measured total Ca (mmol/L)} + 0.02 (40 - \text{serum albumin [g/L]})$

⁹⁵ “Herein is reviewed literature suggesting that magnesium deficiency exacerbates potassium wasting by increasing distal potassium secretion.” Huang CL, Kuo E. Mechanism of hypokalemia in magnesium deficiency. *J Am Soc Nephrol.* 2007;18:2649-52 jasn.asnjournals.org/content/18/10/2649

⁹⁶ “If the hyperkalemia is severe (potassium >7.0 mEq/L) or if the patient is symptomatic, begin treatment before diagnostic investigation of the underlying cause.” Garth D. Hyperkalemia in emergency medicine treatment and management. *Medscape Reference* emedicine.medscape.com/article/766479-treatment#a1126 Accessed June 2011

INFLAMMATION MASTERY

**4TH EDITION: THE COLORFUL AND DEFINITIVE GUIDE
TOWARD HEALTH AND VITALITY AND AWAY FROM THE
BOREDOM, RISKS, COSTS, AND INEFFICACY OF ENDLESS
ANALGESIA, IMMUNOSUPPRESSION, AND POLYPHARMACY**

A Three-Part Learning System of Text, Images, and Video

ALEX VASQUEZ D.C. N.D. D.O. F.A.C.N.

- ♦ Doctor of Osteopathic Medicine, graduate of University of North Texas Health Science Center, Texas College of Osteopathic Medicine (2010)
- ♦ Doctor of Naturopathic Medicine, graduate of Bastyr University (1999)
- ♦ Doctor of Chiropractic, graduate of University of Western States (1996)
- ♦ Fellow of the American College of Nutrition (2013-present)
- ♦ Former Overseas Fellow of the Royal Society of Medicine
- ♦ Editor, *International Journal of Human Nutrition and Functional Medicine* IntJHumNutrFunctMed.org. Former Editor, *Naturopathy Digest*; Former/Recent Reviewer for *Journal of Naturopathic Medicine*, *Alternative Therapies in Health and Medicine*, *Autoimmune Diseases*, *International Journal of Clinical Medicine*, and *PLOS One*
- ♦ Private practice of integrative and functional medicine in Seattle, Washington (2000-2001), Houston, Texas (2001-2006), Portland, Oregon (2011-2013), consulting practice (present)
- ♦ Consultant Researcher and Lecturer (2004-present), Biotics Research Corporation
- ♦ Teaching and Academics:
 - Director of Programs, International College/Conference on Human Nutrition and Functional Medicine ICHNFM.org
 - Founder and Former Program Director of the world's first accredited university-affiliated graduate-level program in Functional Medicine
 - Adjunct Professor, Integrative and Functional Nutrition in Immune Health, Doctor of Clinical Nutrition program
 - Former Adjunct Professor (2009-2013) of Laboratory Medicine, Master of Science in Advanced Clinical Practice
 - Former Faculty (2004-2005, 2010-2013) and Forum Consultant (2003-2007), The Institute for Functional Medicine
 - Former Adjunct Professor (2011-2013) of Pharmacology, Evidence-Based Nutrition, Immune and Inflammatory Imbalances, Principles of Functional Medicine, Psychology of Wellness
 - Former Adjunct Professor of Orthopedics (2000), Radiographic Interpretation (2000), and Rheumatology (2001), Naturopathic Medicine Program, Bastyr University
- ♦ Author of more than 100 articles and letters published in *JAMA—Journal of the American Medical Association*, *BMJ—British Medical Journal*, TheLancet.com, *JAOA—Journal of the American Osteopathic Association*, *Annals of Pharmacotherapy*, *Journal of Clinical Endocrinology and Metabolism*, *Alternative Therapies in Health and Medicine*, *Nutritional Perspectives*, *Journal of Manipulative and Physiological Therapeutics*, *Integrative Medicine*, *Current Allergy and Asthma Reports*, *Nutritional Wellness*, *Evidence-based Complementary and Alternative Medicine*, *Nature Reviews Rheumatology* and *Arthritis & Rheumatism*: Official Journal of the American College of Rheumatology

INTERNATIONAL COLLEGE OF HUMAN NUTRITION & FUNCTIONAL MEDICINE
ICHNFM.ORG


INFLAMMATION MASTERY

4TH EDITION

CLINICAL NUTRITION, FUNCTIONAL MEDICINE, MITOCHONDRIAL DYSFUNCTION, MICROBIOME & DYSBIOSIS, FUNCTIONAL INFLAMMOLOGY, PAIN MANAGEMENT, INTEGRATIVE RHEUMATOLOGY, NUTRITIONAL IMMUNOMODULATION, IMMUNONUTRITION & ANTIVIRAL STRATEGIES

The Colorful and Definitive Guide Toward Health and Vitality
and away from the Boredom, Risks, Costs, and Inefficacy of
Endless Analgesia, Immunosuppression, and Polypharmacy

3-Part Learning System of Text, Illustrations, and Video



DR. ALEX VASQUEZ

ICHNFM.ORG

INTERNATIONAL COLLEGE OF HUMAN NUTRITION AND FUNCTIONAL MEDICINE

Copyrights: © 2004-present by Dr Alex Vasquez. All rights reserved by the author and enforced to the full extent of legal and financial consequences internationally. No part of this book may be reproduced, stored in a retrieval system, used for the creation of derivative works, or transmitted by any means (electronic, mechanical, photocopying, recording, or otherwise) without written permission from the author.



Trademarks: © 2013-present by Dr Alex Vasquez and International College of Human Nutrition and Functional Medicine. The functional immunology/inflammation protocol discussed in this series of videos/notes/books/audios is recalled by the F.I.N.D.S.E.X. acronym trademarked™ in association with Dr Vasquez’s books and videos including but not limited to *Functional Immunology and Nutritional Immunomodulation* (2012), *F.I.N.D. S.E.X. The Easily Remembered Acronym for the Functional Inflammation Protocol* (2013), *Integrative Rheumatology and Inflammation Mastery, 3rd Edition* (2014). Portland, Oregon; Integrative and Biological Medicine Research and Consulting, LLC. All rights reserved and enforced. For additional information and resources, see InflammationMastery.com and/or FunctionalInflammation.com. Additional trademarks referenced/cited in this work include International College of Human Nutrition and Functional Medicine®, International Conference on Human Nutrition and Functional Medicine®, and *International Journal of Human Nutrition and Functional Medicine*®.



Intellectual property: This book contains the creative work and intellectual property of Dr Alex Vasquez, owned and protected internationally by Dr Alex Vasquez, Integrative and Biological Medicine Research and Consulting (“IBMRC”) LLC, and International College of Human Nutrition and Functional Medicine (“ICHNFM” and “ICHNFM.ORG”), based in North America and Europe. Except for quotes and excerpts from other sources, all of the information and images are protected by copyright ©; phrases and terms such as the FINDSEX® acronym are additionally protected by registered trademark. The book is the means of licensed transmittal of this intellectual property; ownership of the book as an instance of licensed private transmittal and access does not equate to ownership of the property. The book also provides individual, private access to proprietary video archives. This work is supported and made possible by revenue from book sales, and readers/purchasers are asked and expected to respect the author’s ownership of the work—specifically to not inappropriately copy or distribute—so that this work can continue. Violations of intellectual property rights, copyrights, and trademarks will be pursued to the highest extent possible internationally. For use permissions and to report violations, please contact admin@ichnfm.org.

Notices: The intended audiences for this book are health science students and doctorate-level licensed medical clinicians. This book has been written with every intention to make it as accurate as possible, and each section has undergone peer-review by an interdisciplinary group of clinicians. In view of the possibility of human error and as well as ongoing discoveries in the biomedical sciences, neither the author nor any party associated in any way with this text warrants that this text is perfect, accurate, or complete in every way, and all disclaim responsibility for harm or loss associated with the application of the material herein. Information and treatments applicable to a specific *condition* may not be appropriate for or applicable to a specific patient; this is especially true for patients with multiple comorbidities and those taking pharmaceutical medications, which are generally associated with multiple adverse effects and drug/nutrient/herb interactions. Given that this book is available on an open market, lay persons who read this material should discuss the information with a licensed medical provider before implementing any treatments and interventions described herein.

associated with complications such as pancytopenia, organ failure, and death⁴⁰⁸, it is not a treatment to be taken lightly nor should inexperienced physicians administer it. Colchicine can be administered orally, but its low therapeutic efficacy in relation to its moderate gastrointestinal toxicity limits its applicability. In a poorly designed study by Schnebel and Simmons⁴⁰⁹, orally administered colchicine was no better yet was more toxic than placebo; this study appears to have been designed specifically to show inefficacy and toxicity of colchicine since the patients were either given *no treatment* alternating with a *gastroirritative toxic dose* of colchicine.



Statue of Silvius Brabo, a mythical Roman soldier who is said to have killed a giant and thrown his hand into the river, hence the name of the city Antwerp, which translates to "hand throwing." Photo at Antwerp City Hall, Belgium 2012 by DrV.

⁴⁰⁸ "Bone marrow depression has been reported, primarily in cases of acute colchicine intoxication, and intravenous administration of the drug has been associated with severe pancytopenia and death." Levy M, Spino M, Read SE. Colchicine: a state-of-the-art review. *Pharmacotherapy*. 1991;11(3):196-211

⁴⁰⁹ Schnebel BE, Simmons JW. The use of oral colchicine for low back pain. A double-blind study. *Spine*. 1988 Mar;13(3):354-7 Use of colchicine in this study varied from abstinence for 3 days followed by a toxic dose on day 4; therefore patients in the treatment group were subjected to no treatment for 75% of the time, followed by a dose that caused gastrointestinal toxicity—vomiting and diarrhea—the other 25% of the time. At neither phase of the study were patients exposed to a treatment that had any possibility of being effective in relation to the potential toxicity. This study was so poorly designed that its publication brings into question the editorial quality of *Spine* during this era.

Index:

- 11-beta hydroxysteroid dehydrogenase, 737
- 12-hydroperoxyeicosatetraenoic acid, 370
- 12-R-HETE, 370
- 12-R-lipoxygenase, 375
- 12-S-HETE, 370
- 12-S-lipoxygenase, 375
- 13-S-HODE, 369
- 15-hydroperoxyeicosatetraenoic acid, 370
- 15-hydroxy-eicosatrienoic acid, 368
- 15-lipoxygenase-1, 375
- 15-lipoxygenase-2, 375
- 15-S-HETE, 370
- 2,4-dichlorophenol, 237
- 2,5-dichlorophenol, 236
- 2010 ACR guidelines for the diagnosis and assessment of FM, 910
- 25(OH) vitamin D, 59, 745
- 2-hydroxyestrone, 693
- 3-3-hydroxyphenyl-3-hydroxypropionic acid, 442, 935
- 5-HETE, 370
- 5-hydroperoxyeicosatetraenoic acid, 369
- 5-hydroxytryptophan, 960
- 5-lipoxygenase, 374
- 5pSPMD, 717
- 8-lipoxygenase, 375
- 8-S-HETE, 370
- Abducens, 23
- Acacia catechu, 535
- ACEI, 807
- Acetaminophen, 913
- Acetyl-L-carnitine, 789
- Acetyl-L-carnitine, 970
- Acinetobacter spp, 94
- Acupuncture, 791, 973
- Acute nontraumatic monoarthritis, 122
- Acute red eye, 119
- Acute-onset HTN, 752
- Adenosine monophosphate (AMP), 571
- Adipokines, 205, 822
- Adipose, 205, 822
- ADP, dosing and clinical use, 493, 720
- Adrenic acid, 367
- Adverse food reactions, 379, 984
- African American, 807
- ALA, 359
- Alcohol, 413, 460, 929
- Aldolase, 1146
- Aldosterone:renin ratio, 748
- Aldosterone-to-renin ratio, 748
- Algal chlorovirus ATCV-1, 441, 935
- Alginate, 1093
- Alkalinization, 267, 770
- Allergy diagnosis, 391
- Allium sativum, 779
- Alpha-2 agonists, 813
- Alpha-adrenergic receptor class-2 agonist, 813
- Alpha-adrenergic receptor type-1 antagonist, 812
- Alpha-linolenic acid, 359
- Alveolar hemorrhage, 1062
- Alzheimer's disease, 92
- Amitriptyline, 912
- Amlodipine, 810
- Amoxicillin, 496
- ANA - interpretation, 78
- ANA - overview, 26
- Analgesia (natural), 266, 267
- ANCA, 1103
- ANCA-associated vasculitis (also called "granulomatosis with polyangiitis", formerly Wegener's granulomatosis), 428
- Andrographis paniculata, 537
- Anesthetics, 298
- Anethum graveolens, 535
- Aneurysm (intracranial), 875
- Angiotensin-2 converting enzyme inhibitors, 807
- Anise, 534
- Ankylosing spondylitis, 1110
- Anti-autoantibody interventions, 1071
- Antibiotic/antifungal drugs, 495
- Anticardiolipin antibodies, 1064
- Anti-CCP antibodies, 81, 1024
- Anticitrullinated protein antibodies, 81
- Anticyclic citrullinated peptide, 1024
- Anti-double stranded (DS, native) DNA antibodies, 1064
- Antidysbiotic lifestyle, 489
- Antifibrillar antibodies, 1092
- Anti-histone antibodies, 1064
- Antihistorical, 196
- Anti-inflammatory & analgesic treatments, 255
- Anti-Jo-1, 1146
- Antimetabolites, 413, 415, 928
- Antimicrobial treatment of SIBO, 963
- Antimutagenesis as a direct antiviral strategy, 573, 582
- Anti-nuclear antibodies, 1064
- Antinuclear antibody - interpretation, 78, 79
- Antioxidant capacity of fruits and vegetables, 209
- Antiphospholipid and Anticardiolipin antibodies, 1064
- Antiphospholipid syndrome, 427
- Antiphospholipid/ anticardiolipin/ Hughes syndrome, 85
- Anti-Ro antibodies, 1064
- Anti-Sm (anti-Smith) antibodies, 1064
- Antiviral (phyto)nutrition, 723
- Aortic coarctation, 735
- Arachidonate avoidance, 769
- Arachidonic acid metabolites formed by cyclooxygenase, 368
- Arachidonic acid, 366
- Arginine, 775, 776
- Arginine, omega-3 fatty acids and nucleotide-supplemented enteral support, 585
- Armour thyroid, 697
- Aromatase, 693
- Aromatase, 828
- Artemisia annua, 494, 533, 722
- Artificial sweeteners, colors and other additives, 212
- Ascorbic acid, 587, 770
- Aspartame, 212
- Asthma & Reactive Airway Disease, 1001
- Atlantoaxial instability in AS and RA, 1111
- Atlantoaxial instability, 120, 121
- Atlas vertebra realignment, 795
- Augmentin, 496, 964
- Authentic living, 221
- Autism, 414, 415, 483, 484, 485, 530
- Auto-brewery syndrome, 459
- Autoimmune hepatitis, 85
- Autoimmune thyroid disease, 85
- Autointoxication, 459
- Autonomization, 224
- Avascular necrosis of the femoral head, osteonecrosis, 123
- Azithromycin for psoriasis, 1048
- Azithromycin, 496
- Babesia, 93
- Bacterial allergy, 434
- Bacterial DNA, 409
- Bacterial overgrowth, 473
- Bacteriophage therapy, 497
- Bacteriophages, 556, 1059
- Balance shoes, 294
- Barrett's esophagus, 1078
- Bed rest, 254
- Beets, 537
- Behcet's Disease, 1133
- Behcet's Syndrome, 1133
- Berberine, 533, 781
- Berberine: dosing and clinical use, 720
- Beta-adrenergic receptor blockers, "beta blockers", 809
- Beta-glucuronidase, 104, 488
- Betaine, 576
- Betulina, 534
- Bile flow, 706
- Biochemical Individuality - overview, 216
- Biochemical individuality, 195
- Biofilms, 439
- Bioflavonoids in the treatment of allergy, 388, 994
- Biotin, 611
- Bismuth, 494, 534, 722
- Blastocystis hominis, 493, 525, 720
- Bleach bath, 515
- Blood Dysbiosis, 511
- Blood pressure measurement, 743
- Body mass index (BMI) for predicting amount and duration of weight loss, 744
- Body Mass Index, 204, 822
- Boerhaavia diffusa, 537
- Bone necrosis caused by NSAIDs, 250
- Borrelia burgdorferi, 93

- Boswellia serrata, 259
 Bowel-associated dermatitis-arthritis syndrome (BADAS), 434
 Bradycardia, 807
 Breath testing, 487
 Bromocriptine, 691, 692
 Brucea javanica, 535
 Buchu/betulina, 534
 Butyrate, 415
 BVG-LOC profile, 753
 Bystander activation, 428
 Cabergoline, 691
 Caffeine, 212
 Calcium channel blockers (dihydropyridine class), 810
 Calcium pyrophosphate dihydrate deposition disease, 124, 125
 Campylobacter, 93
 Canadian Hypertension Education Program recommendations, 761
 C-ANCA, 1103
 Candida albicans, 526
 Candida hypersensitivity, 434
 Cannabis sativa and related variants, 261
 Caprylic acid, 535
 Capsicum annuum, Capsicum frutescens, 260, 1049
 Carbohydrate loading for supercompensation, 211
 Carboxy-methyl-lysine, 904
 Cardiopulmonary examination, 743
 Carica papaya ("papaya"), 567
 Carnitine Insufficiency Caused by Aging and Overnutrition, 789
 Carnitine, antiinflammatory effects, 1049
 Carpal bones myofascial release, 290
 Carpal tunnel syndrome - clinical management, 286
 Carpal tunnel syndrome - manipulative treatment, 292
 Carrageenan, 212
 Cartilage destruction caused by NSAIDs, 250
 Casokinins, 773
 Catecholamine-O-methyltransferase, 737
 Cat's claw, 259
 Cauda equina syndrome, 2, 120
 Cayenne pepper - monograph, 1049
 Cayenne pepper, 260
 CBC – overview, 25
 CCB, 810
 CCP, 81, 1024
 Celiac disease and autoimmunity, 492
 Celiac disease and autoimmunity, 719
 Celiac disease, 85, 429
 Cell wall-deficient bacteria, 408
 Centella asiatica, 1088
 Central neurogenic hypertension, 738
 Cephalixin, 497, 516
 Cervical spine dysfunction, 742
 Cervical Spine: Rotation Emphasis, 280
 CH50, 1064
 Chemistry panel – overview, 25
 Chemistry/metabolic panel, 745
 Chiropractic model of illness and healing, 152
 Chiropractic spinal manipulative therapy, 792, 794
 Chiropractic, 973
 Chiropractic-supervised water-only fasting in the treatment of borderline hypertension, 668, 669, 763
 Chlamydia trachomatis, 93
 Chlamydia/Chlamydophila pneumoniae, 93, 517, 918
 Chlorella pyrenoidosa, 673, 725
 Chlorella, 673, 725, 979
 Chlorovirus ATCV-1, 441, 935
 Chlorpyrifos, 236
 Chocolate, 771
 Chondroitin, 270
 Chronic fatigue syndrome, 94
 Chronic inflammatory disease, sustained inflammatory response, 398
 Churg-Strauss syndrome, 1099
 CIC (circulating immune complexes), 1141
 Ciprofloxacin, 497
 Citrate synthase, 890
 Citrobacter freundii, 526
 Citrobacter rodentium, 526
 Clinical Assessments for HTN, 742
Clinical Case: 45yo HLA-B27+ woman with recurrent UTIs and a 7-year history of ankylosing spondylitis, 501
Clinical Case: Abnormal lactulose-mannitol ratio in a patient with idiopathic peripheral neuropathy, 499
Clinical Case: Elevated hsCRP (high-sensitivity C-reactive protein) in a male patient with metabolic syndrome and rheumatoid arthritis, 500
Clinical Case: Elevated plasma ammonia in the absence of liver disease, 461
Clinical Case: Exemplary case of clinical and laboratory evidence of reversal of "severe, aggressive, drug-resistant" rheumatoid arthritis, 402
 Clinical Management, 752
 Clinical practice involves much more than "diagnosis and treatment", 114
 Clonidine, 813
 Clostridium, especially in autism, 485
 Clove, 534
 Cluster headache - differential diagnosis of head pain, 875
 Cluster headache, 874
 Cluster headaches, treatment with melatonin, 899
 Cocaine, 735
 Cockcroft-Gault formula, 740
 Cocoa, 771
 Cod liver oil, 588
 Coenzyme Q10 (CoQ10) in cardiac disease, 788
 Coenzyme Q-10, 787, 966
 Coffee as a gastrointestinal stimulant, 495
 Cold and stretch treatment for MFTP, 277
 Colonization, 399
 Combination of streptococcal antigen with bacterial DNA, 410
 Combinatorial inflammoly, 478
 Combinatorial multifocal polydysbiosis, 398
 Commiphora molmol, 533
 Complement, 84
 Complements C3 and C4, 54
 Composite seropositivity, 1024
 Composite seropositivity, 81
 Comprehensive parasitology, 102
 Comprehensive parasitology, 102, 501, 529
 Compression - use in injury management, 255
 Conn's syndrome, 739
 Conscious living, 196
 Consciousness-raising, 224
 Consent to treatment, 110
 Contemplation, 194
 Contraceptives, 735
 Controlled breathing, 791
 CoQ-10 in the treatment of allergy, 388, 994
 CoQ-10 treatment for migraine, 890
 CoQ10, 420, 787, 969
 Corrective experience, 224
 Cortef, 695
 Cortical spreading depression, 866
 Cortisol, 694
 Cosmetics, 979
 Cough headache - differential diagnosis of head pain, 875
 Counterthrust, 279
 CPDD, 125
 CPPD, 124, 125
 Cranberry, 534
 Cranial nerve V, pain sensation in migraine, 863
 Cranial nerves, 22, 23
 C-reactive protein - interpretation, 27
 Creatine kinase, 1146
 Creatine monohydrate, 970
 CREST syndrome, 1074
 Cross-reactivity, 423
 CRP - interpretation, 52
 Cryoglobulinemia, 1098
 Curcumin requires piperine for absorption, 308, 377, 389, 996
 Curcumin, 537
 Cushing's disease/syndrome, 735

- Cutaneous dysbiosis/colonization—
introduction to assessment, 90
- Cyclic citrullinated protein antibodies,
81, 1024
- Cyclobenzaprine, 913
- Cyclooxygenase (COX), 373
- Cymbalta, 912
- Cytochrome-c-oxidase, 890
- Cytomegalovirus (CMV), 1054
- Cytomegalovirus (CMV), 548
- Cytomegalovirus (CMV), 92
- Cytomegalovirus—Induction of
vasculopathy, 1084
- Cytomegalovirus—Induction of
vasculopathy, 549
- Cytomel, 697
- Daily living, 190
- DAMP, 417
- Danazol, 1066
- Danger/damage-associated molecular
patterns—DAMP—receptors, 417
- Dark Chocolate, 771
- DASH: Dietary Approaches to Stop
Hypertension, 758
- DDE, 235
- DDT, 235
- Deep tendon reflexes, 24
- Definition of dysbiosis, 396
- Deglycyrrhizinized licorice, 1122
- Delta-4-desaturase, 373
- Delta-5-desaturase, 373
- Delta-6-desaturase, 372
- Dengue virus, 567
- Dental care, 505
- Depuration, 238, 239
- Dermatomyositis sine myositis, 1142
- Dermatomyositis, 1142
- Dermatopolymyositis, 1142
- Detoxification defects caused by leaky
gut, 486
- Detoxification programs are a
necessity, 235
- Detoxification, 239, 921
- Detoxification, problems and
solutions, 704
- Detoxification: An Ultracondensed
Clinical Review, 699
- Devil's claw, 259
- DGLA metabolites formed by 15-
lipoxygenase, 368
- DGLA metabolites formed by
cyclooxygenase, 367
- DGLA, 365
- DHA, 257
- DHA, 361
- DHEA, 1108
- DHEA, 695
- Diabetes mellitus type 1.5, 85
- Diabetes, 512
- Dientamoeba fragilis, 526
- Diet optimization, 957
- Dietary haptization, 382, 988
- Dietary molecular mimicry, 383
- Dietary molecular mimicry, 988
- Differential Diagnoses of HTN, 734
- Diffuse idiopathic skeletal
hyperostosis, 1114
- Diffuse systemic sclerosis, 1074
- Diffucan, 965
- Dihomo-gamma-linolenic acid, 365
- Diindolylmethane, 693
- Dill (antimicrobial actions), 535
- DIM, 693
- Dimercaptosuccinic acid, 709, 920
- DISH, 1114
- D-lactic acid intestinal bacteria in
chronic fatigue syndrome, 413,
929
- D-lactic acid, 924
- D-lactic acidosis, 414
- D-lactic acidosis, 929
- DMSA, 709
- DMSA, 920
- DNA methylation and "folic acid"*, 577
- DNA methylation and histone
acetylation, 449
- DNA methylation as an antiviral
antireplication strategy, 576
- DNA methylation, 1058, 582
- Docere, 131
- Docosahexaenoic acid, 361
- Docosapentaenoic acid, 361, 367
- Docosatrienes, 308, 362
- Dostinex, 691
- Double hit model of microbe
synergism for autoimmunity
induction, 427
- DPA, 361
- D-ribose, 970
- Drop thrust, 283, 607
- Drug treatments for chronic HTN, 805
- Drug-induced lupus, 428
- Drugs for intestinal bacterial
overgrowth, 495
- Dry needling or injection of local
anesthetic or saline
- Duloxetine, 912
- Dysbiosis can be distinguished based
on the location(s) of the dysbiotic
foci/focus, 396
- Dysbiosis in scleroderma, 553
- Dysbiosis treatments, 532
- Dysbiosis—introduction to concepts
and testing, 86
- Ear lobe crease, 743
- Ebola virus infection, 544, 572
- ECG, 749
- Eicosanoid modulation, 267
- Eicosapentaenoic acid, 360
- Eicosatetraenoic acid, 360, 366
- Eicosatrienoic acid, 365
- EKG, 749, 750
- Electrocardiography, 749
- Elimination and challenge technique,
391, 999
- Elongase, 373
- Emergencies, 119
- Emotional literacy, 224
- Emotional, mental, and social health,
221
- Endocrinologic activity of adipose
tissue, 205
- Endolimax nana, 493, 527, 720
- Endoplasmic reticulum (ER) and ER
stress (ERS), 651
- Endotoxins (lipopolysaccharide) from
gram-negative bacteria, 404
- Enemas, 537
- Enhanced processing of
autoantigens, 425, 441, 934
- Entamoeba hartmanni, 493, 720
- Entamoeba histolytica, 471, 479, 527
- Enterococcus, 527
- Enteropathic spondylo-arthropathy,
enteropathic arthritis, 1110
- Enterovirus D68, 544
- Enthesopathies, 1111
- Environmental dysbiosis, 517
- Environmental
dysbiosis/colonization—
introduction to assessment, 90
- Enzyme therapy, 594
- Enzymes in fatty acid metabolism,
372
- EPA - review, 360
- EPA, 257
- Epicatechin, 772
- Epigenetic dysbiosis/eubiosis, 448
- Epigenetic dysfunction, 448
- Epigenetic silencing of viral
sequences, 543
- Epinephrine and norepinephrine, 749
- Epstein-Bar virus (EBV), 92, 548,
1054, 1085
- Erythromycin, 496, 722
- Esophageal dysfunction and GERD in
scleroderma, 1092
- ESR - interpretation, 54
- Essay: Common Oversights and
Shortcomings in the Study and
Implementation of Nutritional
Supplementation, 315
- Essay: Five-Part Nutritional Wellness
Protocol That Produces
Consistently Positive Results, 310
- Essay: Implementing the Five-Part
Nutritional Wellness Protocol for
the Treatment of Various Health
Problems, 312
- Essay: Twilight of the Idiopathic Era
and The Dawn of New Possibilities
in Health and Healthcare, 814, 858
- Essential fatty acid, 358, 365
- Estrogen, 692, 735
- Ethanol, 460, 736
- Eucalyptus oil, 521
- Exceptional living, 195
- Exercise, 201, 791
- Eye and fundoscopic examination,
743
- Facial nerve, 23
- Faecalibacterium, 472
- Family health history, 13
- Fasting (short-term water-only), 762
- Fatty Acid Modulation of Eicosanoid
Production and Genetic
Expression, 309
- Fatty acid supplementation, 769
- Fatty acids, 588
- Fecal transplant, 497

- Ferritin - interpretation, 54
 Ferritin - overview, 26
 Feverfew, 897
 Fibromyalgia clinical criteria:
 description and contrast of the
 1990 criteria and the 2010 criteria,
 909
 Fibromyalgia disease, 902
 Fibromyalgia initiated by dysbiosis,
 463
 Fibromyalgia, 901
 Fibrosis of the skin and internal
 organs, 1074
 Fish oil, 769
 Fish oil, EPA with DHA - rationale for
 use in basic conservative care,
 257
 Flax seed oil, 359
 Flossing, including use of "floss
 picks", 505
 Fluconazole, 965
 Folate deficiency and cervical
 dysplasia, 576
 Food allergen avoidance, 763
 Food allergens, 213
 Food allergy diagnosis, 391, 999
 Food allergy in the induction and
 perpetuation of autoimmunity, 986
 Food allergy, 379, 985
 Food challenges, 391, 999
 Formula SF722, 493, 720
 Fructose avoidance, 767
 Fumaderm, 1141
 Fumaric acid esters, 1141
 Functional assessment, 19
 Functional Medicine (FxMed)
 perspectives, 916
 Fundoscopic examination, 743
 Furosemide, 811
 Gamma delta T cells, 610
 Gamma strep, 527
 Gamma-linolenic acid, 257, 365
 Garlic, 534, 779
 Gastric ulceration and gastrointestinal
 bleeding caused by NSAIDs, 250
 Gastrointestinal dysbiosis, 471
 Gastrointestinal
 dysbiosis/colonization—
 introduction to assessment, 88
 Gene products - amplification by NF-
 kappaB, 376
 Genital mucosal lesions, 1135
 Genitourinary dysbiosis/colonization—
 introduction to assessment, 89
 GERD in scleroderma, 1092
 Gestational hypertension, 736
 Giant Cell (Temporal) Arteritis, 1097
 Giant Cell Arteritis (previously
 Temporal Arteritis), 1100
 Giant cell arteritis, 119
 Giardia lamblia, 527, 528
 Ginger, 258, 537
 GLA - review, 365
 Glial activation, 441, 935
 Gliotoxin, 438
 Glossopharyngeal, 23
 Glucosamine, 270
 Glutamate and the NMDA receptor in
 headache, 870, 872
 Glutamate/NMDA receptor, 442, 935
 Glutamine, 589
 Gluten avoidance, SLE treatment,
 1066
 Glycolytic pathways, 894
 Glycyrrhiza glabra, 565, 737
 Goldhamer, 762
 Gottron's sign, 1144
 Gotu cola, 1088
 Gout, 124
 Granulomatosis with polyangiitis,
 formerly Wegener's
 granulomatosis, 429
 Granulomatous disease (sarcoidosis),
 1138
 Granulomatous uveitis, 1138
 Grape seed extract (GSE), 308, 377,
 389, 571, 996
 Green tea, 308, 377, 389, 618, 996
 Group A streptococci, 531
 Gulf War Illness, 94
 H₂S—hydrogen sulfide, 924, 929
 Haemophilus influenzae, 427
 Haptenization, 428
 Harpagophytum procumbens, 259
 HCTZ, 811
 Helicobacter pylori, 94, 528, 1085
 Heliotrope/purple facial/cheek rash,
 1144
 Hematocolpos, 1113
 Hemochromatosis, 160
 Hemochromatosis, 919
 Hemoglobin A1c, 747
 Henoch-Schonlein purpura, 1099
 Hepatic and renal injury and failure
 caused by NSAIDs, 250
 Hepatic encephalopathy in the
 absence of liver disease, 459
 Hepatitis B virus (HepB, HBV), 92
 Hepatitis C virus (HepC, HCV), 92
 Hepatobiliary stimulation for IgA-
 complex removal, 536
 Herpes simplex virus type-2 (HSV-2),
 560
 Herpes simplex virus types 1 and 2
 (HSV1, HSV2), 92
 Herpes zoster. The treatment and
 prevention of neuralgia with
 adenosine monophosphate, 571
 HERV, 554, 1055
 HFE mutation, 167
 Hgb-A1c, 747
 Hierarchy of Therapeutics, 131
 High glycemic foods, 255
 High-dose mannose-binding lectin
 therapy for Ebola virus infection,
 572
 High-fructose corn syrup, 737
 High-risk pain patients, 109
 History taking, 8
 HLA-B27, 425
 Homologs, 423, 427
 Hormones in the treatment of allergy,
 390, 998
 Hospital/physician errors, 253
 HPPHA, 442, 935
 HPV, 1054
 HPV, 548, 561, 1054
 HTLV (human T-lymphotropic virus) in
 SLE, 549, 1055
 HTN prevalence, 732
 HTN, CVD, 730
 Hughes syndrome, 85
 Human endogenous retroviruses
 (HERVs) play a role in
 autoimmune diseases, 554
 Human herpes virus type-6 (HHV-6),
 92, 560
 Human immunodeficiency virus (HIV),
 92, 558
 Human papilloma virus (HPV), 548,
 561, 1054
 HVLA, 279
 Hydralazine, 813
 Hydrochlorothiazide (HCTZ), 811
 Hydrogen sulfide, 413, 474, 924, 929
 Hydrosoluble coenzyme Q10, 789
 Hydroxocobalamin, 883
 Hyperaldosteronism, 739
 Hypercalcemia, 736
 Hyperglycemia adversely impacts the
 innate immune system, 599
 Hypericum perforatum shows
 impressive antibacterial action,
 494, 533, 722
 Hyperinsulinemia, 211, 736
 Hyperprolactinemia, 689
 Hypersensitivity/allergic dysbiosis,
 474
 Hypertension, see also HTN, 728
 Hypertensive emergency, 752, 752
 Hyperthyroidism, 742
 Hypochlorite, 516
 Hypoglossal nerve, 23
 Hypomethylation, 577
 Hypothyroidism, 742, 801, 917
 I3C, 693
 Iatrogenic neurosis, 265
 Ice/heat, 254
 Idiopathicization, 1143
 IgE and IgG assays, 999
 Immune complex formation and
 deposition, 430, 1053
 Immune complexes, 1141
 Immunodysregulatory dysbiosis, 479
 Immunonutrition (against dysbiosis),
 536
 Immunonutrition, 585
 Immunophenotype determination, 610
 Immunostimulation by bacterial DNA,
 409
 Immunosuppression via gliotoxins,
 438
 Immunosuppressive dysbiosis, 474
 Immunotoxicity, 699

Inadequacies in musculoskeletal education and training among physicians, 247
 Inclusion body myositis, 1145
 Increased intestinal permeability caused by NSAIDs, 250
 Individualize treatment - importance, 255
 Individuation, 196
 Indole, 413, 929
 Indole-3-carbinol, 693
 Inflammation promotes more inflammation, 376
 Inflammatory bowel disease-- laboratory testing, 85
 Inflammatory dysbiosis, 475
 Informed consent, 110
 Inhibition of detoxification by dysbiosis, 434
 Insufficiency dysbiosis, 432
 Insulin resistance and gut dysbiosis, 481
 Insulin resistance, 211, 512, 736
 Insulin, 747
 Internal locus of control, 226
 Intestinal/mesenteric vasculitis, 1062
 Intracranial aneurysm, 875
 Intracranial mass lesion, 876
 Intradependence, 224
 Introduction to Injection Therapies, 298
 Iodine, 697
 Iodine/iodide—oral administration of pharmacologic doses, 569
 Iron overload as a cause of headaches, 877
 Iron Overload, 160, 876, 919
 Juvenile spondylo-arthropathy, 1111
 Kawasaki disease, 552, 1099
 Keflex, 497
 Keratoconjunctivitis sicca, 1120
 Klebsiella pneumoniae, 471, 528
 Koch's Postulates, 399
 LA, 365
 Labile support surface, 294
 Laboratory assessments: general considerations, 25
 Lactoferrin, 104, 488
 Lactokinins, 773
 Lactulose-mannitol assay evaluates paracellular/pathologic and transcellular/physiologic absorption, 487
 Lactulose-mannitol assay, 26, 487
 LADA, 85
 Lambert-Eaton myasthenic syndrome, 1145
 L-Arginine, 775
 Lasix, 811
 Latent autoimmune diabetes in adults, 85
 Laxatives promote eradication of intestinal microbes, 495
 L-carnitine, 789
 Lead accumulation, 748
 Lead and HTN, 77, 748
 Lead, 920
 Leaky gut diagram, 486
 Leaky gut, 101, 416
 Lemon balm (*Melissa officinalis*), 568
 Leukotriene B4, 370
 Leukotriene B-5, 362
 Levothyroxine, 696
 L-form, 408
 Licorice, 565, 737
 Lifestyle habits, 191
 Limited cutaneous scleroderma, 1074
 Linoleic acid metabolites formed by lipoxygenases, 369
 Linoleic acid, 365
 Linolenic acid, 359
 Liothyronine, 697
 Liotrix, 697
 Lipoic acid, 308, 377, 389, 578, 996
 Lipoxygenases (LOX), 374
 Lisinopril, 808
 Liver biopsy in iron overload, 167
 Low starch diet, 492, 719
 Low-back pain: differential diagnostic considerations, 1113
 Low-carbohydrate (low fermentation) supplemented Paleo-Mediterranean diet, 491
 Low-carbohydrate (low fermentation) supplemented Paleo-Mediterranean diet, 718
 LOX, 374
 LPS triggers TLR4 to activate mitochondrial hyperpolarization, 421
 LT-C4, 370
 LT-D4, 370
 LT-E4, 370
 L-tryptophan, 949
 L-tyrosine and iodine, 697
 Lugol's solution against influenza, 569
 Lumbar Roll, 284
 Lupus and Epstein-Barr, 549
 Lupus, 1053
 Lyme disease, 93
 Lyrica, 912
 Lysine, 570
 Madecassol, 1088
 Magnesium, 767, 961
 Malignant HTN, 752
 Manipulation of the Costovertebral Junction, 282
 Manipulation, mobilization, and massage, 266
 ManKind Project, 224
 Manual Medicine, 278
 Marshall protocol, 452
 Mask-like face, 1075
 Massage, 263
 Mechanisms of autoimmune disease induction by microorganisms, 403
 Mechanistic dysbiosis, 479
 Mechanistic Target of Rapamycin, 656
 Medical history, 13
 Meditation, 791
 Melatonin, 200, 592, 802, 969
Melissa officinalis, 568
 Melzack and Wall, 908
 Meningitis, 876
Mentha piperita, 494, 534, 722
 Mercurial myopathy, 920
 Mercury impairs catecholamine degradation, 737
 Mercury toxicity, 237, 702, 737, 920
 Metabolic dysbiosis, 479
 Metabolism of omega-3 fatty acids and related eicosanoids - illustration, 364
 Metabolism of omega-6 fatty acids and related eicosanoids - illustration, 371
 Methylation of DNA, 582, 1058
 Metoprolol, 810
 Metronidazole, 495
 Metronidazole, 722
 MFTP - clinical management, 274
 Microbial colonization, 86
 Microbial dysregulation, 448
 Microbial hypersensitivity, bacterial allergy, 434
 Microbial Induction of Noninfectious Systemic Disease, 403
 Microglial activation, 441, 935
 Migraine - differential diagnosis of head pain, 876
 Migraine with aura, 874
 Milk protein-derived peptide inhibitors of angiotensin-I-converting enzyme, 775
 Milk thistle, 537
 Milnacipran, 913
 Mimotopes, 423, 427
 Mind-Body Approaches, 791
 Minimize factors that promote disease, 241
 Minocycline, 496
 Mitochondrial DAMPs, 417
 Mitochondrial dysfunction and mTOR activation, 420
 Mitochondrial dysfunction promotes central sensitization, 928
 Mitochondrial dysfunction, 904, 905
 Mitochondrial impairment is the origin of migraine and cluster headache, 864
 Mitochondrial myopathy, 905
 Mitophagy, 906, 925, 949, 951, 965, 966
 Mixed connective tissue disease, 1074
 Mobilization, 266
 Molecular mimicry, 423
 Monoarthritis, 122
 Mononeuritis multiplex, 1101
 Mononucleosis, 92
 Motivation, 193
 Motivation: moving from theory to practice, 194
 mTOR, 420, 656
Mucuna pruriens, 690
 Multifocal Dysbiosis, 396, 1152
 Multifocal polydysbiosis, 86
 Multiple chemical sensitivity, 436
 Multiple sclerosis (MS), 93, 94, 514

- Multivitamin/multimineral supplementation, 600
- Muscle strength – grading scale, 24
- Musculoskeletal emergencies, 119
- Musculoskeletal Manipulation, 278
- Mycoplasma species including pneumoniae, fermentans, hominis, penetrans, genitalium, 94
- Mycoplasma species, 918
- Myelopathy, 2, 120
- Myofascial trigger points - clinical management, 274
- Myrrh, 533
- NAC, 580
- N-acetyl-cysteine (NAC), 580
- NADH-cytochrome-c-reductase, 890
- NADH-dehydrogenase, 890
- Nail pitting, 1039
- National Heart, Lung, and Blood Institute (NHLBI), 818
- Nattokinase, 781
- Naturopathic model of illness and healing, 129, 130
- Neisseria gonorrhoeae, 427
- Neoantigens/neoautoantigens, 428
- Neomycin, 964
- Neurogenic hypertension, 738
- Neurologic deficit in the evaluation of head pain - clinical management, 877
- Neurologic examination, 19, 744
- Neuronal autoimmunity, 94
- Neuropsychiatric lupus is a medical emergency, 1061
- Neuropsychiatric lupus, 119
- Neurotoxic dysbiosis, 483
- NF-kappaB, 417, 418, 419
- NFkB and its phytonutritional modulation, 376
- NFkB inhibition as an antiviral antireplication strategy, 578
- Niacinamide, 270
- NLRP3 inflammasome is activated in fibromyalgia, 419
- NLRP3 inflammasome is activated in fibromyalgia, 969
- NMDA receptor, 442, 935
- NMDA-type glutamate receptor (NMDAr), 871
- NOD-like receptors (NLR), 419
- Nonsteroidal anti-inflammatory drugs, 739
- Nuclear transcription factor kappa beta, 376, 419
- Nucleotide-binding oligomerization domain, 419
- Nucleotides, 590
- Nutrigenomics, 217
- Nutrition and Physical Degeneration, textbook by Weston Price,, 206
- Nutritional Genomics, 217
- Nutritional immunomodulation, 307, 609
- Nystatin, 496, 723
- O’Keefe and Cordain in Mayo Clinic Proceedings, 206
- Obesity, 204, 822
- Objective means for the identification of allergens, 999
- Occult infections, 918
- Octreotide, 1083
- Oculomotor, 23
- Oil pulling/swishing, 505
- Olfactory, 23
- Omega-3 fatty acids - review, 359
- Ophthalmic, 23
- Opioid epidemic, 245
- Oral contraceptives, 735
- Oregano oil, 533, 720
- Organic foods rather than industrially-produced foods, 212
- Orodental dysbiosis, 88, 503
- Orthoendocrinology, 688
- Orthomolecular Immunomodulation, 386, 993
- Orthomolecular Medicine - overview, 216
- Orthopedic/musculoskeletal examination: concepts and goals, 20
- Orwellian newspeak, 249
- Osteochondritis dissecans, 123
- Osteomyelitis, 2, 121
- Osteopathic manipulation, 798, 973
- Osteopathic manipulative treatment for adult pneumonia, 606
- Osteopathic Medicine, 149
- Overlap syndromes, 1074
- Oxygen, for cluster headaches, 892, 970, 973
- PABA, 1088
- Pain/fatigue syndromes and SIBO, 480
- Paleo-, 758
- Paleo-Mediterranean Diet, 219, 492, 597, 756
- Pancreatic and proteolytic enzymes, 273, 594
- Papaya, 567
- PAR, 110
- Paradigms, and their reasonable alternatives, 197
- Parasitology, 102
- Parasitology, 501, 529
- Parasites, 525
- Parenchymal dysbiosis/colonization— introduction to assessment, 91
- Parenchymal/Blood Dysbiosis, 511
- Parvovirus B-19 (PvB19), 548, 561, 1054, 1085
- Pasteurian paradigm, 399
- Pathophysiologic responses, 416
- Patient (mis)education in standard medicine, 914
- Pattern recognition receptors—PRRs, 417
- P-cresol, 415
- Penicillin treatment of psoriasis, 1048
- Pentosedine, 904
- Peppermint, 494, 534
- Peppermint, 722
- Peptidoglycans and exotoxins from gram-positive bacteria, 406
- Peripheral neurogenic hypertension, 738
- Pesticide exposure, 237
- Phenolic content, 209
- Pheochromocytoma, 739
- Phlogenzym, 595
- Phospholipase-A2, 373
- Physical examination, 19, 743
- Physical exertion, 201
- Physical medicine: spinal manipulation, mobilization, 605
- Physician errors, 253
- Phytochelators, 711
- Phytochemicals, 208
- PI3K/Akt/mTOR pathway, 422
- Picrorhiza, 537
- Plasminogen activator inhibitor, 362
- Pleomorphic, "cell wall-deficient" bacteria, 408
- Political and social action, 238
- Polyarteritis nodosa, 1098
- Polymicrobial dysbiosis in scleroderma, 553
- Polymyalgia Rheumatica, 1100
- Polymyositis, 1142
- Polyphenolics and phytonutrients, 581
- Porphyria cutanea tarda, 162
- Post-isometric stretching treatment for MFTP, 276
- Potaba, 1088
- Potassium supplementation, 764
- Potassium-sparing diuretic: spironolone, 812
- Povidone iodine, 515
- Prazosin, 813
- Pre-contemplation, 194
- Preeclampsia, 736
- Pregabalin, 912
- Preparation, 194
- Primary biliary cirrhosis, 85
- Primary sclerosing cholangitis, 85
- Primary/Genetic Hemochromatosis, 160
- Primum Non Nocere, 130
- Probiotic supplementation, 535
- Probiotics, 490, 603, 782, 962
- Progressive Systemic Sclerosis, 1074
- Proinflammatory and endocrinologic activity of adipose tissue, 205
- Pro-inflammatory foods, 255
- Prolactin, 689
- Prolotherapy, 298
- Propionic acid, 414
- Propolis, 308, 377, 389, 996
- Proprioceptive rehabilitation and retraining, 293, 300
- Proprioceptive retraining, 266
- Prostacyclin, 368
- Prostaglandin D2, 368
- Prostaglandin E-1, 367
- Prostaglandin E2, 308, 368

- Prostaglandin E-3, 362
 Prostaglandin F2-alpha, 369
 Prostaglandin G2, 369
 Prostaglandin G-3, 362
 Prostaglandin H2, 369
 Prostaglandin H-3, 362
 Prostaglandin I2, 368
 Prostaglandin I-3, 362
 Prostaglandin synthase complex, 373
 Protect & prevent re-injury, 254
 Protein - calculation of daily intake, 206, 268, 328
 Proteolytic enzymes (used in the treatment of dysbiosis), 535
 Proteolytic enzymes, 273, 594
 Proteus mirabilis, 471
 PRRs, 417
 Pseudomonas aeruginosa, 94, 471
 Psoriasis, main chapter, 1038
 Psoriatic rheumatism, 1038
 Putrescine, 413, 929
 Pyridoxine lowers serum/blood glutamate levels, 886
 Pyridoxine, 288, 689, 885
 Pyruvate dehydrogenase complex, 894
 Qigong, 791, 973
 Quorum sensing, 439
 Raynaud's phenomenon in scleroderma, 1094, 1129
 Raynaud's phenomenon, 94, 1129, 1133
 Reactive arthritis, 93, 466, 1110
 Reasons to avoid the use of nonsteroidal anti-inflammatory drugs (NSAIDs), 247, 249
 Referred pain with compression, 274
 REFLEXES – grading scale, 24
 Relative rest - definition and application in basic holistic care, 254
 Renal artery (renovascular) stenosis, 740
 Renal disease survey, 743
 Renal failure, cause of death in patients with SLE, 1061
 Renal injury and failure caused by NSAIDs, 250
 Resolvins, 363
 Restless leg syndrome, 949
 Retinal vasculitis, 1062
 Review of systems, 12
 Rheumatic psoriasis, 1038
 Rheumatoid Factor - interpretation, 80
 Rib manipulation, 282
 Riboflavin, 290
 Rifaximin, 496
 Rifaximin as treatment for SIBO and IBS, 954
 Rifaximin, 954, 964
 ROS: review of systems, 12
 Rosacea, 482
 Rose Bengal staining, 1121
 Roseburia intestinalis, 427
 Rosemary, 308, 377, 389, 996
 Saccharomyces boulardii, 492, 719
 SAD: Standard American Diet, 757
 S-adenosyl-methionine, 576, 962
 Safe patient + safe treatment = safe outcome, 110
 Salivary gland biopsy, 1121
 Salmonella, 93
 SAME, 576
 Sarcoidosis, 1138
 Savella, 913
 Schirmer test, 1121
 Schober test, 1114
 Scleroderma, 741
 Scleroderma secondary to xenobiotic immunotoxicity, 1074
 Scleroderma, 1074
 Screening laboratory tests in the evaluation of patients with musculoskeletal complaints, 25
 Secondary Hemochromatosis, 160
 Secretory IgA, 103, 488
 SEID, 479
 Selective estrogen receptor modulators inhibit Ebola virus infection, 572
 Selenium, 573
 Septic arthritis, 121, 125, 126
 Septic arthritis, in rheumatoid arthritis, 1023
 Seropositivity, 81, 1024
 Serotonin synthesis, 211
 Serum IgE and IgG assays, 391
 Shigella, 93
 Short-chain fatty acids, 104, 488
 SIBO, 922
 Sicca syndrome, 1120
 Sick role, 265
 Silibinin/silybin from Silymarin marianum, 593
 Silymarin, 168
 Sinorespiratory dysbiosis, 508
 Sjögren Syndrome/Disease, 550, 1120
 Skatole, 413, 929
 Skin taping to increase afferent stimuli, 296
 Skin-prick testing, 391, 999
 SLE, 1053
 Sleep apnea, 741
 Sleep, 199
 Slipped capital femoral epiphysis, 124
 Small intestinal bacterial/microbial overgrowth, 473
 Small intestine bacterial overgrowth in fibromyalgia, 923
 Social history, 13
 Sodium avoidance, 613
 Sodium benzoate, 212
 Sodium chloride, 763
 Sodium hypochlorite, 516
 Somatic dysfunction, 149
 Somatostatin analog, 1083
 Special considerations in the evaluation of children, 112
 Spinal accessory nerve, 23
 Spinal cord compression, 2, 120
 Spinal manipulation, 605
 Spironolactone, 812
 SPMD, 717
 Sporothrix schenckii, 570
 St. John's Wort, 533
 Standard Medical Treatment for Fibromyalgia, 912
 Staphylococcus aureus, 531
 Stearidonic acid, 360
 Stool analysis and comprehensive parasitology, 487
 Stool analysis, 103
 Streptococcal infections, 94
 Streptococcus pyogenes, 531
 Stress is a "whole body" phenomenon, 222
 Stress management and authentic living, 221
 Subluxation, 742
 Superantigens, 411
 Supercompensation (carbohydrates), 211
 Supplemented Paleo-Mediterranean Diet, 219, 256
 Syndemic obesity, inflammation, cardiometabolic syndrome, and brain dysfunction, 652
 Synthroid, 696
 Systemic exertion intolerance disease, 479
 Systemic Lupus Erythematosus, main chapter, 1053
 Systemic Sclerosis, 741, 1074
 Systolic hypertension, 788
 Syzygium species, 534
 Takayasu arteritis, 1098
 Tanacetum parthenium, 897
 Tartaric acid, 413, 929
 Tartrazine, 212
 Television, 191
 Temporal arteritis, 119, 1100
 Testing for Occult Infections and Dysbiosis, 86
 Testosterone, 694
 Tetanus toxoid, 427
 Tetracycline, 497
 Th17 cells, 609
 Therapeutic dependency - defined, 265
 Therapeutic exercise, 266
 Therapeutic Interventions, 956
 Therapeutic passivity - defined, 265
 Thrombocytopenia, 719
 Thromboxane A-2, 368
 Thromboxane A-3, 362
 Thromboxane B2, 368
 Thrust vectors, 279
 Thyme, 534
 Thymus vulgaris, 534
 Thyroid (insufficiency or autoimmunity), 696, 697
 Thyroid disease, 742
 Thyroid glandular—nonprescription T3, 697
 Thyroid hormone, 689
 Thyroid stimulating hormone - interpretation, 64
 Thyroid testing, 745
 Thyrolar, 697
 Tinidazole, 495

- Tissue/Parenchymal/Blood Dysbiosis, 511
- Tolle Causam, 130
- Toll-like receptors (TLR), 417
- Toll-like receptors (TLR, e.g., TLR2 and TLR4), 651
- Toll-like receptors, 418
- Total inflammatory load (TIL), 479
- Total microbial load (TML), 479, 1054
- Toxic oil syndrome, 1076
- Toxicant Exposure and Detoxification/Depuration, 705
- Toxoplasma gondii, 1086
- Tramadol, 913
- Transcendental meditation, 791
- Transgenic food avoidance, 613
- Transient synovitis, irritable hip, 123
- Treatment for MFTP, 277
- Treatment-resistant hypertension, 731
- T-regulatory cells, 609
- Tricycline, dosing and clinical use, 494, 720
- Trigeminal nerve, pain sensation in migraine, 863
- Trigeminal, 23
- Tripterygium wilfordii Hook F, 690
- Triptolide, 690
- Trochlear, 23
- Truncated self, 226
- Tryptamine, 413, 929
- Tryptophan, 960
- TSH: thyroid stimulating hormone - interpretation, 64
- Turmeric, 537
- Twitch response, 274
- Tyramine, 413, 483, 929
- Una de gato, 259
- Uncaria guianensis and Uncaria tomentosa, 259
- Undecenoic acid, 493, 720
- Undecylenic acid, 535
- Undecylenic acid, dosing and clinical use, 493, 720
- Unfolded protein response (UPR), 650
- Unhistorical, 196
- Uric acid reduction, 767
- Uric acid, 746
- Urinalysis (UA), 745
- Urinary alkalization, 770
- Urine pH, 746
- Urine sodium and potassium, 746
- Uva Ursi, 534
- Vagal stimulation, 443, 923
- Vancomycin, 964, 496
- Varicella zoster virus (VZV), 561
- Varicella zoster virus in giant cell arteritis, 552
- Varicocele, 693
- Vasculitic Diseases, 1095
- Vasculitis, 464, 508
- Vasodilators, 813
- Vegetarian diet for fibromyalgia, 958
- Vegetarian diet, 758
- Vestibulocochlear, 23
- Vinyl chloride disease, 1076
- Viruses, part 1—Known/popular "epigenomic" viruses, 1054
- Viruses, part 2—Human endogenous retroviruses (endoretroviruses, HERVs or ERVs), 1055
- Viruses, part 3—Bacteriophages of the gastrointestinal bacteria, 1059
- Viruses, part 4—Bacterial synergism via NFkB activation and immunosuppression, 1060
- Vis Medicatrix Naturae, 130
- Viscous Agents, 298
- Visual analog scale, 23
- Vitamin A for all patients with measles, 587
- Vitamin A, 587
- Vitamin A, retinoic acid, RA, 615
- Vitamin B-12 in the treatment of allergy, 388
- Vitamin B-12 in the treatment of allergy, 995
- Vitamin B-6, 288
- Vitamin C (ascorbic acid), 587
- Vitamin C in the treatment of allergy, 388, 994
- Vitamin C purge, 494, 720
- Vitamin C, 273, 770
- Vitamin D - antiinflammatory benefits, 378, 450
- Vitamin D deficiency - assessment in patients with musculoskeletal pain, 26, 916
- Vitamin D status testing, 59
- Vitamin D, 728, 742, 746, 769, 770, 801, 815, 816
- Vitamin D, 982, 983
- Vitamin D3 (cholecalciferol, not ergocalciferol), 586
- Vitamin E in the treatment of allergy, 388, 994
- Vitamin E, 612
- Vitex astus-cagnus, 690
- Wall, neurophysiology researcher, 908
- Wall-less bacteria, 408
- Waterhouse, 456
- Wegener's granulomatosis, 428, 1097, 1102
- Weight optimization, 265, 791
- Wellness, 4
- Whey peptides, 773
- Whey protein isolate, 591
- Williams, Roger J, 195
- Willow bark, 258
- Wobble board, 294
- Wobenzym, 595
- WomanWithin, 224
- Work ethic, 198
- Xenobiotic Immunotoxicity, 699
- Xenobiotics, 920
- Xerostomia, 1120
- Xifaxan, 496, 964
- Yellow dye #5, 212
- Yersinia, 93
- Yoga, 290
- Zeff, Jared N.D., 189
- Zingiber officinale, 258
- Zonulin, 404
- Zygomycosis, 570

potential clinical applications

- 1) Food & Basic Nutrition
- 2) Infections: Dysbiosis / Viral
- 3) Nutritional Immunomodulation
- 4) Dysmetabolism, Mitochondrial Dysfunction, ERS/UPR, mTOR
- 5) Special Considerations: Sleep, Sociopsychology, Stress, Surgery
- 6) Endocrine Imbalances
- 7) Xenobiotic Immunotoxicity

Volume 2: Chapter 5—Clinical Applications of the Functional Inflammation Protocol

- 1) Hypertension
- 2) Diabetes Mellitus
- 3) Migraine & Headaches
- 4) Fibromyalgia
- 5) Allergic Inflammation
- 6) Rheumatoid Arthritis
- 7) Psoriasis and Psoriatic Arthritis
- 8) Systemic Lupus Erythematosus
- 9) Scleroderma & Systemic Sclerosis
- 10) Vasculitic Diseases
- 11) Spondyloarthropathies & Reactive Arthritis
- 12) Sjögren Syndrome/Disease
- 13) Raynaud's Syndrome/Phenomenon/Disorder